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Summary vii 
Summary 
Forensic Systematic Toxicological Analysis (STA) deals with the chemical analysis of 
biological samples in a logical sequence designed to detect a wide range of exogenous 
materials, including drugs and other chemical substances. The ideal approach would be to 
detect qualitatively and quantitatively all substances of interest in a single method 
involving a single extraction procedure and a single end-step analytical technique. In 
recent years solid phase extraction based on modified silica sorbents has become the most 
widely-used extraction procedure in forensic toxicology. More recently, new polymeric 
sorbents with different selectivities have become available which promise to provide the 
single extraction technique required for STA. Also, one of the principal end-step 
analytical techniques used for STA is gas chromatography-mass spectrometry, which 
is 
applicable to volatile and thermally-stable materials but which can be extended to cover a 
significantly wider range of toxicologically-relevant materials by use of chemical 
derivatisation procedures during sample preparation. The aim of this thesis was to 
investigate both the extraction and end-step components of STA. 
The introductory section reviews the background to forensic toxicology and systematic 
toxicological analysis, whether dealing with the analysis of an individual drug or with a 
group of drugs within the same class, and introduces details about the blood matrix - the 
most commonly used sample type in forensic toxicology. Subsequently, some of the 
background theory of Gas Chromatography-Mass Spectrometry used in this project is 
examined including the historical development of chromatography. The detectors which 
are available, such as the mass spectrometer in combination with gas chromatography and 
the ionization methods used are also described. The background to drugs of abuse, which 
form an important group of drugs within STA, is discussed, including their chemistry and 
pharmacology and information on the main classes of drugs of abuse analysed in this thesis 
and their metabolism is given. Lastly, derivatisation methods are reviewed, including the 
different types of derivatisation used in this project. 
Three different derivatisation procedures were evaluated for their general applicability to 
STA, involving (a) acylation with pentafluoropropionyl anhydride (PFPA) and 
pentafluoropropanol (PFP-OH), (b) acylation/esterification (methylation) with 
pentafluoropropionyl anhydride (PFPA) and a novel methylating agent 
trimethylsilyldiazomethane (TMS-diazomethane), used as a chromatographic 
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derivatisation reagent for the first time in this study, and (c) silylation with tertiary- 
butyldimethylsilyl-trifluoroacetamide (MTBSTFA). Model compounds were selected for 
the evaluation process including a primary amine (amphetamine), a secondary amine 
(methamphetamine), alicyclic and aromatic hydroxy compounds (morphine, 
tetrahydrocannabinol), and carboxylic acids (benzoylecgonine, 11-nor 
tetrahydrocannabinol-9-carboxylic acid). Microwave assisted derivatisation was evaluated 
as a replacement for conventional heating on a hotplate. Effective conditions for rapid 
derivatisation required only one minute in the microwave oven instead of 30 minutes in a 
heating block. 
For method (a) derivatisation was successful for all of the test compounds and mass spectra 
were obtained for each of them. These derivatives gave good gas chromatographic 
behaviour, in terms of peak shape and thermal stability, and the mass spectra had 
prominent molecular ions and also prominent diagnostic fragment ions at high mass, 
suitable for use as qualifier ions in selected ion monitoring GC-MS. For method (b), the 
novel methylating agent trimethylsilyl-diazomethane was used to convert carboxylic acids 
into the corresponding methyl esters. This reaction was found to proceed rapidly and 
quantitatively at room temperature and holds potential for future use in toxicology to 
replace diazomethane, a hazardous and toxic material. The products of acylation of 
alcohol remained unchanged from method (a). However, the primary amine 
(amphetamine) and secondary amine (methamphetamine) gave less satisfactory results in 
terms of poor method linearity. The acylated/methylated products gave good gas 
chromatography and had mass spectra which are suitable for both identification and 
quantification by GC-MS-SIM. Method (c) gave derivatives with all test compounds 
except the secondary amine, methamphetamine, and the alcohol, morphine. The gas 
chromatographic behaviour of these derivatives was good and the mass spectra had 
prominent ions suitable for GC-MS-SIM, often characterised by prominent M-57 ions due 
to the loss of the butyl substituent in the silyl derivatives. 
The extraction of multiple drugs from blood was evaluated using the novel polymeric SPE 
sorbent Strata-X. The same test compounds were used to assess the extraction step in 
terms of recovery and variation (within day and between days). The extracts were 
analysed by GC-MS-SIM using each of the three types of derivative. Recoveries of the 
test compounds were in the range of 50-100 percent depending on the analyte and its 
concentration in blood. All calibration curves were linear and had correlation coefficients 
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higher than 0.99. Within day variations and between day variations were in the range of 
2-22% relative standard deviation. Limits of detection and quantitation were measured for 
the model compounds and were found to be in the ranges 0.4-7.3 ng/ml and 1.1-24.4 ng/ml 
respectively. The full method, combining extraction with each of the derivatisation 
reactions was finally evaluated for the presence of interferences with real case blood 
samples. 
A particular application of extraction and derivatisation was investigated in which two 
isomers of hydroxybutyric acid (gamma-hydroxy butyric acid, GHB, and beta- 
hydroxybutyric acid, BHB) were analysed in small (0.2 ml) whole blood samples. GHB is 
of interest as an abused drug which has been implicated in drug assisted assault while BHB 
is of interest in alcohol related deaths as a potential marker of fatal alcoholic ketoacidosis. 
Both compounds were extracted with Clean Screen GHB solid phase extraction cartridges 
with recoveries in the range 44-89% depending on the analyte concentration. The extracts 
were analysed by GC-MS-SIM after derivatisation with bistrimethylsilyl- 
trifluoroacetamide. Calibration curves were linear, with correlation coefficients above 
0.99. Limits of detection and quantification were acceptable for the intended application, 
being in the range of 0.1-4 mg/L depending on the analyte. The method was applied to 
authentic case samples from alcoholics and non-alcoholics. It was noted that when alcohol 
levels were high, the BHB levels were also high. When BHB levels were high, there was 
some indication that the GHB levels were affected, in that the higher the BHB levels, the 
lower the GHB levels. However this did not reach statistical significance. 
Benzodiazepines form one class of drugs which is commonly encountered in STA and 
which often requires derivatisation prior to GC-MS analysis. The three derivatisation 
procedures were evaluated using four test compounds comprising diazepam plus its three 
metabolites nordiazepam, temazepam and oxazepam. The hydroxylated metabolites 
(temazepam and oxazepam) formed derivatives readily with all three reagent mixtures but 
nordiazepam (secondary aromatic amine) did not react except with MTBSTFA. 
Based on the work of this study it is concluded that a method is possible for STA based on 
a polymeric sorbent, to give a general extract, followed by a generalised derivatisation 
procedure such as acylation, with PFPA/PFP-OH prior to GC-MS. 
List of Figures 
List of Figures 
Figure 1-1: - The seven major groups of poisons ................................................................. 1 Figure 2-1: - A modem instrument for Gas Chromatography - Mass Spectrometry ............. 
6 
Figure 2-2: - Components of a chromatograph .................................................................... 7 Figure 2-3: -Chromatogram nomenclature ........................................................................... 
8 
Figure 2-4: - Distribution Constant ...................................................................................... 8 Figure 2-5: - Determination of analyte concentration .......................................................... 
9 
Figure 2-6: - Split Injection Mode ..................................................................................... 
11 
Figure 2-7: - Splitless Injection Mode ............................................................................... 
11 
Figure 2-8: - Capillary Column (open tubular) .................................................................. 
12 
Figure 2-9: - Types of Stationary Phase ............................................................................. 
12 
Figure 2-10: - Components of a mass spectrometer ........................................................... 
14 
Figure 2-11: -Ion source (electron impact) ........................................................................ 
16 
Figure 2-12: -A plan view of the ion source ...................................................................... 
16 
Figure 2-13: -Acceleration of ions from the ion source ...................................................... 
17 
Figure 2-14: - Magnetic sector analyser ............................................................................ 
17 
Figure 3-1: - Pharmacokinetic characteristics of an orally absorbed drug .......................... 
20 
Figure 3-2: - Phase 1 metabolic pathways ......................................................................... 22 Figure 3-3: - Phase 2 conjugation reactions ....................................................................... 
23 
Figure 3-4: - Chemical structure of amphetamine ............................................................. 
25 
Figure 3-5: - Metabolic pathways for Amphetamine .......................................................... 
26 
Figure 3-6: - Chemical structure of methamphetamine .................................................... 
26 
Figure 3-7: - Metabolic pathways for Methamphetamine .................................................. 
27 
Figure 3-8: - Chemical structure of Cocaine ...................................................................... 
27 
Figure 3-9: - Metabolic pathways for Cocaine ................................................................... 28 Figure 3-10: -Chemical structure of Morphine showed with its heterocyclic rings 
distinguished 
............................................................................................................ 
29 
Figure 3-11: - Pathways for metabolism of selected opioids .............................................. 31 Figure 3-12: - Chemical Structure of delta-9-tetrahydrocannabinol ................................... 32 Figure 3-13: -Metabolic pathways for THC ....................................................................... 33 Figure 4-1: - Typical silylation reaction, in which A represents ......................................... 37 Figure 4-2: - Derivatisation by Silylation Reaction ............................................................ 37 Figure 4-3: - Typical acylation reaction ............................................................................. 40 Figure 4-4: - Typical alkylation reaction, where RI and R2 are organic groups ................. 41 Figure 4-5: - Pentafluorobenzyl bromide (left) and N, N-Dimethylformamide (right)........ 42 
Figure 4-6: - Structure of PFPA anhydride ........................................................................ 44 Figure 4-7: - Structure of PFP-OH alcohol ........................................................................ 44 Figure 4-8: - Structure of trimethylsilyl-diazomethane ...................................................... 44 Figure 4-9: - Structure of MTBSTFA+1% TBDMCS ...................................................... 45 Figure 4-10 :- Amphetamine and Amphetamine-d5 .......................................................... 45 Figure 4-11: - Methamphetamine and Methamphetamine-d5 ............................................. 46 Figure 4-12: - Morphine and Morphine-d3 ........................................................................ 46 Figure 4-13: - Benzoylecgonine and Benzoylecgonine- d3 ................................................. 46 Figure 4-14: - THC-OH and THC-OH-d3 .......................................................................... 46 Figure 4-15: - THC-COOH and THC-COOH-d3 ............................................................... 47 Figure 4-16: - Microwave Oven ........................................................................................ 48 Figure 4-17: - TIC Chromatograms and Mass Spectra for test drugs following reaction with 
PFPA, PFP-OH and ethyl acetate ............................................................................. 52 Figure 4-18: - Mass Spectrum of Amphetamine -PFP ....................................................... 55 Figure 4-19: - Mass Spectrum of Methamphetamine -PFP ................................................ 56 
List of Figures xi 
Figure 4-20: - Fragmentation of Amphetamine PFP derivative .......................................... 56 Figure 4-21: - Fragmentation of Methamphetamine PFP derivative ................................... 56 Figure 4-22: - Mass Spectrum of Morphine - PFP ............................................................ 58 Figure 4-23: - Fragmentation of Morphine PFP derivative ................................................ 58 Figure 4-24: - Mass spectrum of Benzoylecgonine -PFP ................................................... 59 Figure 4-25: - Fragmentation of Benzoylecgonine PFP derivative ..................................... 60 Figure 4-26: - Mass Spectrum of THC-OH-PFP ................................................................ 61 Figure4-27: -Fragmentation of THC-OH PFP derivative ................................................... 61 Figure 4-28: - Mass Spectrum of THC-COOH PFP derivative ........................................ 62 Figure 4-29: - Fragmentation of THC-COOH PFP derivative ........................................... 63 Figure 4-30: - TIC chromatogram of amphetamine PFP derivative .................................... 
66 
Figure 4-31: - TIC chromatogram of methamphetamine PFP derivative ............................ 
66 
Figure 4-32: - TIC Chromatogram and Mass Spectrum for Morphine-PFP ........................ 
66 
Figure 4-33: - Selected ion chromatograms for benzoylecgonine methyl ester (cocaine).... 67 
Figure 4-34: -TIC chromatogram for THC-OH PFP derivative .......................................... 
67 
Figure 4-35: - TIC chromatogram for THC-COOH PFP/methyl ester derivative ............... 
67 
Figure 4-36: - Mass Spectrum Benzoylecgonine PFP-TMS-diazomethane derivative 
(Cocaine) 
................................................................................................................. 68 Figure 4-37: - Fragmentation for benzoylecgonine PFP/TMS- diazomethane derivative 
(cocaine) 
.................................................................................................................. 69 Figure 4-38: - Mass Spectrum for THC-OOOH-PFP-TMS-diazomethane ......................... 70 Figure 4-39: - Fragmentation for THC-COOH-PFP/TMS- diazomethane .......................... 71 Figure 4-40: - TIC Chromatogram for Amphetamine -TBDMS, (A) without Catalyst (B) 
with Catalyst ........................................................................................................... 73 Figure 4-41: - Ion Chromatogram for m/z 158 and Mass Spectrum for Amphetamine - 
TBDMS 
................................................................................................................... 74 Figure 4-42: - Fragmentation of Amphetamine -TBDMS .................................................. 75 Figure 4-43: - TIC Chromatogram and Mass Spectrum for Morphine-TBDMS (also 
containing the internal standard Morphine-d3) .......................................................... 76 Figure 4-44: - Fragmentation of Morphine-bis-TBDMS derivative ................................... 77 Figure 4-45: -Ion Chromatogram m/z 282 and Mass Spectrum for Benzoylecgonine 
TBDMS (also containing the internal standard Benzoylecgonine-d3) ........................ 78 Figure 4-46: - Fragmentation of Benzoylecgonine -TBDMS ............................................. 79 Figure 4-47: - TIC Chromatogram and Mass Spectrum for THC-OH TBDMS .................. 80 Figure 4-48: - Fragmentation of THC-OH-TBDMS .......................................................... 81 Figure 4-49: - Ion Chromatogram m/z 515 and Mass Spectrum for THC-COOH TBDMS 82 
Figure 4-50: - Fragmentation of THC-COOH-TBDMS ..................................................... 83 Figure 5-1 :- Components of an analytical method ........................................................... 86 Figure 5-2: - strata X ..................................................................................................... 88 Figure 5-3: - Calibration curve for Amphetamine analysed as the PFP derivative .............. 95 Figure 5-4: - Calibration curve for Methamphetamine analysed as the PFP derivative....... 96 
Figure 5-5: - Calibration curve for Morphine analysed as the bis-PFP derivative ............... 96 Figure 5-6: - Calibration curve for Benzoylecgonine analysed as the PFP ester derivative. 97 
Figure 5-7: - Calibration curve for THC-OH analysed as the PFP derivative ..................... 97 Figure 5-8: - Calibration curve for THC-COOH analysed as the PFP/PFP ester derivative 97 Figure 5-9: - Recoveries of drugs from blood using StrataTMX and analysed as the PFP- PFP-OH derivatives 
......... ............................................................................... 102 Figure 5-10: - Recovery of methamphetamine from blood using Strata TM X and analysed after derivatisation with PFPA-PFP-OH and PFPA/Methyl ester ............................ 109 Figure 5-11: - TIC Chromatogram blank for Strata Tm X SPE (A) with 1 ml methanol (B) with 1.5 methanol ...................... ............................................................... ... 110 Figure 5-12: - Calibration curve for Amphetamine analysed as the PFP derivative.......... 112 
List of Figures xii 
Figure 5-13: - Calibration curve for Methamphetamine analysed as the PFP derivative... 112 
Figure 5-14: - Calibration curve for Morphine analysed as the bis-PFP derivative........... 113 
Figure 5-15: - Calibration curve for Benzoylecgonine analysed as the methyl ester 
derivative 
............................................................................................................... 
113 
Figure 5-16: - Calibration curve for THC-OH analysed as the PFP derivative ................. 
113 
Figure 5-17: - Calibration curve for THC-COOH analysed as the PFP/methyl ester 
derivative 
............................................................................................................... 
114 
Figure 5-18: - Recoveries of drugs from blood using Strata X ..................................... 
118 
Figure 5-19: - Calibration curve for Amphetamine-TBDMCS derivative ........................ 
125 
Figure 5-20: - Calibration curve for Benzoylecgonine-TBDMCS derivative .................... 
125 
Figure 5-21: - Calibration curve for THC-OH-TBDMCS derivative ................................ 
126 
Figure 5-22: - Calibration curve for THC-COOH-TBDMCS ........................................... 
126 
Figure 5-23: - Recoveries of drugs from blood using strata X and analysed as the 
TBDMS derivative 
................................................................................................. 
129 
Figure 6-1 Ketone Bodies 
.............................................................................................. 
138 
Figure 6-2: - The cells produce ketone bodies for energy ................................................ 
139 
Figure 6-3: - Chemical structures of GABA and GHB ..................................................... 
140 
Figure 6-4: - Chemistry and Synthesis Sodium Gamma-Hydroxy Butyrate (NaGHB)..... 140 
Figure 6-5: - GABA metabolism to GHB in body ........................................................... 
141 
Figure 6-6: - Metabolism of 1,4 BD to GHB in the body ................................................ 
142 
Figure 6-7: - Major metabolic sources of acetyl CoA ...................................................... 
142 
Figure 6-8: - First step is formation of acetoacetate-CoA ................................................ 
143 
Figure 6-9: - Second step is formation of 3-hydrox-3-methlglutaryl-CoA 
(1 MG CoA) 
... 
143 
Figure 6-10: - Third step is formation of acetoacetate and acetyl CoA ............................. 
144 
Figure 6-11: - Fourth step is formation of B-hydroxybutyrate ......................................... 
144 
Figure 6-12: - Formation of acetone from acetoacetate by decarboxylation ..................... 
144 
Figure 6-13: - Chemical structure of BSTFA ................................................................... 
147 
Figure 6-14: - UCT-GHB-SPE Solid Phase Extraction .................................................... 
149 
Figure 6-15: - SIM Chromatograms for GHB .................................................................. 150 
Figure 6-16: - (a) Selected ion chromatograms from repetitive full scan GC-MS and (b) 
mass spectrum for GHB (M248) - TMS derivative ................................................ 151 
Figure 6-17: - Fragmentation for GHB TMS derivative ................................................... 152 
Figure 6-18: - Scatter plot of blood alcohol concentration versus blood BHB concentration. 
............................................................................................................................... 163 
Figure 6-19: - Scatter plot of blood alcohol concentration versus blood GHB concentration. 
............. .................................................................................................................. 
164 
Figure 6-20: - Scatter plot of blood BHB concentration versus blood GHB concentration. 
............................................................................................................................... 164 Figure 6-21: - GHB and BHB combined with alcohol ..................................................... 165 Figure 7-1: - General benzodiazepine structure ............................................................... 170 Figure 7-2: - Structures of some benzodiazepines ............................................................ 171 Figure 7-3: - Metabolic pathway of diazepam ................................................................. 172 Figure 7-4: - Ion Chromatogram and Mass Spectrum for Temazepam with PFPA-PFP-OH 
............................................................................................................................... 175 Figure 7-5: - Chromatogram and Mass Spectrum for Temazepam with TBDMS ............. 176 Figure 7-6: - Chromatogram and Mass Spectrum for Oxazepam with PFPA- PFP-OH .... 
177 
Figure 7-7: - Chromatogram and Mass Spectrum for Oxazepam with TBDMS (also 
contains oxazepam-d5) ........................................................................................... 178 Figure 7-8: - Chromatogram and Mass Spectrum for Desmethyldiazepam with TBDMS 179 
Figure 7-9: - Chromatogram and Mass Spectrum for Diazepam with PFPA - PFP-OH (also 
contains diazepam-d5) ............................................................................................ 180 
PAGE 
NUMBERING 
1 
AS ORIGINAL 
List of Tables v 
List of Tables 
Table 4-1: - Conditions for GC-MS ...................................................................................... 
49 
Table 4-2: - Results of derivatisation reactions ..................................................................... 
53 
Table 4-3: - retention and migration of charge ..................................................................... 
57 
Table 4-4: - Selected Ions used for GC/MS-SIM with PFPA-TMS-Diazomethane ............. 
65 
Table 4-5: - Selected Ions used for GC/MS with MTBSTFA 
derivatisation ........................ 
72 
Table 5-1: - Final concentrations of drug standards ............................................................. 
92 
Table 5-2: -Summary of Values of correlation coefficient 
(R2) for all compounds analysed 
as the PFP-PFP-OH derivatives ................................................................................... 
95 
Table 5-3: - Intra-Day variation for Amphetamine and Methamphetamine analysed as 
the 
PFP-PFP-OH derivatives ............................................................................................. 
98 
Table 5-4: - Intra-Day variation for Morphine analysed as the 
bis-PFP derivative .............. 
98 
Table 5-5: - Intra-Day variation for Benzoylecgonine analysed as the 
PFP ester derivative 
...................................................................................................................................... 
99 
Table 5-6: - Intra-Day variation for THC-OH and THC-COOH analysed as 
the PFP/PFP 
ester derivatives ............................................................................................................ 
99 
Table 5-7: - Inter-Day variation for Amphetamine and 
Methamphetamine analysed as the 
PFP derivatives .......................................................................................................... 
100 
Table 5-8: - Inter-Day variation for Morphine analysed as the 
bis-PFP derivative............ 100 
Table 5-9: - Inter-Day variation for Benzoylecgonine analysed as the 
PFP ester derivative 
.............................................................................. ...................................................... 
luu 
Table 5-10: - Inter-Day variation for THC-OH and THC-COOH analysed as 
the PFP/PFP 
ester derivatives .......................................................................................................... 
101 
Table 5-11: - Recovery of six drugs analysed as PFPA-PFP-OH 
derivatives .................... 
102 
Table 5-12: - Limits of Detection and Limits of 
Quantitation of the six drugs analysed as 
the PFP-PFP-OH derivatives ...................................................................................... 
103 
Table 5-13: - Results of GC/MS for drug-positive cases analysed as 
PFPA-PFP-OH 
derivatives .................................................................................................................. 
104 
Table 5-14: - Results of GC/MS analysis of extracts containing other 
drugs using PFP/PFP- 
OH reagent ................................................................................................................. 
106 
Table 5-15: - Recovery, intra and inter-day assay precision with PFPA-PFP-OH at 
different 
concentration .............................................................................................................. 
107 
Table 5-16: - Correlation coefficient (R2) for calibration curves for all compounds analysed 
as the PFP/methyl ester derivatives ........................................................................... 
112 
Table 5-17: - Intra-day variation for Amphetamine and Methamphetamine analysed as the 
PFP derivatives .......................................................................................................... 
114 
Table 5-18: - Intra-day variation for Morphine analysed as the PFP derivative ................. 115 
Table 5-19: - Infra-day variation for Benzoylecgonine analysed as its methyl ester.......... 115 
Table 5-20: - Intra-day variation for THC-OH and THC-COOH analysed as their 
PFP/methyl ester derivatives ...................................................................................... 115 
Table 5-21: -Inter-day variation for Amphetamine and Methamphetamine analysed as their 
PFP derivatives .......................................................................................................... 116 
Table 5-22: -Inter-day variation for Morphine analysed as the bis-PFP derivative............ 116 
Table 5-23: - Inter-day variation for Benzoylecgonine analysed as the methyl ester 
derivative .................................................................................................................... 116 
Table 5-24: -Inter-day variation for THC-OH and THC-COOH analysed as the PFP/methyl 
ester derivatives ........................................... 117 ............................................................... 
Table 5-25: - Recovery for six drugs analysed as the PFP/methyl ester derivatives .......... 117 Table 5-26: - LOD and LOQ for Test Drugs analysed as the PFP/methyl ester derivatives 
.................................................................................................................................... 118 
List of Abbreviations 
List of Abbreviations 
AM 
BZE 
BHB 
EI 
EDDP 
Amphetamine 
Benzoylecgonine 
Beta-hydroxybutyrate 
Electron Impact 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
GHB Gamma-hydroxybutyrate 
GC-MS Gas Chromatography-Mass Spectrometry 
LOD limit of detection 
LOQ limit of quantitation 
R2 Linear Correlation Coefficient 
m/z mass-to-charge ratio 
METH Methamphetamine 
µg/ml micrograms per millilitre 
mg/ml milligrams per millilitre 
MW molecular weight 
MOR Morphine 
ng/µl nanograms per microlitre 
MTBSTFA +1% TBDMCS N-Methyl-N-(tert-butyl-dimethylsilyl)-trifluoroacetamide 
+1% Tert-butyl-dimethylchlorosilane 
BSTFA N, O-Bis-trimethylsilyl-trifluoroacetamide 
THC-COOH 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid 
PFPA Pentafluoropropionic anhydride 
PFP-OH 2,2,3,3,3-pentafluoro-propanol 
List of Tables vi 
Table 5-27: - Results of GC/MS for cases analysed using the PFP/TMS diazomethane 
reagent ........................................................................................................................ 119 Table 5-28: - Results of GC/MS analysis of extracts containing other drugs using PFP/TMS 
diazomethane reagent ................................................................................................. 121 Table 5-29: - Accuracy, intra and inter-day assay precision for the test substances analysed 
at different concentrations with PFPA-TMS-diazomethane derivatisation .............. 123 Table 5-30: - Correlation coefficients (R2) for all compounds analysed as TBDMS 
derivatives 
.................................................................................................................. 
125 
Table 5-3 1: - Intra-Day variation for Amphetamine analysed as the TBDMS derivative.. 127 
Table 5-32: - Intra-Day variation for Benzoylecgonine analysed as the TBDMS derivative 
.................................................................................................................................... 127 
Table 5-33: - Intra-Day variation for THC-OH/THC-COOH analysed as the TBDMS 
derivatives 
.................................................................................................................. 
127 
Table 5-34: - Inter- Day variation for Amphetamine analysed as the TBDMS derivative. 128 
Table 5-35: - Inter- Day variation for Benzoylecgonine analysed as the TBDMS derivative 
.................................................................................................................................... 
12 8 
Table 5-36: - Inter- Day variation for THC/THC-COOH ................................................... 
128 
Table 5-37: - Recovery for test substances analysed as MTBSTFA derivatives ................ 129 
Table 5-38: - Limits of detection and quantitation for TBDMS derivatives ...................... 130 
Table 5-39: - Results of GC/MS for cases analysed with MTBSTFA derivatisation......... 130 
Table 5-40: - Accuracy, intra and inter-day assay precision with MTBSTFA at different 
concentration .............................................................................................................. 
132 
Table 6-1: - Preparation of different concentrations of GHB ............................................. 147 
Table 6-2: - Preparation of different concentrations of BHB ............................................. 148 
Table 6-3: - selected Ions used for GC-MS SIM ................................................................ 150 
Table 6-4: - Recovery for GHB .......................................................................................... 155 
Table 6-5: - Limit of Detection and Quantitation for GHB ................................................ 156 
Table 6-6: - Inter-Day precision .......................................................................................... 157 
Table 6-7: - Intra-Day Precision ......................................................................................... 157 
Table 6-8: - Recovery of BHB from blood samples ........................................................... 158 
Table 6-9: - Limits of Detection and Quantitation .............................................................. 159 
Table 6-10: - Intra-Day precision ........................................................................................ 159 
Table 6-11: - Inter-Day precision ........................................................................................ 160 
Table 6-12: - Results of GC/MS analysis of cases for GHB/BHB ..................................... 160 Table 6-13: - Statistical summary of the four groups: ........................................................ 165 Table 6-14: - P-values from T-test comparison of the four groups: ................................... 166 Table 7-1: - Chemical structures of selected 1,4-benzodiazepine ..................................... 170 Table 7-2: - Pharmacokinetic data of some of benzodiazepines of interest ........................ 173 Table 7-3: - Retention times and selected ion data for diazepam and its metabolites with 
different derivatising reagents .................................................................................... 186 
List of Abbreviations xvi 
pKa pH at which 50% of the analyte is ionised and 50% is non- 
ionised. 
SIM Selected Ion Monitoring 
SPE Solid Phase Extraction 
Strata X SPE Solid phase extraction with Strata XrM 
STA 
THC-OH 
D3 
TMCS 
TMS 
systematic toxicological analysis 
delta-9-Tetrahydrocannabinol 
tri-deuterated 
Trimethylchlorosilane 
Trimethylsilyl-diazomethane 
Chapter One 
I Introduction 
1.1 Toxicology 
Page 1 
Toxicology is the study of poisons which affect the function of the body and can 
cause deatht131. Forensic toxicology is part of general toxicology in which the 
results of toxicological analysis are used in legal proceedings. It is a branch of 
science that incorporates many areas of knowledge including pharmacology, 
analytical and organic chemistry, physiology and pathology. Traditionally, the 
forensic toxicology laboratory analyses biological specimens for the presence of 
alcohol, drugs and other toxic compounds as part of post-mortem investigations[49] 
However, the field now also includes samples from living subjects, such as clinical 
cases, workplace drug testing and road traffic cases"o, 111, The toxicology laboratory 
performs qualitative and quantitative chemical analysis of tissues and body fluids 
to determine the presence or absence of drugs and other toxic substances [12-19]. 
Drugs and poisons can be classified according to the method used for extraction. 
Seven major groups are usually considered: gases, volatile substances, drugs, 
metals, pesticides, anions and miscellaneous substances (Figure 1-1). 20,211 
Poisons 
Group 3. Drugs 
Group 5. Pesticides, 
Group7. Miscellaneous substances 
Group 2. Volatile substances 
Group 4. Metals 
Group 6. Anions 
.f 
Figure 1-1: -The seven major groups of poisons. 
Samples submitted to the toxicology laboratory for analytical tests can include 
blood, urine, stomach contents, tissues from all body organs, hair, nails, and, from 
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living subjects, oral fluid. Blood consists of plasma (55% by volume) and cells 
(45% by volume) [221 There are three types of cells: the white blood cells, which are 
part of the immune response against bacteria and other invading organisms, red 
blood cells, which transport oxygen and carbon dioxide, and platelets, which are 
important for normal blood clotting (haemostasis)1221 In general, the blood has 
many functions as it delivers nutrients from the digestive system, transports oxygen 
from the lungs to all of the cells in the body, transports waste from the body to the 
excretory organs, and carries hormones from the endocrine glands to target tissues 
to regulate body temperature and fluid balance, amongst others. [231 Blood is 
considered very important in forensic toxicology as it can indicate the amount of 
drug in the system at time of death and blood concentrations of drugs and poisons 
can in principle be interpreted in terms of their probable toxicity hazard by 
comparing them with published or in-house data for clinical subjects and post- 
mortem cases. 161 The amount of blood in the body is usually five litres (about 7% 
of body weight) and the normal pH of blood is slightly alkaline, ranging between 
7.3-7.4. The toxicology laboratory routinely receives blood samples of more than 5 
ml in volume. However, sometimes only small volumes of blood are available, as 
with live patients, especially infants and children, or conversely from much 
decomposed bodies: this makes it difficult to do a full toxicological screen. 
1.2 Systematic Toxicological Analysis (STA) 
Forensic systematic toxicological analysis is essentially a logical sequence of 
analytical methods which are applied to samples in order to detect and (usually) 
quantify a wide range of exogenous materials, including drugs and other chemical 
substances. 11124291 This is in contrast to an analytical method which targets a 
specific substance, such as alcohol or carbon monoxide. STA is an important part of 
forensic toxicology since, in many cases; no information is available concerning 
which poisons may be present. The International Association of Forensic 
Toxicologists (TIAFT) has a specialist committee on STA. 125' 30-331 
Until recently, gas chromatography - mass spectrometry (GC-MS) was considered 
the most useful technique for identifying and quantifying poisons, including drugs of 
abuse. However, in the last few years, LC-MS-MS has become more widely 
available, more reliable and less expensive than previously and in future may replace 
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GC-MS as the analytical method of choice. 0"' Nevertheless, many laboratories 
still depend on GC-MS as their gold standard technique, lacking equipment for LC- 
MS-MS. There remains a lot of interest and a great deal to be obtained by extending 
the capabilities of GC-MS in STA as far as possible as it provides higher 
chromatographic resolution than is currently available by liquid chromatography, is 
often more sensitive than LC-MS-MS and is more useful for screening for unknowns 
because of its library search capabilities. 147-571 
The limitations of GC-MS frequently result from thermal instability of analytes 
resulting in turn from their chemical structures. Some drugs contain polar functional 
groups which are thermally unstable and which will interact with the column or 
injection port, affecting peak shape and sensitivity. The most common approach to 
overcoming this problem is to modify the analytes chemically, usually referred to as 
chemical derivatisation. 1581 Derivatisation improves separation and reduces tailing 
by increasing volatility, reducing polarity and increasing thermal stability. 
Depending on the functional group present, different derivatising mechanisms can 
be used, namely, silylation, acylation and alkylation, including methylation 
(esterification). For the analysis of drugs of abuse, individual extraction and 
derivatising procedures are required because different drugs need to be derivatised in 
different ways depending on the functional groups present. This is a major 
disadvantage because of the time required to identify and quantify a wide range of 
drugs. If a unified approach to the toxicological analysis could be developed which 
allows the detection of a wide range of substances of medicolegal interest in a 
minimum number of chromatographic analyses, this would be greatly advantageous 
in terms of time saved. 1591 
1.3 Aims and Objectives 
The aim of this project was to investigate the possibility of creating a unified 
analytical approach to toxicological screening. Different derivatising agents would 
be investigated using selected drugs of abuse with different functional group 
chemistry as model compounds. Based on the results of the evaluation of 
derivatisation chemistries, a method for the simultaneous detection and quantitation 
of multiple drugs and metabolites using only 1 ml of sample would be developed 
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and validated. The derivatives would also be evaluated for their use with 
benzodiazepines commonly encountered in forensic toxicology. 
A particular application of derivatisation chemistry would also be investigated. 
Gamma-hydroxybutyrate (GHB) and beta-hydroxybutyrate (BHB) are endogenous 
to the human body and there is a relationship between GHB and BHB. When BHB 
concentrations are elevated, it can significantly inhibit the metabolism of GHB. [601 
GHB has been abused recreationally for relaxation effects [61] and also has reputedly 
been used for drug facilitated sexual assault because of its sedative and amnesic 
effects at high doses. [62-651 BHB is one of the "ketone bodies" present in the body, 
the others being acetone and acetoacetate. When blood alcohol concentrations in 
the body are high, this will increase the production of BHB. This in turn increases 
the blood pH, causing death as a result of ketoacidosis. By measuring BHB in 
blood the forensic pathologist can obtain additional information to assist in 
assigning the cause of death in known alcohol abusers. The aim of this part of the 
project was to investigate and validate methods for the simultaneous determination 
of GHB and BHB in small blood samples, with particular emphasis on short 
processing times. 
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2 Gas Chromatography - Mass Spectrometry 
2.1 Introduction 
Gas chromatography-mass spectrometry (GC-MS, Figure 2-1) is an instrumental technique 
used in analytical chemistry which can separate, identify and quantify chemical substances 
in samples containing complex mixtures of substances, such as those extracted from 
biological specimens used in forensic toxicology. l"01 GC-MS dynamically combines two 
techniques: gas chromatography (GC) which can separate the chemical mixtures into their 
separate chemical components and mass spectrometry (MS) which can identify and 
quantify the chemicals. It is a sensitive technique which has the ability to detect low 
concentrations of analytes. The use of chromatographic techniques to introduce samples 
dynamically to the mass spectrometer (as opposed to an off-line method of trapping 
materials eluting from the GC column and introducing them on a sample probe) first 
appeared in the 1960's, when all gas chromatography was performed using packed 
columns. The initial problem that needed to be solved was to remove the carrier gas, which 
for packed columns had a flow rate of 30 ml/min, which would destroy the vacuum needed 
for efficient mass spectrometry. The Ryhage jet separator achieved this but the problem 
subsequently disappeared when capillary columns became routinely available, as the 
pumping system used to maintain the vacuum in the mass spectrometer could easily cope 
with their flow rate of 1-2 ml/min. [71-91] 
Gas chromatographic analysis is, however, restricted to a fairly narrow range of 
compounds which: 
" are relatively volatile, having boiling points generally below 400°C. Substances 
with very high boiling points are usually not amenable to assay by GC-MS. 
" Have low molecular weights, generally below 500 Daltons. 
" Are relatively non-polar compounds. GC columns often have, or develop, 
undesirable active sites that interact with polar compounds, 
" Are thermally stable: The bulk of GC analysis relies on the injection of samples 
into a vaporising inlet and thermally unstable compounds are liable to breakdown at 
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such temperatures, often resulting in inlets contaminated with non-volatile matrix 
products. 
Despite its great capabilities, GC-MS has some disadvantages: most analyses are time 
consuming and involve labour-intensive steps. [71,80,821 
The separate techniques and principal applications of GC-MS are considered to be very 
important for drugs of abuse, and because of that, this section will provide details about 
gas chromatography and mass spectrometry. 
Figure 2-1: - A modem instrument for Gas Chromatography - Mass Spectrometry 
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2.2 Chromatography: Overview 
Pump or 
Gas cylinder 
-Do 
Source of mobile phase 
Sample 
Inl 
ým 
Column 
r= 
Oven 
Detector Recorder 
eg: UV spectrometer for 
liquid chromatography or 
flame ionisation detector 
for gas chromatography 
Figure 2-2: - Components of a chromatograph 
Chromatography is a separation method that is used in many branches of science (Figure 2- 
2). It was invented by the Russian botanist Mikhail Tswett. 166 ' 801 He used the word 
chromatography to describe this technique, deriving it from two Greek words, chroma 
meaning colour and graphy meaning to write. [66' 831 
Chromatography basically involves the separation of a mixture of components due to 
differences in equilibrium distribution of sample components between two different 
phases. One of these phases is a mobile phase that does move and the other one is a 
stationary phase that does not move. All chromatographic separations are governed by 
distribution constant (KD, see para 2.2.2) 
Chromatography has advantages as it can separate very complex mixtures, cope with very 
small sample volumes, separated components can be collected individually and analyses 
can be highly accurate and precise. 1801 It is used for determining concentrations where each 
chromatographic peak in a chromatogram corresponds to a separate component and 
therefore the area of each peak is proportional to its amount (Figure 2-3). [71.80] There are 
general factors which will increase resolution, which describes the degree with which 
adjacent peaks are separated: longer column lengths, smaller column diameters, decreased 
flow rates, uniform stationary phase particle size (packing material in packed column 
chromatography), decreased sample size, selection of the correct stationary and mobile 
phases, using the correct pressure and using gradient elution. There are terms and symbols 
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which are very important for chromatography such as those described in the following 
'[71paragraphs. ý 80,84] 
sample injection point 
A 
detector 
signal 
Figure 2-3: -Chromatogram nomenclature 
retention time 
of component 1 
void time 
2.2.1 Retention time 
This is the time taken after sample injection for an analyte peak to reach the detector and is 
denoted by the symbol t, [661 
2.2.2 Distribution constant (KD) 
The distribution constant KD is equal to the ratio of the concentrations of the solute C in 
stationary phase CS divided by concentration in the mobile phases CM (Figure 2-4). 
KD =C s/ CM 
Figure 2-4: - Distribution Constant 
The value of KD should remain constant across a wide range of solute concentrations 
where difference KD to affect on the migration rates of solutes through a Column [80,83, Bad 
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2.2.3 Column 
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When selecting an analytical column, the basic choices to be made are in the stationary 
phase, column diameter, length and the thickness of stationary phase or stationary phase 
loading. 171,801 A non polar stationary phase is often the most useful in analytical 
toxicology. The highest resolution is afforded by the narrowest columns with the thinnest 
stationary phase. Thin film, narrow bore columns are especially good for separating 
mixtures of high-boiling-point compounds that are retained too strongly on thick film 
columns. Short retention times provide high-speed analyses. However, thin film, narrow 
bore columns have very low sample capacity and require high sensitivity detectors. Thick 
film, narrow bore columns can be used with most detectors and with compounds of high 
volatility. Retention times are longer than on thin-film columns. Thick-film, wide-bore 
columns are required for use with thermal conductivity and infrared detectors. These 
detectors are relatively insensitive and require relatively large sample sizes to be loaded on 
the column, which usually requires the higher sample capacity of a thick film column. 
Columns used in gas chromatography are further discussed in section 2.3.3.172,80,851 
2.2.4 Detectors 
The detector can provide information on each compound as it elutes from the column. Its 
signals are proportionate to the quantity of each solute, making quantitative analysis 
possible (Figure 2-5). 1801 
Analyte Internal 
Standard 
Standard 
chromatogram 
Standard Ratio= AJA, 
Sample Ratio= A/A, 
Analyte concentration = Standard Sample ratio in sample concentration x Standani ratio 
Figure 2-5: - Determination of analyte concentration 
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The most common detector is the flame ionisation detector (FID) but there are many other 
detectors such as the mass selective detector (MSD), the nitrogen-phosphorus detector 
(NPD), the electron capture detector (ECD), the flame photometric detector and the 
thermal conductivity detector (TCD). A common detector now is the mass spectrometer 
(MS), which will be explained in more detail in Section 2.4 F2861 
2.3 Gas Chromatography 
2.3.1 Introduction 
Gas chromatography is one of the most widely used analytical techniques for quantitative 
analysis. 172,871 Gases are used in gas chromatography as the mobile phase which transports 
the sample components through the column to the detector. Selection of the best carrier 
gas is important, because it affects both the column separation processes and detector 
performance. The carrier gas which is used should be inert chemically with respect to the 
column materials and sample components as well as being dry and free of oxygen. The 
carrier gas should be of high purity because impurities such as oxygen and water can 
chemically attack the liquid phase in the column and ultimately destroy the column. Gases 
with the smallest diffusion coefficients such as hydrogen (H2) and helium (He) which are 
widely used will give better separation efficiencies than higher molecular weight gases 
such as nitrogen (N2), carbon dioxide (C02) and argon (Ar). 180' 881 The ratio of viscosity to 
diffusion coefficient should be a minimum for rapid analysis. The choice of gas is often 
dictated by the type of detector. Generally, gas chromatography consists of three major 
components: an injection system, a chromatographic column and a detector. 189-911. 
2.3.2 Injection system: 
The sample injection port is connected to the top of the column and should be hot enough 
to vaporize the sample rapidly. The most common introduction techniques are split and 
splitless injection modes. Split injection can be considered to be the oldest and simplest 
technique (Figure 2-6). This procedure involves injection of approximately 1µl of the 
sample into a heated injection port and usually 1-2% of the vapour enters the column with 
the rest being lost to the waste outlet. There are advantages to split injections as the 
sample amount introduced to the column is very small, flow rate up to the split point is 
fast, there is no need to dilute the sample and the samples can be introduced by putting a 
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plug of deactivated glass wool in the inlet liner to trap non volatile compounds. One 
disadvantage is that trace analysis is limited. [721 
Syringe 
seplum 
102 mUmný 2 mL/mný 
F, 
mA-/min 
septum 
purge 
II mUmin 
ýUf 
Split IL"ef 1 
Cdý mUmin 
1 mUminI 
Split ir"cbon 
1 mVminI 
Spmmeee injection 
Figure 2-6: - Split Injection Mode. Figure 2-7: - Splitless 
Injection Mode. 
In splitless injection (Figure 2-7), the injector is kept hot enough to vaporize the specimen 
and solvent, but the column temperature remains below the boiling point of the analyte. It 
uses the same hardware as split injection, but the split valve is closed when the sample is 
injected. The sample is diluted with a volatile solvent and I to 51il is injected in the heated 
injection port. The big advantage of splitless injection is the improved sensitivity over 
spilt injection and it is commonly used in trace analysis. There are some disadvantages, 
for Split 
, 
it is time-consuming as each chromatographic analysis starts with a cold column 
and uses a temperature programme, and also the sample must be diluted with a volatile 
solvent. 172,80,921. 
2.3.3 GC Column: 
Often the columns are coiled to allow housing within a fan-assisted thermostatically 
controlled oven. Two types of column are currently used in GC. Firstly, capillary columns 
(open tubular columns, Figure 2-8) which do not contain any packing material and are 
usually now constructed from fused silica with a polyimide protective coating. Fused 
silica capillary columns are extremely inert as the column wall is constructed of very high 
purity silica (<lppm metals). Resistance to flow is very low therefore long lengths, coiled, 
up to 100m are possible. Internal diameters are in the range 0.1-0.7 mm, with a very thin 
layer (0.1-5µm) of a liquid or solid stationary phase coated or chemically bonded to the 
surface of the inner wall. They can be used with both spilt and splitless injection systems. 
The sample volume capacity of a narrow bore column is < 0.1 µl, and the thinner the 
J-- 220°C 
ý-ý 
I0 mUmin 
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coating the greater the efficiency, but the lower the sample capacity before overloading 
causes peak tailing and deterioration of resolution. By contrast, megabore columns having 
an internal diameter of 0.5mm or more can accommodate sample volumes up to lOµ1. 
They are, however, less efficient, but have the highest sample capacity, so special injection 
techniques are not needed. The preferred carrier gas for capillary columns is helium or 
hydrogen. There are many advantages of capillary columns, such as they have very high 
efficiencies and resolving powers for complex mixtures of up to 100 or more components 
and solutes elute at lower temperatures than with corresponding packed column. However, 
capillary columns are expensive. [80,931 
Figure 2-8: - Capillary Column (open tubular) 
They can be further subdivided according to the method of supporting the stationary phase 
(Figure 2-9). [721 
Sta'. onary coated with 
licu: d sta"unary, 
Column wall 
Stationary 
soi! d-phase 
Wall-coated Support-coated Porous-layer 
open tubular open tubular open tubular 
column column column 
(WCOT) (SCOT) (PLOT) 
(c) 
Figure 2-9: - Types of Stationary Phase*rr4 
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1- Wall coated open tubular (WCOT) columns: 
These feature a 0.1-5 µm thick film of stationary liquid on the inner wall of the column and 
they provide the highest resolution of all gas chromatographic columns-1721 Tubing internal 
diameters commonly manufactured commercially are 0.1,0.2,0.3,0.32 and 0.53mm. 
Lengths typically vary from 10 to 50 meters. Thin films provide high resolution and fast 
analysis, but they have limited sample capacity. Thicker films have higher sample 
capacity but show lower resolution and are typically used for only very volatile 
compounds. They also having the advantage that direct injection techniques without 
splitting may be used. 1801 
2- Support coated open-tubular (SCOT) columns: 
This type of column has solid particles coated with the stationary liquid phase and attached 
to the inner wall. SCOT columns can hold more liquid phase and have a higher sample 
capacity than the thin films common to the early WCOT columns but SCOT columns are 
less efficient. SCOT columns are not available in fused silica. 1801 
3- Porous layer open-tubular (PLOT) columns: 
These contain a porous layer of a solid adsorbent such as alumina or molecular sieve. 
PLOT columns are well suited for the analysis of light fixed gases and other volatile 
compounds. PLOT columns represent a small proportion (<5%) of capillary columns in 
use. 1801 
2.4 Mass Spectrometry 
2.4.1 Introduction 
The general method of operation of a mass spectrometer is to create ions under vacuum 
then separate the ions based on their mass-to-charge (m/z) ratios and measure the quantity 
of ions of each mass-to-charge ratio. 1941 In 1919 Francis Aston produced the first mass 
spectrometer as an instrument for determining the mass of an atom. He examined positive 
ions from neon and found that there were two types of ion present, with relative isotopic 
masses of 20 and 21. He had found a way of separating and identifying isotopes. Since 
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then, the method has been developed so that it is now a very valuable tool for analysing 
atoms and molecules of gases, liquids and solids (Figure 2-10). 
Inlet I---N Ion Source 
Detector Mass Analyser 
Vacuum system 
Figure 2-10: - Components of a mass spectrometer 
Computer 
Mass spectrometry (MS) is a technique in which materials are ionized and dissociated into 
fragments characteristic of the molecules or elements present in the sample. The numbers 
of ions at each m/z value provide information for qualitative and quantitative analysis. It is 
considered to be the most powerful detector for gas chromatography because the 
spectrometer is sensitive to low concentrations of analyte 
[801 
2.4.2 Sample inlet: 
When the sample is not a gas or a volatile liquid, it has to be heated to produce a vapour 
before it can be introduced into the mass spectrometer. The exceptional sensitivity of the 
instrument means that only picograms of sample are required. 
2.4.3 Ion Source: 
Once inside, the vaporized sample is ionized by bombardment with high energy electrons. 
The bombarding electrons scatter electrons from the atoms or molecules in the sample, 
creating positively charged ions (Figure 2-11, Figure 2-12, Figure 2-13): 
M+e --> M+' + 2e 
Sample high - energy electron molecular ion 
These positive ions are expelled from the ion source into the mass analyser by the ion 
repeller plate, which is another metal plate carrying a slight positive charge. 1951 There are 
two common ionization methods used in GC-MS. 
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2.4.3.1 Electron Impact (EI) ionization 
The EI mass spectrum is obtained by the impact of a beam of electrons, usually generated 
from a tungsten filament, with the sample molecules in the gas phase, under vacuum. It is 
the oldest and best-characterized of all the ionization methods and it is usually considered 
to be a "hard" ionization method as sufficient energy is transmitted to the sample 
molecules to produce fragmentation in addition to simple ionisation. It can be used for 
GC-MS systems and direct inlet techniques. EI is best suited to relatively non-polar, 
volatile samples. An EI mass spectrum usually contains the molecular ion, M, and many 
fragment ions, making EI useful for structure characterization. A beam of electrons passes 
through the gas-phase sample. An electron that collides with a neutral analyte molecule 
gives a positively charged radical ion M. The ionization process can produce a molecular 
ion, which will have the same molecular weight and elemental composition as the starting 
molecule. The ionization potential is the energy required to produce a molecular ion. 
Most mass spectrometers use electrons with energy of 70 electron volts for EI, which is 
higher than the ionisation potential for most atoms or molecules and which results in the 
formation of energetic molecular ions containing enough excess energy to break internal 
bonds within the molecule and produce fragment ions. Decreasing the electron energy can 
reduce fragmentation but it also reduces the number of ions formed. The useful mass 
range for EI is generally up to 1,000 Daltons. [93' 961 
2.4.3.2 Chemical Ionization (CI) 
This is known as a "soft" ionization method because the analyte is ionized without the 
transfer of excessive energy to the resultant ions and few fragments are produced. CI uses 
ion-molecule reactions to produce ions from the analyte and often a CI mass spectrum 
contains a protonated molecule, [M+H]+, referred to as a pseudo-molecular ion. The 
chemical ionization uses a reagent gas such as methane, isobutane or ammonia at a 
relatively high pressure, which is ionized first by electron impact because of the large 
number of molecules of the gas which are present in the source. The high reagent gas 
pressure results in ion-molecule reactions between the reagent gas ions and uncharged 
reagent gas molecules. Some of the products of these ion-molecule reactions can react 
with the analyte molecules to produce analyte ions. The results depend on reagent gas 
type, reagent gas pressure or reaction time, and the nature of the sample. Because less 
fragmentation occurs in CI than with EI ionisation, a fragment pattern is obtained which is 
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not informative or reproducible enough for a library search. The mass range for CI is up to 
1,000 Daltons. CI is better suited than EI to more polar compounds. The sample is heated 
to generate gas phase molecules which undergo proton transfer reactions with the CI 
gas. [93,971 
Figure 2-11: -Ion source (electron impact) 
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Figure 2-12: -A plan view of the ion source 
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Figure 2-13: -Acceleration of ions from the ion source 
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2.4.4 Mass analyser: 
The original method of separating ions according to their mass-to-charge ratios used a 
magnetic field or a combination of magnetic and electrostatic fields. More recently, 
alternative methods have become more common and these include the quadrupole, time of 
flight and ion trap mass analysers. The work carried out for this thesis used a quadrupole 
instrument. 
In the original magnetic sector mass spectrometer, the positive ions formed are accelerated 
by an electric field of several thousand volts. The ions then enter a strong magnetic field, 
which deflects them by different amounts. The amount of deflection depends on firstly the 
mass of the ion - meaning lighter ions are deflected more than heavier ones, and secondly 
the charge on the ion - meaning ions with two or more positive charges are deflected more 
than ions with only one positive charge. These two factors are combined into the 
mass/charge ratio (m/z) (Figure 2-14). 
electromagnet 
1 
Figure 2-14: - Magnetic sector analyser 
When the magnetic field is correct for a particular m/z value, ions with this m/z ratio are 
deflected to the collector and recorded. By continuously varying ("sweeping") the 
magnetic field, each separated positive ion beam can be focused on the collector in 
sequential order of mass/charge ratio, to build up the mass spectrum. 
The quadrupole mass analyser is based on a quadrupole field created between four 
electrodes (the quadrupoles). Ions transit the quadrupole field at a velocity dependent on 
their mass, since each ion gains the same momentum during acceleration from the ion 
source. To enable the ions to transit the quadrupole region, the quadrupole field is switched 
in an alternating manner (at approximately radio frequency), otherwise the ions would 
simply collide with the quadrupole of opposite charge. The mass spectrum is recorded for 
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the desired range of m/z values by sweeping through a range of frequencies in the 
alternating quadrupole field. Major advantages of this type of analyser over the 
conventional magnetic sector include their smaller size, lower cost, lower operating 
voltages and ease of computer control. 
The time of flight mass analyser has recently come to the fore in the field of proteomics, 
for the analysis of peptides. As mentioned earlier, ions leave the ion source at velocities 
dependent on their masses, i. e. they are travelling at different speeds. It follows that the 
time taken for them to reach the detector, if they travel in a straight line, can be used to 
measure the m/z ratio. Literally this is the time of flight between source and detector. The 
start time of the flight must be precisely known also and this is obtained by using a pulsed 
ionisation process, usually involving a laser. 
2.4.5 Detector: 
Ions impinging on a detector surface contain a significant amount of energy and this is 
used to generate a more easily recorded material, usually electrons or photons, which are 
detected using an electron- or photo-multiplier. Both of these multipliers can enormously 
amplify the signal created by the ions themselves. This amplified signal is converted into 
digital form with a high frequency analogue-to-digital converter and relayed to the 
computer data acquisition system. 
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3 Drugs of Abuse: Pharmacokinetics and Drug 
Metabolism 
3.1 Introduction 
Model compounds were chosen for this study from amongst the major groups of abused 
drugs, including the amphetamines, cocaine, opioids and cannabinoids. The following 
sections review some basic concepts in pharmacology and some background information 
on these drug groups. 
3.2 Introduction to some pharmacological concepts 
Generally, the toxicological study of chemicals or drugs requires a basic knowledge of how 
they affect the biological system (pharmacodynamics) and how the biological system 
absorbs and disposes of them (pharmacokinetics). The field of pharmacodynamics is one 
of the most important in pharmacology science which involves studying the behaviour of 
substances in the blood, whether the effects are desired effects or toxic side-effects. 
[99-1021 
The people who take drugs may experience changes in mood and emotion, increase in 
body temperature, muscle tension, teeth clenching, nausea, anxiety, rapid eye movement, 
chills, sweating, faintness and blurred vision. However, the most serious health risks are 
depression, sleep problems, increase in heart rate and blood pressure, brain damage, 
muscle breakdown, liver damage, kidney failure, heart failure and psychological problems. 
People who need drug treatment have become addicted to drugs and have lost the ability to 
choose between using and not using the substance. Drug use becomes the only way that 
they feel normal. This is a very involved process, and we do not know exactly what each 
drug does. For example, alcohol is a drug and one of its effects is to dehydrate protoplasm. 
This prevents the cell wall from operating properly. This happens in every cell in the 
body, but it has its most noticeable effect on the central nervous system where it suppresses 
the higher cortical centres in the brain. This reduces a subject's normal ability to perceive 
the environment. There are many drugs of abuse but the more important ones will be 
discussed below as these were the model compounds used in this study. 1103,1°41 There are 
also terms which are very important for pharmacokinetics such as those described in the 
following paragraphs. 
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Pharmacokinetics includes absorption of the substances into the body, which describes 
how are the drugs absorbed through the skin, the intestine and the oral mucosa, 
distribution, which describes how the substances spread through the organism and 
elimination, which describes how the substances are metabolised and excreted (Figure 
3-1). 
Figure 3-1: - Pharmacokinetic characteristics of an orally absorbed drug 
11051 
Drugs can enter the body by several different routes including orally - by mouth, injection, 
or inhalation and by skin absorption. The transport of drugs across the plasma membrane 
of cells is one of the most important factors involved in delivery of drugs or other 
substances to the target organ. The cell is the basic building block of the body tissues. 
Each cell has a wall that protects the cell from harm, a nucleus which is the core of the cell 
and it also has a variety of other specialized parts with specialized functions called 
organelles. The nucleus contains deoxyribonucleic acid or DNA which determines how 
the cell is made and how it works. Drugs enter cells through the cell membrane, which is a 
phospholipids bilayer that is non-polar and so is hydrophobic. Most importantly, for the 
effective use of most drugs, non-polar molecules can cross cell membranes but less lipid 
soluble (lipophobic) molecules do not penetrate the lipid membrane and must enter cells by 
a different route, either by active transport or diffusion through specialised channels. 
When a weakly acidic or basic drug is administered to the body, the drug will ionise to a 
greater or lesser extent depending on the pK. and the pH of the body fluid in which it is 
dissolved. t1061 Therefore the degree of ionization of a drug is most often determined by the 
relationship between its pK. and the pH of its environment (as demonstrated in Equation 3- 
1 below). The pH of the body varies widely but the most important biological solution is 
the blood, which normally has a pH of 7.4. The relationship between pK. and the ratio of 
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acid-base concentration to pH is expressed by the Henderson-Hasselbach equation 
(Equations 3-2 and 3-3 as shown below). 1106-11°1 
pH = pKa - log 
non - protonated species 
protonated species 
Equation 3-1 
For acids: pH = pKa + log [ionized]/ [un-ionized] Equation 3-2 
For bases : pH =pKa + log [un-ionized]/ [ionized] Equation 3-3 
This equation is useful in determining how much drug will be found on either side of a 
membrane that separates two compartments that differ in pH. 
1101,1111 Examples of this 
include the absorption of drugs through the gastric mucosa (actually a series of membranes 
and layers) into blood. The pH of gastric juice is acidic (typically pH 3) and so basic 
drugs 
will be ionised (protonated) and therefore will be poorly absorbed from the stomach. By 
contrast, acidic drugs such as aspirin or ibuprofen will be largely non-ionised and will 
be 
more readily absorbed through the gastric mucosa. However, this situation is altered if an 
antacid is also administered, which increases the gastric pH. If the pH is increased by one 
unit, the percentage of a basic drug which is ionised will decrease by a factor of 10, which 
will affect its absorption from the stomach. Another common example is the effect of 
urine pH on the excretion of drugs. Basic drugs are more rapidly excreted through the 
kidney when the urine pH is acidic than when it is basic. 
3.2.1 Drug metabolism 
Drugs and other substances are usually metabolized by phase one reactions, which involve 
oxidation, reduction and hydrolysis processes which modify the molecule by changing the 
nature of a functional group or by adding a functional group. These can involve 
hydroxylation, oxidation and dealkylation routes of metabolism and may be considered 
degradation reactions. Phase two metabolism involves the production of compounds 
(conjugates) and may be considered conjugation reactions. Conjugation reactions often 
involve the addition of sulphuric acid or glucuronic acid to an existing functional group 
forming sulphates and glucuronides. However, other acids may be involved such as glycine 
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and glutamine conjugates. 1'°5' 1121 Phase two metabolism produces substances which are 
easily eliminated from the body through the kidney into the urine (Figure 3-2, and Figure 
3-3). 
Hydroxylation 
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Figure 3-2: - Phase I metabolic pathwaystlO 
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Figure 3-3: - Phase 2 conjugation reactionsn0m 
3.2.2 Clearance 
Clearance is a term that defines the ability of the body to remove a drug from one part of 
the body e. g. kidneys, liver. 1'°51 the most common definitions are the two expressions 
shown below in Equations 3-4 and 3-5: 
CL = dose / AUC Equation 3401051 
CL = KO /Css Equation 3-511051 
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Where CL is the clearance in ml/min, dose is the actual dose absorbed by the body, AUC is 
the area under the plasma drug concentration versus time curve, Ko is the infusion rate of 
the drug in a controlled clinical setting, delivering the drug intravenously, and Css is the 
steady state plasma concentration of the drug under these controlled conditions. 
Clearance will vary depending on the physiological state of the organs such that organ 
disease and organ damage may reduce clearance. 11051 The concept of clearance is also 
extremely useful in clinical pharmacokinetics because clearance of a given drug is usually 
constant over the range of concentrations encountered clinically. This is true because 
systems for elimination of drugs are not usually saturated and the absolute rate of 
elimination of the drug is essentially a linear function of its concentration in plasma. 
1113,114] 
3.2.3 Plasma half - life (Tyj: 
This is the most commonly used pharmacokinetic term in court. 1'°51 It defines the ability of 
the body to eliminate a drug from circulation in plasma and reflects how often a drug needs 
to be administered. The plasma half - life defines the time required for the body to remove 
50% of the drug from plasma after absorption and distribution are complete. The half - life 
is usually in hours, although some drugs have a half - life of minutes or weeks. The half - 
life is calculated from the slope of the terminal region of the plasma drug concentration 
versus time curve from Equation 3-6: 
Half - life = 0.693 /ß Equation 3-6 
Where ß is the slope of the terminal part of the plasma concentration versus time curve. 
The half - life of a drug is dependent on its volume of distribution and its clearance. 11051 
The half - life is useful in estimating the concentration of drug at an earlier time by back 
calculation, for example, a drug with a half -life of 12 h and a blood concentration of 2.0 
mg/L will be expected to have a concentration of 1.0 mg /L 12 h later. This will reduce to 
0.5 mg/L at 24 h and 0.125 mg/L after two days. 
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3.3 Amphetamine type stimulants 
CH2 
CH3 
I 
CH-NH2 
Figure 3-4: - Chemical structure of amphetamine (C, 1-113N, MW 135, pK. 9.9). 
Amphetamine (Figure 3-4) is used as a central nervous system stimulant in the treatment of 
certain conditions, such as attention deficit hyperactivity disorder, depression and 
narcolepsy and is abused illegally as a stimulant. It is a synthetic phenethylamine 
derivative available since 1935111s-1171. It appears as crystal, chunks and fine to coarse 
powders, off- white to yellow in colour, and is supplied loose or in capsules and tablets of 
various sizes and colours. The drug may be sniffed, smoked, injected or taken orally in 
tablet or capsule form. It is also a metabolite of a number of other drugs, including 
fenethylline, fenproporex and methamphetamine. The half-life of Amphetamine varies 
from a few hours to more than day depending on the value of the urine pH, where the half- 
life is normally 5-8 hours but decreases to 3-6 hours with low urine pH and increases to 9- 
16 hours with high urine pH. Y1051 Amphetamine is largely excreted unchanged but a 
percentage is also inactivated during metabolism, being deaminated to phenylacetone 
which is subsequently oxidized to benzoic acid and excreted as conjugates (Figure 3-5). 
However, a small amount is converted by oxidation to norephedrine and this compound 
and its parent are hydroxylated on the benzene ring in the pars position. Following a 
single oral dose of 10 mg of d-amphetamine sulphate in a 66 kg adult, the blood 
concentration reached a peak of about 0.035 mg/L at 2 hours and declined with a half- life 
of 11-13 hours. Urine amphetamine concentrations are usually less than 4.5 mg/L in adults 
given a single 20 mg oral dose, while a patient taking 30 mg daily on a chronic basis had 
urine concentrations of 1.1-18 mg/L and amphetamine abusers often have urine 
117 concentrations in the range of 10-100 mg/Lt"u°ý 
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Figure 3-5: - Metabolic pathways for Amphetaminen'83 
3.4 Methamphetamine 
CH3 
I 
CH2-CH - NH 
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Figure 3-6: - Chemical structure of methamphetamine (C, oH15N, MW 149, pK, 10). 
Methamphetamine (Figure 3-6) is an alkaloid similar in structure to amphetamine but with 
an N-methyl substituent. It was first synthesized in 1919 and is a powerful central nervous 
system stimulant. This stimulant can be swallowed, snorted, smoked or dissolved in water 
and injected. Generally it affects heart rate, body temperature, blood pressure, appetite, 
attention and mood. Methamphetamine users feel a short yet intense rush when the drug is 
initially administered. Methamphetamine hydrochloride is a salt commonly known as 
meth or speed. The smokeable form of the drug is called LA or, because of its clear, 
chunky crystals which resemble frozen water, ice, crystal, 64 glasses or quartz. A single 
oral methamphetamine dose of 0.125 mg/Kg (8.75 mg/70 Kg) given to 6 adults produced 
an average peak plasma concentration of 0.020 mg/L at 3.6 hours. The plasma elimination 
half-life averaged 10 hours (range 6-15 hours) for 24 subjects. Methamphetamine 
undergoes some N-demethylation to amphetamine, its major active metabolite (Figure 
3-7). During normal physiological conditions, up to 45% of a dose is eliminated unchanged 
in the 24 hour urine, and about 4-7 % is excreted as amphetamine. In acidic urine, up to 
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76% is found in urine as unchanged drug and 7% as amphetamine in 24 hours, whereas in 
alkaline urine the corresponding values are 2% and less than 0.1% respectively. [62,121,1221 
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Figure 3-7: - Metabolic pathways for MethamphetamineL"81 
3.5 Cocaine 
Figure 3-8: - Chemical structure of Cocaine (C17H21NO4, MW 303, pKa 8.6) 
Cocaine (Figure 3-8) is isolated from Erythroxylon coca which has been grown in 
numerous countries around the world but mostly in South America. There are more than 
250 varieties of coca plants but only three are widely used in the illegal cocaine drug trade. 
These are Huanuca coca, grown in Bolivia and Peru, Amazonian coca, grown in the 
Amazon river basin and Colombian coca grown primarily in Colombia. [48,1231 The 
properties of cocaine include a molecular weight of 303 and a pK, of 8.6 and it is 
considered to be a powerful stimulant. The routes of administration include chewing, 
snorting, injecting and smoking. It can be absorbed into the body through any mucous 
membrane. The chewing of powdered coca leaves containing 17-48 mg of cocaine by 6 
volunteers produced peak plasma cocaine concentrations in the range 0.011-0.149 mg/L 
within 0.4-2 hours. 11181 The half- life of cocaine ranges from 40 min to 4h depending on 
how the elimination phase is estimated. 11051 There are short term effects on the user, 
including increased energy, decreased appetite, mental alertness, increased heart rate and 
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blood pressure, constricted blood vessels and increased temperature. 11241 There are also 
long term effects such as addiction, irritability and mood disturbances, restlessness, 
paranoia and auditory hallucination. [124,125] Cocaine is considered a powerfully addictive 
drug. 80 to 90 % of cocaine is metabolised to ecgonine methyl ester by enzymatic 
hydrolysis and to benzoylecgonine by spontaneous hydrolysis at physiological and alkaline 
pH. 11251 Rapid enzymatic hydrolysis by plasma and liver esterases yields ecgonine methyl 
126-1281 ester. Other metabolites include norcocaine (Figure 3-8)E 
NH ý }- OCO 
,, 
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Figure 3-9: - Metabolic pathways for Cocaine11 . 
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3.6 Opioids 
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Figure 3-10: -Chemical structure of Morphine (C, yHj9N03, MW 285, pKa 9.85 and 7.87) 
showed with its heterocyclic rings distinguished. 
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The opioids are a large family of drugs and are the most important therapeutic components 
in the treatment of moderate to severe pain. 1t051 Opiates" are drugs directly derived from 
the opium poppy and include opium, morphine and codeine. Opium is a very ancient drug 
which has been used as an analgesic for many thousands of years. The term opioid refers 
to all natural and synthetic drugs with morphine-like properties and so includes a wider 
range of drugs than the opiates. Morphine (Figure 3-10), hydromorphone, meperidine, 
heroin and fentanyl are agonists at opioid receptors and, as they are very lipid soluble, are 
rapidly and extensively distributed to tissues. Synthetic opioids like fentanyl, or semi- 
synthetic opioids such as hydromorphone, have higher lipid solubilities than morphine 
which allows them to cross the blood brain barrier quickly, leading to a more rapid onset of 
their effects. Due to the diversity of their chemical structures, the metabolism of opioids 
varies significantly between members (Figure 3-11). [b05.1301 
Morphine is essentially completely metabolized by glucuronidation at the 3- and 6- 
positions, whereas methadone is dealkylated leading to a product which readily forms a 
cyclic structure. Dealkylation pathways are also important for drugs with larger 
substituents on the N-atom, e. g. buprenorphine, butorphanol and pentazocine. 1105' 
Morphine has the following properties: molecular weight 285, pKa values 9.85 and 7.87. 
It is an alkaloid narcotic drug extracted from opium and is a highly addictive analgesic 
which can be administered by several routes i. e. injected, smoked, sniffed or 
swallowed. 1105,118.1311 The trade names for morphine are Roxinal, MS contain, or 
aromatic ring 
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morphine sulphate. The common street name for morphine is Morph. [1321 There are many 
symptoms of overdose which include cold clammy skin, flaccid muscles, fluid in the lungs, 
lowered blood pressure, pinpoint or dilated pupils, sleepiness, stupor, coma, slowed 
breathing and slow pulse rate. 
The plasma half -life for a lot of the common opioids is relatively short; for instance, 
morphine which has a half-life only a few hours. 11051 Morphine is rapidly excreted through 
the kidneys into the urine as glucuronides, with up to 85% of the dose recovered in urine 
within 24 hours. Only small amounts (2-10%) are excreted unchanged. 1'°51 
The formation of glucuronide conjugates is an important feature of the pharmacokinetics 
and toxicology of morphine. Laboratories will often measure morphine as total morphine, 
which includes free morphine and the sum of the two glucuronide conjugates. This is due 
to the greater ease associated with measuring these higher concentrations of total 
morphine, since morphine levels are often undetectable after several hours1133"135ß 
However, since LC-MS became available, individual glucuronides are measured without 
hydrolysis. This is important since morphine-6-glucuronide is pharmacologically more 
active than morphine itself [1361 
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3.7 Cannabis 
C5Hr 
Figure 3-12: - Chemical Structure of delta-9-tetrahydrocannabinol, THC (C21H30O2, MW 314, 
p1,10.6) 
Cannabis is a green or grey mixture of dried leaves of the hemp plant Cannabis sativa. 
There are three drugs derived from the cannabis plant - herbal cannabis, hashish and 
hashish oil. 1137,138] There are over 200 slang terms for cannabis including boom, Mary 
Jane, gangster, cannabis and chronic. However, the names maryuana or marihuana are 
not used in UK legislation, which uses the name cannabis exclusively. The drug is usually 
smoked as cannabis cigarettes. The main active drug substance in cannabis is THC (delta - 
9-tetrahydrocannabinol, Figure 3-12) Although most of the THC in cannabis plants is 
concentrated in the resin, all parts of the plant, apart from the seeds and roots, have been 
found to contain THC. 1105,118,1391 
After inhaling cannabis smoke for a few minutes, the bronchial passages relax and become 
enlarged and the blood vessels in the eyes expand, making the eyes look red. The heart 
rate, normally 70 to 80 beats per minute, may increase by 20 to 50 beats per minute or, in 
some cases, even double-11183 This effect can be greater if other drugs are taken with 
cannabis. The whole blood/plasma concentration ratio for THC is 0.55. Estimates of its 
elimination half-life have ranged from 20-57 hours in infrequent users and from 3-13 days 
in frequent users. The elimination plasma half-life of 11-carboxy-THC averaged 33 hours 
in infrequent users of cannabis and 40 hours in frequent users. 11181 THC is metabolized to 
two monohydroxy compounds, 11-hydroxy-THC and 8-beta-hydroxy-THC (Figure 3-13) 
which, although pharmacologically active, do not achieve appreciable plasma 
concentrations and probably do not contribute significantly to the acute effects of the drug 
after smoking. 1105 A third metabolite, and quantitatively the most important, 11-nor-9- 
carboxy-delta-9-THC, has been identified and is believed to be a product of further 
oxidation of 11-hydroxy-THC. 11401 About 70% of a dose of THC is excreted within 72 
hours in the faeces (40%) and urine (30%). 11051 The urinary elimination half-life of 9- 
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carboxy-THC averaged 3 days (range 0.8-9.8) in heavy smokers of cannabis. 11051 Passive 
inhalation of cannabis smoke has resulted in plasma THC levels of 1-7pg4L and urine 9- 
carboxy-THC levels as high as 39pg/L, as measured by a specific assay. [141, lazy 
COOH 
THC 
8-Hydroxy-THC 
11-Hydroxy-THC 
Hydroxylation 
OH 
OH 
2-Hydroxy-THC 
Figure 3-13: -Metabolic pathways for THCCIO51 
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4 Comparison of Derivatisation Procedures 
4.1 Introduction and Aims 
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Systematic forensic toxicology involves a logical sequence of analytical procedures 
designed to detect a wide range of drugs and poisons in cases for which there is no 
information about which substances might be present, i. e. a general unknown. Ideally, all 
possible substances will be detected but inevitably there are restrictions. Conventional 
methods used for the purpose have included UV spectroscopy, thin layer chromatography, 
gas chromatography and high pressure liquid chromatography, usually with a diode array 
detector. [11,143-157] More recently, combined techniques involving a chromatographic 
technique and spectrometry have become more accessible to the majority of forensic 
toxicology laboratories and as a result are now the techniques of choice. [36,39,54,158-1731 
One of the main requirements in systematic toxicological analysis is often chemical 
derivatisation, which is the process of chemically modifying a molecule to produce a new 
compound which has properties that make it suitable for analysis. 
[1521 Derivatives are 
made for most chromatographic techniques but are especially important for analyses 
involving GC-MS. Historically in the forensic sciences the use of derivatising agents with 
GC-MS has been largely within the scope of the forensic toxicology and chromatography 
of drugs and metabolites in biological fluids and tissues. [154,174,1751 
There are several GC-MS methods for the determination of drugs of abuse which have 
been published, most of them dealing with determination of individual drugs of abuse or 
else with groups of related drugs. Derivatising procedures for systematic forensic 
toxicological analysis have included the silylation, acylation and esterification reactions 
described below in Section 4.2. [176-1833 However, no systematic comparison has been made 
of the different derivatives for forensic toxicology. 
The ultimate aim of this work was to create a unified procedure for systematic 
toxicological analysis which would enable a wide range of drugs and metabolites to be 
detected in a minimum number of analyses, thereby making the procedure suitable for the 
complete toxicological analysis of small samples. The intention was to develop a simple, 
fast method based on solid phase extraction of acid, neutral and basic analyses followed by 
a comprehensive derivatisation procedure which would enable the extracts to be analysed 
Chapter Four Page 35 
by GC-MS. The study described in this chapter is concerned with the end-step 
derivatisation and analysis, which required to be set up before extraction procedures could 
be evaluated. Drugs were subsequently extracted from whole blood by solid phase 
extraction followed by derivatisation and analysis by GC-MS-SIM, and that study is 
described in Chapter 5. 
The present study describes a comparison of three derivatisation methods involving 
silylation, acylation and esterification reactions for the analysis of drugs of abuse. Several 
existing reagents and a new reagent, trimethylsilyl-diazomethane were evaluated to 
establish which would be most suitable for a unified procedure. In addition, the literature 
records that derivatisation is more rapid when microwave irradiation is used rather than 
direct thermal heating, reducing the incubation time from more than thirty minutes to one 
minute, [184-190] and this was also evaluated in the present study. 
Model compounds which feature each of the functional groups commonly found in target 
analytes of interest in forensic toxicology (amphetamine, methamphetamine, morphine, 
benzoylecgonine, THC-OH and THC-COOH) were used to evaluate the reagents. The 
justification for this approach is that functional groups usually react independently and are 
not significantly influenced by the molecule in which they are located. 
4.2 Chemistry of Derivatisation Reactions 
4.2.1 Introduction 
Chemical derivatisation has long been a useful adjunct in the characterization of organic 
compounds using techniques that include chromatography and spectroscopy. 
Derivatisation is the process of chemically modifying a compound to produce a new 
substance which has properties that are suitable for analysis using a particular technique, 
such as GC. 180' 191-194] Volatility and thermal stability of the analytes are required in GC 
and GC-MS analysis. Other reasons for derivatisation are to enable analysis of functional 
groups, to provide selective detection, to produce mass shifts in mass spectra, to modify 
fragmentation and to improve chemical ionization. E80,1951 
Derivatisation prior to analysis involves an additional chemical step that is not only time 
consuming but also introduces potential impurities, uncertainties about the completeness of 
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the conversion and possible interpretation difficulties associated with the adopted chemical 
reaction. Many drugs are, however, derivatized prior to undergoing GC analysis to confer 
volatility to the analytes and improve their stability, separation and chromatographic 
properties. This is because most drugs, both licit and illicit, are organic in structure, and 
their analyses by chromatographic methodology often can be facilitated by chemical 
derivatisation. [80,174,191] 
Generally, derivatisation is performed to convert polar N-H, O-H and S-H groups into 
thermally stable, nonpolar groups and derivatives are therefore used to increase sensitivity 
and chromatographic performance for specific compounds such as acids, alcohols and 
amines, which are difficult to analyse because of the presence of reactive hydrogen atoms. 
When attempting to analyse these types of compound, they can react with the surface of 
the injection port or the analytical column which can result in tailing peaks and low 
response. They may also be highly soluble in the sample matrix, causing very poor 
headspace content and low response. 
GC derivatisation methods can be classified into 4 groups according to the reagents used 
and reaction achieved. These are silylation, acylation, alkylation and esterification 
reactions. Therefore the choice of a derivatising reagent is based on the functional group 
requiring derivatisation, the presence of other functional groups in the molecule, and the 
reason for performing the derivatisation. The chemical structure and properties of the 
molecule influence the reagent choice. In choosing a suitable derivatisation reagent certain 
criteria must be used as guidelines. A good reagent produces a derivatisation reaction that 
is 95-100% complete, will not cause any rearrangements or structural alterations during 
formation of the derivative, does not contribute to loss of the sample during reaction, 
produces a derivative that will not interact with the analytical (GC or HPLC) column, and 
one which is stable with respect to time °$'I The main requirements for a successful 
derivatisation reaction are that a single derivative should be formed for each compound, 
the derivatisation reaction should be simple and rapid and should occur under mild 
conditions. [196-2071 
The following Sections review the derivatisation reactions used in this study. 
Chapter Four 
4.2.2 Silylation 
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The term silyl refers to derivatives containing silicon and usually, but not exclusively, 
relates to the trimethylsilyl group, (CH3)3Si. Trimethylsilylation involves the introduction 
of the trimethylsilyl group into a molecule (Figure 4-1), usually in substitution for an 
active hydrogen atom. [194,208] 
OSI(CH3)3 OSi(CH3)3 
II 
RR + R- C= N- Si(CH3)3 -ý -A-Si(CH3)3 -I- R- C= NH 
Figure 4-1: - Typical silylation reaction, in which A represents 
a heteroatom such as 0 or N. 
The reagents that have been used for this purpose are derivatives of trimethylsilane, 
(CH3)3SiH. The replacement of active hydrogen by the trimethylsilyl group reduces the 
polarity of the compound and decreases the possibilities of hydrogen bonding (Figure 4-2). 
CH3 
i - Si 
i 
BSTFA 
R- OH 
Alcohol 
-Si - 
i 
CF3 
CH3 ii - CH3 
CH3 
IN 
li 
CH3 i 
CH3 
CF3 
BSTFA 
I 
R -O-Si- 
TMS- Alcohol 
BSTFA I 
R-NH2 R-NH-Si- 
Amine 
TMS-Amine 
Figure 4-2: - Derivatisation by Silylation Reaction 
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The advantages of volatility and stability imparted by silylation make the process a natural 
tool for gas-phase purification and analysis[208-214]. The derivative is simply and 
conveniently prepared. In many case the reactants are mixed at room temperature and the 
reaction is complete in a few minutes. Nearly all functional groups which present a 
problem in gas chromatographic separation (hydroxyl, carboxylic acid, amine, thiol, 
phosphate) can be derivatized by silylation reagents. Even sugars and polar steroids have 
successfully been derivatised and analysed by GC-MS. Silylation reagents are influenced 
by both the solvent system and the addition of a catalyst. A catalyst such as 
trimethylchlorosilane or pyridine increases the reactivity of the reagent. [215] 
Silylation has some disadvantages, as silylation reagents are moisture sensitive. The 
reaction must therefore be performed using anhydrous conditions. TMS derivatives are 
more sensitive to hydrolysis than other derivatives containing more sterically crowded 
alkyl substituents on the silicon atom and silylation must use aprotic organic solvents. 
[216- 
2271 
A large number of silylating reagents is available commercially or else they are easily 
prepared, including N, O-bis(trimethylsily)acetamide (BSA), N, O-bis 
(trimethylsily)trifluoroacetamide (BSTFA), hexamethyldisilazane (HMDS), N-methyl-N- 
trimethylsilyl-trifluoroacetamide (MSTFA), N-tert-butyl-dimethylsilyl-N-methyl- 
trifluoracetamide (MTBSTFA), tert-butyl-dimethylchlorosilane (TBDMCS), N-tert-butyl- 
dimethylsilylimidazole (TBDMSIM), trimethylchlorosilane (TMCS), N-trimethylsilyl- 
diethylamine (TMSDEA) and trimethylsilylimidazole (TMSIM). MSTFA is the most 
volatile TMS amide available. 
Typical reaction conditions involve heating samples with a silanising reagent on a hotplate 
at 60°C for 30-60 minutes, but molecules containing sterically-hindered hydroxyl or other 
groups often require prolonged exposure at high temperatures. Examples in forensic 
toxicology include buprenorphine, which has a sterically hindered alcohol group on the 
side chain and some anabolic steroids. 
Silyl derivatives have been widely used in forensic toxicology and STA since their 
introduction in the 1950's. [144,205,211,228-2303 Formation of trimethylsilyl derivatives is 
commonly used before the GC-MS analysis of drugs, including the opiates, cocaine 
metabolites and cannabinoids. [2311 However, trimethylsilylation is not often used for 
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amphetamines because incomplete conversion occurs unless suitable catalysts are used 
such as ethanethiol and ammonium iodide. [2321 
In the present study, MTBSTFA reagent was selected for evaluation because previous 
work had shown that methyl-tertiary-butylsilyl derivative mass spectra are characterized by 
abundant ions at [M-57]+ which are good for identification of drugs and for quantification. 
[228,233,2341 MTBSTFA is a liquid at room temperature, and so can often be used for 
derivatisation without a solvent. It is sensitive to moisture [2351 . The advantage of using 
MTBSTFA is enhanced reactivity including its ability to silylate carboxyls, hydroxyls, 
thiols and primary and secondary amines, short reaction times often at room temperature, 
and simplified work-up owing to derivatisation by-products being neutral and largely 
volatile, so providing the possibility for direct injection of the reaction mixture for GC 
analysis. [2081 During the course of the work for this study, a literature publication appeared 
on the analysis of benzodiazepines in biological samples, based on the methyl-tertiary- 
butylsilyl derivative, in which the authors showed that MTBSTFA forms sensitive, 
reproducible and stable derivatives with benzodiazepines which have active hydrogen 
atoms in either a secondary amine (for example desmethyl diazepam) or in a hydroxyl 
group (for example, Temazepam). [2361 Tertiary-butyl dimethylsilyl derivatives were found 
to be preferable to trimethylsilyl derivatives because stable trimethylsilyl derivatives are 
formed only with benzodiazepines which have a hydroxyl group. 
4.2.3 Acylation 
Acylation, an alternative to silylation, is the conversion of compounds with active 
hydrogen atoms such as OH, SH and NH into esters, thioesters and amides, respectively 
(Figure 4-3). A classic example of this method is the insertion of perfluoracyl groups into 
a substance to enable or enhance electron capture detection (ECD) [2371 and negative ion 
chemical ionisation (NICI) mass spectrometry. 1238,239] Carbonyl groups adjacent to 
halogenated carbons enhance the response of ECD. A further benefit of acylation is the 
formation of fragmentation-directing derivatives for GC-MS analysis, which produce 
strong ions at high mass, suitable for GC-MS in the selected ion monitoring mode. 
Acylation reactions can be performed using three main types of reagents: acyl halides, acid 
anhydrides or reactive acyl derivatives such as acylated imidazoles. Acyl halides and acid 
anhydrides (including perfluoro acid derivatives) readily form derivatives of alcohols, 
phenols and amines which are both stable and highly volatile. Acyl imidazoles (including 
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perfluoracyl imidazoles) react readily with hydroxyl groups and secondary or tertiary 
amines to form acyl derivatives. 
RCOC1 + R-OH --30 RCOOR + HC1 
Figure 4-3: - Typical acylation reaction 
As for silylation reagents, the acylation reagents can be used for highly polar, 
multifunctional compounds, such as carbohydrates and amino acids. Acylation is normally 
carried out in pyridine, tetrahydrofuran or another solvent capable of accepting the acid by- 
product. The tendency of acyl derivatives to direct the fragmentation patterns of 
compounds in MS applications provides helpful information on the structure of these 
materials. Other advantages of acylation are obtained because the derivatives are 
hydrolytically stable and give increased sensitivity and selectivity in GC-MS by increasing 
the molecular weight. Acylation can also be used as a first step to activate carboxylic acids 
prior to esterification, which was used in the present study. 
However there are disadvantages with acyl derivatives as they can be difficult to prepare 
and reaction products (acid by-products) often need to be removed before analysis. 
Acylation reagents are moisture sensitive and are hazardous and odorous. There are many 
acylation reagents used, such as perfluorinated anhydrides, including trifluoroacetic 
anhydride (TFA), pentafluoropropionic anhydride (PFPA) and heptafluorobutyric 
anhydride (HFBA), fluoroacylimidazoles, including trifluoroacetylimidazole (TFAI), 
pentafluoropropanoylimidazole (PFPA), and heptafluorobutyrylimidazole (HFBD, N- 
methyl-bis-trifluoroacetamide (MBTFA), and also acid chlorides such as 
pentafluorobenzoyl chloride (PFBCI)[24°, 241]. PFPA is one of the most commonly used 
acylation reagents, as derivatives are suitable for both FID and ECD, the reagent reacts 
with alcohols, amines and phenols to produce stable and highly volatile derivatives. The 
acid by-product should be removed, via a stream of nitrogen, before injection on to the 
column. Bases, such as triethylamine, can be added as an acid receptor and promote 
reactivity. 
Typical reaction conditions for acylation involve heating samples with an acylating reagent 
at 60°C for 30-60 minutes. The reagent can be used directly or can be diluted with a 
suitable solvent such as ethyl acetate. If necessary, a basic catalyst can also be added[242, 
243] 
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Acyl derivatives have been used widely in forensic STA. 1229,230,242,243] In the present 
study, PFPA was selected for evaluation because of previous experience within Forensic 
Medicine and Science of its use for a range of drug types including amphetamines, 
antidepressants such as fluoxetine, opioids such as buprenorphine and acidic drugs. [228 
4.2.4 Alkylation 
Alkylation involves adding an alkyl group to an active functional group(Figure 4-4) 
containing a replaceable hydrogen atom, such as those contained in carboxylic acids, 
alcohols, thiols, phenols, primary and secondary amines, amides and sulfonamides. 
[244-247] 
These are the main functional groups that can be subjected to alkylation reactions. 
R2-OH 
R1-AH - R1-A-R2 + H2O 
catalyst 
Figure 4-4: - Typical alkylation reaction, where RI and R2 are organic groups 
and A represents a heteroatom 
Replacement of hydrogen with an alkyl group is important because the derivative has 
lower polarity relative to the parent substance. Alkylation of weakly acidic groups such as 
alcohols requires strongly basic catalysts such as sodium or potassium methoxide. 
[2441 
More acidic OH groups such as those contained in phenols and carboxylic acids require 
less basic catalysts and can even be Lewis acids such as hydrogen chloride or boron 
trifluoride. Alkylation can be used alone to form esters, ethers and amides or it can be 
used in conjunction with silylation or acylation, as in the present study. [246] 
Esterification is the most common type of alkylation and is used to derivatise carboxylic 
acids and other acidic functional groups. Esterification involves the condensation of the 
carboxyl group of an acid and the hydroxyl group of an alcohol, with the elimination of 
water' [244] Results are best in the presence of a catalyst, like BF3 or HCI, which is then 
removed with the water. Alkyl esters have excellent stability and can be isolated and 
stored for long periods of time. There are many advantages for example, the wide range of 
alkylation reagents available, reaction conditions can vary from strongly acidic to strongly 
basic, some reactions can be done in aqueous solutions and alkyl derivatives are generally 
stable. Some disadvantages are that the reaction is limited to amines and acidic hydroxyls, 
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reaction conditions can be severe and the reagents are often toxic. Typical reaction 
conditions for esterification involve heating the acid with an alcohol and catalyst either 
under reflux (large scale) or in a sealed tube at 60°C for 30-60 minutes. [244,247] 
There are many alkylating reagents such as dimethylformamide (DMF - dialkylacetals), 
tetrabutylammonium hydroxide (TBH), BF3 in methanol or butanol and pentafluorobenzyl 
bromide (PFBBr) (Figure 4-5). (245,246,2481 
IOI 
H3C. Jý 
NH 
I 
CH3 
Figure 4-5: - Pentafluorobenzyl bromide (left) and N, N-Dimethylformamide 
(right) 
In the present study, pentafluoropropanol was used to alkylate (esterify) carboxylic acid 
groups in the selected model compounds (THC-COOH and benzoylecgonine) with the 
corresponding acid anhydride (PFPA) as the catalyst. This combination has previously 
been used in forensic toxicology for the analysis of THC-COOH [249,250]. 
4.2.5 Methylation (esterification) 
Methylation is a particular form of the alkylation reaction in which a methyl group (CH3-) 
is introduced into a molecule. A specific example is the replacement of a hydrogen atom 
by a methyl group. It is widely used for derivatisation of carboxylic acids. It is a stable 
reaction, the reagents are easy to evaporate, the retention time of the product is usually 
well-defined, a good mass spectrum is obtained and the reagents are readily available and 
inexpensive. On the other hand, methylation can not distinguish benzoylecgonine and 
cocaine. 
Conventional reagents for methylation include boron trifluoride in methanol, 
tetramethylammonium hydroxide, methyl iodide and diazomethane? 51-2571 Diazomethane 
is an ideal methylating agent in that it reacts quantitatively at room temperature and is 
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readily volatile. However, it is hazardous to prepare and use because of its toxicity and 
potential for detonation. More recently an alternative reagent, trimethylsilyl- 
diazomethane, became commercially available as a solution in hexane for applications in 
organic synthesis and this was evaluated in the present study. [251,253,254,258-2601 
4.3 Microwave assisted derivatisation 
Microwaves are commonly used to heat things containing water but can also heat organic 
molecules as in microwave assisted derivatisation. E189' 1901 Water molecules consist of two 
hydrogen atoms carrying a small positive charge and an oxygen atom carrying a negative 
charge. The oscillating electric field of the microwave interacts with these charged atoms 
to cause the molecule to twist. This rotation causes friction, producing heat. 
Technically, in a microwave oven the mains voltage is stepped up by a transformer and 
capacitor to around 3000V, to power the magnetron and generate microwaves which are in 
effect high - frequency radio waves, at about 2.5GHz. The radiation is conducted through 
the waveguide into the heating chamber, and then the microwaves are reflected from the 
walls and door, and penetrate the material in the oven from the sides and above. A 
turntable rotates the target slowly to give even exposure. Some ovens achieve this by 
using a microwave stirrer instead. 
The derivatisation reactions described in Section 4.2 are normally carried out using a dry- 
block (oven) for a period of typically 30 minutes up to several hours. This time delay is a 
major disadvantage of [187,188,261,2621 261,262 By using a microwave a much shorter 
time has been found to be needed for the same derivatisation, e. g. 1 minute at 900 
Watts. [184-186] 
4.4 Experimental Section 
4.4.1 Reagents and materials 
a) PFPA (pentafluoropropionic anhydride, C6F10O3, MW 460, Figure 4-6) was supplied by 
Fluka Chemicals, The Old Brickyard New Road, Gillingham, Dorset, SP8 4JL, England. 
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Figure 4-6: - Structure of PFPA anhydride 
b) PFP-OH (2,2,3,3,3-pentafluoropropanol, 97%, C3F5H3O, MW 150, Figure 4-7) and 
TMS (trimethylsilyl-diazomethane, 2.0 M solution in hexane, C4H10N2Si. MW 114, Figure 
4-8) were supplied by Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BH12 
40H, England. 
iii 
1-1- OH F? 
FFH 
Figure 4-7: - Structure of PFP-OH alcohol 
H CH3 
ii N2- C- Si - CH3 
II 
H CH3 
Figure 4-8: - Structure of trimethylsilyl-diazomethane 
c) MTBSTFA, (N-Methyl-N-tert-butyldimethysilytrifluoroacetamide, C9H18F3NOSi, MW 
238, Figure 4-9) containing 1% by volume of TBDMCS was supplied by Perbio Science 
UK Limited, Century House, Tattenhall, Cheshire, CH3 9RJ. 
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Figure 4-9: - Structure of MTBSTFA+1 % TBDMCS 
(d) ReactiVials® (1 ml and 3 ml sizes) for microwave-assisted derivatisation were obtained 
from Perbio Science UK Limited, Century House, Tattenhall, Cheshire, CH3 9RJ. These 
were sealed with the standard ReactiVial screw cap and septum. 
4.4.2 Drug standards and internal standards 
Drug standards and internal standards used were amphetamine, amphetamine-d5 (Figure 
4-10), methamphetamine, methamphetamine-d5 Figure 4-11), morphine, morphine-d3 
(Figure 4-12), benzoylecgonine, benzoylecgonine-d3 (Figure 4-13), A9- 
tetrahydrocannabinol (THC-OH), tetrahydrocannabinol-d3 (Figure 4-14) and 11-nor-A9- 
tetrahydrocannabinol-9-carboxylic acid (THC-COOH, Figure 4-15). Stock standard 
solutions of all drugs were obtained at concentrations of 0.1 mg/mL in methanol from 
Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BH12 40H, England. THC- 
OH and THC-COOH were supplied by LGC Promochem Group Company, Queens Road, 
Teddington, TW11 OLY, and Middlesex. Working standards were prepared at 10 µg/mL 
by dilution with methanol. Further details of standard solutions are given in Section 5.1. 
CH3 
I 
CH, -CH-NHz II 
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Figure 4-10 :- Amphetamine and Amphetamine-dg 
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Figure 4-11: - Methamphetamine and Methamphetamine-ds 
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Figure 4-12: - Morphine and Morphine-d3 
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Figure 4-13: - Benzoylecgonine and Benzoylecgonine- d3 
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Figure 4-14: - THC-OH and THC-OH-d3 
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Figure 4-15: -THC-000H and THC-COOH-d3 
4.4.3 Derivatisation procedures 
CDs 
During the initial studies of derivatisation reactions, standards were reacted individually 
rather than in mixtures. Aliquots of working standard solution (10 µg/ml, 100 µl) were 
pipetted into ReactiVials® and evaporated to dryness under a stream of nitrogen, without 
heating, to avoid evaporation of amphetamines. The residues were then dissolved in the 
three selected reagents and subjected to microwave heating as described in Section 4.4.4. 
Reagents were evaluated as follows 
a) Acylation/alkylation was carried out with a mixture of PFPA and PFP-OH. Different 
ratios of PFPA and PFP-OH were prepared (0.5: 1,1: 1 and 2: 1 v/v) and different 
volumes of reagent mixture were reacted with the standards (50,100 and 150 µl). In 
addition, the effect of adding the reagents sequentially instead of simultaneously was 
tested. 
b) Acylation/methylation (esterification) was carried out with PFPA/TMS-diazomethane. 
Different volumes of PFPA (50,100,150 µl) and TMS-diazomethane (10,20,50 µl) 
were tried and the effect of adding the sequentially was tested. 
c) Silylation was carried out with MTBSTFA containing 1% TBDMCS. Different 
volumes of reagent were tried (20,30,50 µl). 
The yield of derivatisation reactions was indicated by the peak size of the products when 
measured by GC-MS. Comparisons were carried out within batches of samples and no 
internal standards were used except for morphine and benzoylecgonine TBDMS. 
OH 
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4.4.4 Microwave heating 
The microwave oven used in this study was a Micro Chef Model ST23W manufactured by 
Proline, with a maximum power output of 750Watts. The irradiation intensity and length 
of the irradiation time is dictated by the power level chosen. Vials were arranged on the 
glass plate in the oven in a circle as shown in (Figure 4-16) to balance their exposure to the 
microwave radiation. 
0 00 1 00 0O 
Figure 4-16: - Microwave Oven 
Different power settings and reaction times were evaluated to establish practical conditions 
for derivatisation. In addition, different types of reaction vial were tested to identify a 
suitable type for use in the microwave oven, as initial tests found that some types of screw 
cap were damaged by the oven. 
4.4.5 Instrumental methods 
After heating in the microwave oven, the vials containing reaction mixtures were then 
cooled to room temperature and, except for those derivatised with MTBSTFA reagent, 
evaporated to dryness under a stream of N2. The derivatised extracts were reconstituted in 
50µl of ethyl acetate prior to analysis by GC-MS. MTBDMS derivatives were injected in 
the reagent. 
GC-MS was carried out on a Thermo-Finnigan trace quadrupole instrument operated in 
EI+ repetitive full scan mode. Operational parameters used were based on those used in 
the Forensic Medicine and Science routine laboratory, many of which were the standard 
default settings recommended by the instrument manufacturer. Data was acquired and 
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processed using ExcaliberTM software from Thermo-Finnigan. It was equipped with a fused 
silica capillary column (HP-5,30m x 0.32 mm x 0.25 gm film thicknesses) and Supplied 
by J&W Scientific (Agilent Technologies). Helium was used as the carrier gases at flow 
rate of 1.2 ml/min. 1l of samples were injected via a split-splitless injection mode with an 
injection temperature of 200 °C. The initial column temperature was 100 °C and was 
programmed to 300 °C at a rate of 10 °C/min. The spectrometer was used in the EI mode 
with electron energy of 70 eV and source temperature 200 T. The emission current was 
180µA with detector voltage 350V, as shown in Table 4-1. 
Table 4-1: - Conditions for GC-MS 
Parameter Setting 
Column HP-5 column, 
0.25 gm film 
J&W Scientific 
30 mx0.32 mm x 
thickness. Supplied by 
(Agilent Technologies) 
Carrier Gas Helium, 1.2 ml/min 
Injector Temperature 280 T 
Injection volume 1 1, 
Injection mode split -splitless, purge time 0.7 min 
Temperature Programme 100 to 300 °C at 10 °C /minute 
Interface temperature 200°C 
Electron energy 70 eV 
Source temperature 200°C 
Emission current 180 A 
Detector voltage 350V 
4.5 Results and Discussion 
4.5.9 Microwave assisted derivatisation procedures 
Microwave heating instead of a conventional heating block was used to assist 
derivatisation. It required less time to achieve complete derivatisation. 
Initial tests of the microwave oven indicated that the conditions applied should be suitable 
for the vials and vial caps, particularly the power setting used. During trials of the 
procedure, it was found that conventional vial caps such as Bakelite caps (used on the 
standard laboratory %z-Drachm and 1-Drachm vials) or autosampler caps (used on screw- 
top autosampler vials) may melt at high power settings. Metallic crimp-top vials could not 
be used in a microwave oven. This problem was solved by using resistant ReactiVial® 
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type vials and caps, although these are relatively expensive and require to be re-used rather 
than being treated as disposable. 
A disadvantage of using the microwave was that the distribution of power was uneven and 
the arrangement of the vials on the glass plate in the oven was found to be important. 
Regular laboratory test tube racks manufactured using plastic-coated wire could not be 
used because the plastic coating melted in the oven. However, ReactiVials are of 
heavy 
glass construction and were found to be stable in the oven without any additional support. 
It was found to be convenient to arrange the vials in a circle shape as shown 
in (Figure 
4-16) so that the temperature distribution was balanced, which would 
help the 
derivatisation reaction. [263-265] 
The use of a microwave oven instead of a conventional heating block gave a significant 
saving of time in the derivatisation step since tests showed that derivatisation reactions 
with all three reagents were complete in 1 minute instead of 30 minutes 
(usually) in a 
heating block. However, there were also disadvantages of using the microwave oven. 
One disadvantage was that expensive vials were needed with caps that were able to resist 
the effects of the oven. Tests carried out with conventional vials such as those used 
in 
autosamplers showed that the caps melted or were damaged leading to loss of reagents by 
evaporation. The only suitable vials which were found were ReactiVialsTM which are 
heavy-duty vials with thick bases and which cost several pounds each. This cost would 
prevent the vials being disposed of after use, which would lead to the risk of cross- 
contamination in forensic toxicology casework and which would be unacceptable unless a 
quality-controlled cleaning system was introduced by which vials were checked before use. 
Another disadvantage was that volatile reagents were lost due to evaporation, even when 
ReactiVials were used. As a result, relatively large volumes of PFPA and PFPOH reagents 
was required so that the reaction mixture did not dry our during the derivatisation step. 
The use of 100 microlitres of this reagent mixture per sample would also be expensive for 
routine toxicology. This problem might be solved by adding a "keeper" solvent with a 
high boiling point, which has been done in the past when volatile analytes such as 
amphetamines are analysed, to prevent losses by evaporation. One example is the addition 
of dimethylformamide to SPE extracts of amphetamines before they are evaporated to a 
low volume. [2311 
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The aim of the investigation was to optimise the time for complete derivatisation especially 
for some drugs such as THC-COOH, which requires the derivatisation of two functional 
groups. The temperature, power and time of irradiation were investigated. The time to 
derivatise was varied from 1 to 5 minutes. It was found that using 3 or 5 minutes at the 
high power setting affected the integrity of the caps and the sample was lost. The optimum 
time was found to be 1 minute at the high power setting (750 Watts), which was found to 
be sufficient for all of the reactions which were under evaluation. Longer derivatisation 
time periods did not lead to higher yields of derivatives, based on the peak sizes of the 
products, but could lead to evaporation of the reagents. These settings were therefore 
retained for the rest of the study. 
Based on the trails of different reagent mixture compositions, the following were found to 
be the optimum amounts. 
a) Acylation/alkylation: 
Acyl derivatives were formed using 100 µl PFPA and 50 µl PFP-OH. Better results 
were obtained when these reagents were added individually and consecutively, 
beginning with PFPA, which reacts with alcohols and amines. PFP-OH added 
subsequently reacts with carboxylic acids. Trials were carried out of different volumes 
of the reagents as it was important to know the effect of the reagent amount on the 
reaction. Chromatograms were recorded of. the derivatives formed by the test drugs 
after reaction with 200µL PFPA, 50 µL PFP-OH and 60 µL ethyl acetate, which 
showed that all the drugs reacted well except THC-OH and THC-COOH (Figure 4-17). 
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Figure 4-17: - TIC Chromatograms and Mass Spectra for test drugs following reaction with 
PFPA, PFP-OH and ethyl acetate. 
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b) Acylation/methylation (esterification): 
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Acyl derivatives were formed using 100 µl PFPA and methylation was subsequently 
carried out using 20 µl TMS-diazomethane in hexane (2M solution). 
c) TBDMS derivatives: 
These were prepared using 30 gl of MTBSTFA reagent containing 1% TBDMS, which 
was enough to dissolve the sample for derivatisation in the microwave without 
evaporation to dryness during the heating process. 
4.5.2 GC-MS analysis of derivatives of model compounds 
A summary of the products obtained using the three derivatisation reagents with each of 
the model compounds is given in Table 4-2 The derivatives formed by the deuterated 
internal standards are similar to those formed by the unlabelled compounds and have 
similar retention times, which were only 1-2 seconds less than those of the unlabelled 
compounds. The chromatography and fragmentation patterns observed in their mass 
spectra are discussed in detail below. 
Table 4-2: - Results of derivatisation reactions 
Model Compound Reagent Product Retention Time 
Amphetamine (AM) PFPA/PFP-OH AM-PFP 4.54 
PFPA/TMS- 
diazomethane 
AM-PFP 4.54 
MTBSTFA AM-TBDMS 6.92 
Methamphetamine 
(METH) 
PFPA/PFP-OH METH-PFP 5.73 
PFPA/TMS- 
diazomethane 
METH -PFP 5.73 
MTBSTFA None formed - Morphine (MOR) PFPA/PFP-OH MOR-bis-PFP 13.98 
PFPA/TMS- 
diazomethane 
MOR-bis-PFP 13.98 
MTBSTFA BZE-bis-TBDMS 14.76 
Benzoylecgonine 
(BZE) 
PFPA/PFP-OH BZE-PFP ester 12.36 
PFPA/TMS- 
diazomethane 
Cocaine 13.98 
MTBSTFA BZE-TBDMS ester 15.86 
Chapter Four Page 54 
THC PFPA/PFP-OH THC-PFP 13.01 
PFPA/TMS- THC-PFP 13.01 
diazomethane 
MTBSTFA THC-TBDMS 15.86 
THC-COOH PFPA/PFP-OH THC-COOH-PFP 14.35 
PFP ester 
PFPA/TMS- THC-COOH-PFP 15.29 
diazomethane methyl ester 
MTBSTFA THC-COOH-bis- 19.33 
TBDMS 
4.5.3 PFPAIPFP-OH Derivatives: 
Derivatisation was successful for all of the test compounds and mass spectra were obtained 
for each of them. These derivatives gave good gas chromatographic behaviour, in terms of 
peak shape and thermal stability, and the mass spectra had prominent molecular ions and 
also prominent diagnostic fragment ions at high mass, suitable for use as qualifier ions in 
selected ion monitoring GC-MS. The ions used for the identification and quantification are 
shown in Table 4-3. 
The optimum derivatisation reagent composition was regarded as the one which produced 
a good chromatographic peak with the correct fragmentation pattern. These reagents react 
with alcohols, amines and phenols (Figure 4-18, Figure 4-19, Figure 4-22 and Figure 
4-26). PFPA will replace the proton (H) of a functional group with -C3F50. In the case of 
benzoylecognine and THC-COOH, which contain carboxylic acid groups (Figure 4-24 and 
Figure 4-28) the reaction will be with PFP-OH with addition of -C3H2F5. 
Table 4-3: - Selected Ions used for GC/MS-SIM with PFPA-PFP-OH 
Target analyte Retention 
time 
(min) 
Qualifier Ions 
(m/z) 
Internal Standard Selected 
Ions 
(m/z) 
Amphetamine 4.51 118 Amp-Ds 122 
Methamphetamine 5.71 204 Meth-D5 208 
Morphine 13.86 414 Mor-D3 417 
Benzoylecgonine 12.43 82 Bze-D3 85 
THC-OH 12.94 417 THC-OH-D3 420 
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THC-COOH 14.35 
(a) Amphetamine and Methamphetamine: 
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The mass spectra of amphetamine and methamphetamine PFP derivatives are shown in 
Figures 4-17 and 4-18. 
Lo06pNV0lýlti IýT f.! i AY " Nl ! Tt!! 
T: 10 01 ""! 1 MOW AO Iu11 ft NAOlN. 001 
ýý 
III. 1 
M 
ý 
ý So 
ýs 
" 
a 
: 
a 
16 
1 
"q. A 
LL1DA 
THC-COOH-D3 
CH3 0FF 
I 11 1I 
CH', -CH-NH C-C-C 
II FF 
m/z 281M+ 
a. t I 
Figure 4-18: - Mass Spectrum of Amphetamine -PFP 
The molecular ions for amphetamine and methamphetamine PFP derivatives are at m/z 281 
and m/z 295 respectively. These molecular ions fragment as shown in Figures 4-19 and 4- 
20. Amphetamine and methamphetamine PFP derivatives produce base peaks at ni/z 118 
and m/z 204 repectively and correspond to the fragments [C6H5-CH2-C2H3] + for 
amphetamine and [CH CH3 NCH3 C2OF5]+ for methamphetamine. PFP derivatives of both 
amphetamine and methamphetamine share a fragment ion at m/z 119 which corresponds to 
the loss of C3F5ONH and C4H3F5NO for amphetamine and methamphetamine respectively. 
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Figure 4-19: - Mass Spectrum of Methamphetamine -PFP 
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Figure 4-20: - Fragmentation of Amphetamine PFP derivative 
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Figure 4-21: - Fragmentation of Methamphetamine PFP derivative 
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The fragmentation reactions can therefore be classified according to where the cleavage 
occurs in the molecule: amphetamine derivatives show a typical alpha cleavage reaction 
adjacent to the carbon holding the nitrogen atom (charge retention on nitrogen) as well as a 
charge migration reaction resulting in cleavage between the carbon atom and the nitrogen 
atom plus loss of 1 proton Table 4-3: 
Table 4-3: - retention and migration of charge 
Compound Reaction 
Charge retention Charge migration 
AM 190 118 
AM-d5 194 122 
METH 204 118 
METH-d5 208 122 
Fragment ions at m/z 118,122,204 and 208 were selected for use as quantitation ions in 
subsequent work. 
(b) Morphine: 
The mass spectrum of morphine is shown in Figure 4-21. Morphine has 2 hydroxyl groups 
and so will react with PFPA producing a molecular ion at m/z 577. This ion fragments as 
shown in Figure 4-22. Significant reactions involve loss of the pentafluoropropanoyl ion 
from the phenolate hydroxyl group and of the pentafluoropropionyl ion from the alicyclic 
hydroxyl group to give the base peak at m/z 414. This fragment ion and the corresponding 
one at m/z 417 for morphine-d3 were used as quantitation ions. 
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Figure 4-22: - Mass Spectrum of Morphine - PFP 
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(c) Benzoylecgonine: 
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Benzoylecgonine has a carboxylic acid group which reacts with PFP-OH to form the 
corresponding ester with a molecular ion at m/z 421 as shown in Figure 4-24. The 
molecular ion for benzoylecgonine fragments as shown in Figure 4-25. The base peak is at 
m/z 82, which consists of part of the ecgonine ring system, and the intense ion at m/z 300 
is formed by loss of benzoic acid. Notably, the loss of the pentafluoropropanol fragment is 
not favoured and gives a relatively weak ion at m/z 272. The base peak ion and the 
corresponding ion in benzoylecgonine-d3 at m/z 85 were used as quantitation ions. 
8s01001 RT 1IA1 AY. 1 NL: 1 TOES 
T (00) "a910o160000f01 10ý18500450001 
100= 
822 
95 
ee 
7& 
7 
6 
30- 
Y 
ý 
, 
, O-A 
Sol 
s 
101 
942 
131.1 
2191 
3002 
2722 3182 
CH3 
Ný_ 
A II Ir 
ýýt- COO- C- C- C- F 
öýýý 
I O-C 
HFF 
m/z 421 M+ 
4212 
ft 11. I +e +sv+ z+ zGG. z 
207 + 231 + zGe1 
, 
317 z 3432 3761 114,1 {es + 602 + 514 + ee1 + 7e 1 6141 73 
100 160 200 260 300 350 400 160 600 550 000 6e 
mh 
Figure 4-24: - Mass spectrum of Benzoylecgonine -PFP 
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Figure 4-25: - Fragmentation of Benzoylecgonine PFP derivative 
(d) THC-OH and THC-COOH 
THC-OH has a phenolic hydroxyl group so will react with PFPA producing a PFP 
derivative with a molecular ion at m/z 460 as shown in Figure 4-26, which is also the base 
peak. This ion fragments as shown in Figure4-27. A number of strong ions are present at 
high mass, which are useful as qualifier ions 
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THC-COOH also has a carboxylic acid group which reacts with PFP-OH and PFPA to 
produce a bis-PFP derivative with a molecular ion at m/z 622 as shown in Figure 4-28. 
The molecular ion for THC-COOH will fragment as shown in Figure 4-29. The base peak 
ion at m/z 459 is formed by loss of pentafluoropropanoate, and this ion together with the 
corresponding ion for THC-COOH-d3 at m/z 462 was used as quantitation ions. 
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Figure 4-28: - Mass Spectrum of THC-COOH -PFP derivative 
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Figure 4-29: - Fragmentation of THC-COOH PFP derivative 
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4.5.4 PFPA/TMS-diazomethane Derivatives: 
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The second derivatisation procedure investigated used PFPA and TMS-diazomethane. 
PFPA does not react with carboxylic acid groups but the novel methylating agent TMS- 
diazomethane was added in order to convert these to methyl esters. This reaction was 
found to proceed rapidly and quantitatively at room temperature and holds potential for 
future use in toxicology to replace diazomethane, a hazardous and toxic material[252,255] 
Trimethylsilyl-diazomethane potentially provides a safer alternative to diazomethane, 
which is prepared in small batches just before use because of its high toxicity and 
explosion risk. Diazomethane is an almost ideal reagent for methylation because it is a 
gaseous reagent used in solution which reacts with carboxylic acids immediately and can 
even be used with aqueous samples. Trimethylsilyl-diazomethane is available 
commercially, dissolved in hexane or ether as a 2M solution, and so avoids the hazards and 
risks of preparing diazomethane in the laboratory. The present study found that a small 
volume of the reagent (20 microlitres) was sufficient to methylate the test compounds used. 
However, the commercial product is not of "derivatisation grade" as are other reagents 
used for trace analysis and it contains impurities derived from its manufacture. The 
originally-published method for this involves a Grignard rection in ether or hexane and 
distillation to obtain a solution of trimethylsilyl-diazomethane. [2661 Some of the reaction 
bi-products and reagents are present in the trimethylsilyl-diazomethane solution which is 
obtained and these may potentially cause interference. Interferences due to the reagent in 
toxicological analyses were assessed in the second phase of this study (Chapter 5). 
However, the reagent has also been advocated for the analysis of acidic pesticides in 
wastewater. [2551 Also, the reagent was used for the analysis of acidic metabolites of the 
riot control agent 2-chlorobenzylidene malononitrile (CS gas) in post mortem liver 
samples. [267] In the present study, no interference was found in the GC-MS analysis of the 
test compounds. 
The products of acylation of amines and alcohol remained unchanged from those obtained 
with PFPA/PFP-OH but the acylated/methylated products also gave good gas 
chromatography and had mass spectra which are suitable for both identification and 
quantification by GC-MS-SIM. The ions for use in selected ion monitoring are given in 
Table 4-4. 
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Table 4-4: - Selected Ions used for GC/MS-SIM with PFPA-TMS-Diazomethane 
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Target analyte Retention time 
(min) 
Selected 
Ions (m/z) 
Internal 
Standard 
Selected Ions 
(m/z) 
Amphetamine 4.51 118 Amp-d5 122 
Methamphetamine 5.71 204 Meth-d5 208 
Morphine 13.86 414 Mor-d3 417 
Benzoylecgonine 12.43 82 Bze-d3 85 
THC-OH 12.94 417 THC-OH-d3 420 
THC-COOH 14.35 489 THC-COOH-d3 492 
Therefore, in this reaction PFPA reacts with all drugs as before (Figure 4-18, Figure 4-19, 
4-21 and Figure 4-26) except benzoylecgonine and THC-COOH which contain carboxylic 
acid groups. These acid groups are derivatised with TMS-diazomethane, substituting a 
proton from the functional group with a methyl group (Figure 4-36, Figure 4-38). The mass 
spectra of PFP acyl derivatives of AM, METH, MOR and THC are not repeated here but 
specimen chromatograms are given in Figure 4-30 to Figure 4-35, which illustrate the 
symmetrical peak shapes obtained with this reagent. 
Chapter Four 
.., z,,:, s 
ww , u]UG)NU I'll 3ý]E) 
,ý ,ý 
iýmý ýmýnl 
Figure 4-30: - TIC chromatogram of amphetamine PFP derivative 
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Figure 4-31: - TIC chromatogram of methamphetamine PFP derivative 
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Figure 4-32: - TIC Chromatogram and Mass Spectrum for Morphine-PFP 
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Figure 4-33: - Selected ion chromatograms for benzoylecgonine methyl ester (cocaine) 
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Figure 4-34: -TIC chromatogram for THC-OH PFP derivative 
Figure 4-35: - TIC chromatogram for THC-COOH PFP/methyl ester derivative 
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The molecular ion for benzoylecognine with PFPA/TMS- diazomethane was m/z 303, i. e. 
methylation of benzoylecgonine produces cocaine as shown in Figure 4-36. This is a 
disadvantage of methylation compared to other derivatising agents as the product cannot be 
distinguished from cocaine which was in the sample. This problem could be overcome by 
using an analogue of TMS-diazomethane such as TMS-diazopropane. TMS-diazoethane 
would also cause a problem because cocaethylene may also be present in blood following 
simultaneous administration of cocaine and ethanol, which is a common practice. 
The molecular ion fragments as shown in Figure 4-37. The mass spectrum has a base peak 
at m/z 182 and with elemental composition [C10H12NO2]+. The PFPA/TMS-diazomethane 
and PFPA/PFP-OH derivatives of benzoylecgnine share the m/z 82 and m/z 272 ions, 
which have elemental composition [C5H8N] + and [C18H803] +, because the ester group is 
lost when each of these ions is formed. 
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Figure 4-36: - Mass Spectrum Benzoylecgonine PFP-TMS-diazomethane derivative (Cocaine) 
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Figure 4-37: - Fragmentation for benzoylecgonine PFPITMS- diazomethane derivative 
(cocaine) 
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The molecular ion for THC-COOH with PFPA/TMS-diazomethane was at m/z 504 as 
shown in Figure 4-38. This ion fragments as shown in Figure 4-39. It has a base peak at m/z 
489 and has the composition [C24H2605F5 
Figure 4-38: - Mass Spectrum for THC-COOH-PFP-TMS-diazomethane 
The methyl ester/PFP derivative and PFP-OH ester/PFP derivative share a common ion at 
m/z 489, which indicates that the ester substituent is lost, as this removes the structural 
difference between the two derivatives. 
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Figure 4-39: - Fragmentation for THC-COOH-PFPITMS- diazomethane 
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4.5.5 TBDMS Derivatives: 
The third derivatisation method investigated was using MTBSTFA. In this reaction 
analytes react with (CH3)2SiC(CH3)3 from MTBSTFA reagent to produce the structures 
shown in (Figure 4-41, Figure 4-43, Figure 4-45, Figure 4-47 and Figure 4-49). The 
advantage of this reagent is its ability to react with alcohols, primary amines, phenols and 
carboxylic acid groups and this method gave derivatives with all test compounds except 
the secondary amine, methamphetamine, despite the addition of a catalyst, 
MTBDMCS, Figure 4-40. Gas chromatographic behaviour of these derivatives was good, 
but although using MTBSTFA to derivatise morphine produced good peak shapes and 
looked to be sensitive, these results were for a standard at a high concentration. At a low 
concentration, it was difficult to detect morphine. The mass spectra had prominent ions 
suitable for GC-MS-SIM, often showing ions due to the loss of the butyl substituent in the 
silyl derivatives. Ions for use in selected ion monitoring are given in Table 4-5. 
Table 4-5: - Selected Ions used for GCIMS with MTBSTFA derivatisation 
Target analyte Retention 
time(min) 
Selected 
Ions(m/z) 
Internal 
Standard 
Selected 
Ions 
(m/z) 
Amphetamine 6.92 158 Amp-D5 162 
Morphine 15.72 342 Mor-D3 345 
Benzoylecgonine 14.76 282 Bze-D3 285 
THC-OH 15.86 342 THC-OH-D3 345 
THC-COOH 19.33 515 THC-COOH-D3 518 
The molecular ions for amphetamine, morphine, benzoylecgonine, THC-OH and THC- 
COOH TBDMS derivatives were at m/z 249, m/z 513, m/z 403, m/z 428 and m/z 572 
respectively. These ions fragment as shown in (Figure 4-42, Figure 4-44, Figure 4-46, 
Figure 4-48 and Figure 4-50). 
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Figure 4-40: - TIC Chromatogram for Amphetamine -TBDMS, (A) without Catalyst (B) with 
Catalyst 
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Figure 4-41: - Ion Chromatogram for m/z 158 and Mass Spectrum for Amphetamine -TBDMS 
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Figure 4-42: - Fragmentation of Amphetamine -TBDMS 
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Amphetamine has a primary amine and produces a base peak at m/z 158 assigned the 
fragment composition [C8H2OSiN]+. This ion is formed by the characteristic reaction of 
amphetamines, alpha cleavage, beside the carbon holding the nitrogen atom. The other 
high-mass fragment ion, at m/z 192, is formed by loss of the tertiary butyl group from the 
derivative. The molecular ion at m/z 249 is not visible but there is a weak ion at m/z 234 
due to loss of a methyl group. 
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Figure 4-43: - TIC Chromatogram and Mass Spectrum for Morphine-TBDMS (also containing 
the internal standard Morphine-d3). 
Chapter Four Page 77 
CH3 CH3 
II 
CHý- C-SI- 
CH3 CH3 
II 
CiH3 ' 
CH3 
/ 
CH3 CH3 
CH3 CH3 
II 
_ C-Si- 
ii CH3 CH3 
J111 
CH3 CH3 m/z 499 
M+" 513 
N- CH3 
CH3 m/z 442 
Figure 4-44: - Fragmentation of Morphine-bis-TBDMS derivative 
The mass spectrum of morphine-bis-TBDMS derivative contains strong ions at m/z 399 
and m/z 342. Note that the internal standard, present in the GC peak, gives analogous ions 
3 mass units higher at m/z 502 and m/z 345, but other ion doublets are not clearly visible, 
suggesting that other fragments have lost the N-methyl group which contains the deuterium 
atoms. The ion at m/z 499 is formed by loss of the silyl group on the phenolic hydroxyl 
group together with a proton transfer to the ion (a similar reaction occurs with 
diamorphine). The ion at m/z 442 is then formed by loss of the tertiary butyl group from 
the initial product. This is suggested by the absence of an ion corresponding to loss of the 
tertiary butyl group from the molecular ion, which would have appeared at m/z 456. 
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Figure 4-45: -Ion Chromatogram m/z 282 and Mass Spectrum for Benzoylecgonine TBDMS 
(also containing the internal standard Benzoylecgonine-d3) 
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Figure 4-46:. Fragmentation of Benzoylecgonine -TBDMS 
Benzoylecgonine has a carboxylic acid group and forms an MTBDMS ester. The base 
peak in the mass spectrum is at m/z 282 and is assigned to the fragment [C14H22O4Si]+ . It 
is 
formed by loss of the benzoyl group, as in cocaine, which produces the ion at m/z 182 in 
the mass spectrum of cocaine. The loss of the tertiary butyl group occurs directly from the 
molecular ion to give the fragment at m/z 346. The presence of the internal standard helps 
in identifying the fragmentation reactions by providing a parallel series of ions for those 
fragments which retain the deuterium, which is held by the N-methyl group. 
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Figure 4-47: - TIC Chromatogram and Mass Spectrum for THC-OH TBDMS 
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Figure 4-48: - Fragmentation of THC-OH-TBDMS 
I 
The molecular ion of THC-OH TBDMS derivative is too small to be visible in the mass 
spectrum. High mass fragment ions are present at m/z 399 and m/z 342, corresponding to 
the loss of C2H5 and then C4H9 fragments. This sequence is indicated by the absence of a 
strong M-57 ion, which would have appeared at m/z 371. The source of the C2H5 fragment 
is suggested in Figure 4-48 but is not known with certainty. The source of the C4H9 
fragment could either be the tertiary butyl group or else the side-chain, as there is a loss of 
57 in the mass spectrum of THC which comes from the side chain. [1921 However, if the 
fragment came from the side chain this would result in the loss of deuterium from the 
internal standard, as the deuterium is on the end carbon of the side chain. The mass 
spectrum clearly shows that this does not happen as there is an ion at m/z 345 for the 
internal standard. 
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Figure 4-49: - Ion Chromatogram m/z 515 and Mass Spectrum for THC-COOH TBDMS 
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Figure 4-50: - Fragmentation of THC-COOH-TBDMS 
Benzoylecogonine and THC-COOH have carboxylic acid groups and base peaks at m/z 
282 and m/z 515 and are assigned to the fragments [C14H22O4Si]+ and [C29H47O4Si2]+. 
THC-OH has a hydroxyl group and a base peak at m/z 342 assigned to the fragment 
[C21H30SiO2] +. 
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4.6 Conclusions 
Several conclusions were drawn from this study, which was the initial step in the 
development of a method for use in systematic forensic toxicology. 
1. PFPA/PFP-OH derivatisation: 
This reagent produced derivatives with all of the test compounds, including the secondary 
amine (methamphetamine) and the two carboxylic acids (benzoylecgonine and THC- 
COOH). The derivatives gave good gas chromatographic properties in terms of peak shape 
and had mass spectra with strong ions which were suitable for selected ion monitoring 
either as the quantification ion or else as qualifier ions. The reagent is volatile which 
allows it to be evaporated before GC-MS analysis, which would help to preserve the GC 
column, injector liner and mass spectrometer source from contamination. 
It was concluded that this reagent had a potentially wide range of applications in STA and 
it was investigated further in phase 2 of this study. 
2. PFPA/trimethylsilyl-diazomethane derivatisation: 
Comments on trimethylsilyl- diazomethane as a reagent are given above. When used as a 
derivatising agent in combination with PFPA, all of the test compounds gave derivatives 
with good chromatographic and mass spectrometric properties. The mass spectra of 
amines and alcohols were identical to those obtained with PFPA and PFP-OH described 
above. Methyl esters were easily formed from benzoylecgonine and THC-COOH and 
these derivatives had good mass spectra with suitable ions for selected ion monitoring. 
The only potential disadvantages with this reagent was that benzoylecgonine was 
converted to cocaine and so could not be distinguished from it and there is a risk of 
interference in GC-MS analysis due to the impurities in the TMS-diazomethane reagent 
mentioned above. It was concluded that trimethylsilyl-diazomethane is a useful reagent for 
forensic toxicology but care must be taken to check for potential interference from the 
reagent during method validation. 
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3. MTBSTFA derivatisation: 
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This reagent gave good derivatives with all of the test compounds except 
methamphetamine where secondary amines not react very well with MTBSTFA. 
Chromatographic and mass spectrometric properties were good. However, although 
morphine with MTBSTFA derivatision had a good peak shape and the presence of strong 
ions gave the potential for sensitive detection by GC-MS, it was found that low 
concentration standards were not well detected in practice. This reagent had previously 
been used for analysis of carboxylic acids in urine of racing greyhounds and was effective 
in identifying unknown acids because the mass spectra had strong ions at m/z values 
corresponding to loss of the tertiary butyl group from the molecular ion, thereby allowing 
the molecular weight to be obtained. [2281 The reagent was also found to be effective in a 
subsequent part of this research project for the analysis of benzodiazepines (Chapter 7). 
The conclusion from this study is that conventional heating would be preferable to 
microwave heating as the time saved is usually less important than the overall cost of a 
routine analysis, especially if large numbers of samples are being analysed. This might be 
different under different circumstances, for example in emergency toxicology in hospital, 
where rapid turn-around is potentially life saving. Each of the reagents used in this study 
showed some advantages and all three of them were considered to have potential use in 
forensic STA. In phase 2 of the study, the reagents were applied to the derivatisation of 
extracts of the test compounds from whole blood. 
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5 Study of a Unified Method 
5.1 Introduction 
Methods of analysis generally have the steps shown in Figure 5-1 consisting of sample 
preparation followed by extraction of the substances of interest, derivatisation if required 
and then the end step analysis. 
Sample pre-treatment pH, protein precipitation, homogenisation, 
dialysis, digestion, hydrolysis of conjugates 
4. 
Extraction and clean-up Liquid-liquid extraction, solid phase 
extraction, heads ace analysis 
4. 
Chemical derivatisation if required Formation of esters, ethers, oximes etc 
4. 
End-step Analysis Spectrometric and chromatographic 
methods 
Figure 5-1 :- Components of an analytical method 
As mentioned previously, the ultimate aim of this work was to create a unified procedure 
for systematic toxicological analysis which would enable a wide range of drugs and 
metabolites to be detected in a minimum number of analyses, thereby making the 
procedure suitable for the complete toxicological analysis of small samples. The usual 
way of developing a new method is to start at the end step, so that knowledge is gained 
about the possibility of detecting extracted analytes with instrumental techniques. This 
part of the method is carried out with standards of the substances of interest. Similarly, 
derivatisation methods can be tested using reference standards without the need to extract 
them from a biological material such as blood. When the end detection method is 
available, it can be used to test extraction procedures. 
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The previous Section described the investigation of the derivatisation and GC-MS analysis 
steps. This section deals with the extraction step for selected drugs in whole blood, with 
the aim being to develop a general extraction procedure which would work with most types 
of drug. 
Solid Phase Extraction (SPE) is an extraction method that uses a solid phase and a liquid 
phase to isolate one or many type of analyte from a solution is usually used to clean up a 
sample before using a chromatographic technique. The separation properties of the 
components in a mixture are constant under constant conditions. [249,268-271] SPE is a well- 
known method for rapid sample preparation in which a solid stationary phase is typically 
packed into a syringe barrel and used to selectively extract, concentrate, and purify target 
analytes prior to analysis by HPLC or GC[272]. SPE methods usually have four steps in 
which (i) the cartridge is conditioned, (ii) the sample for analysis is loaded on the cartridge, 
(iii) the cartridge is washed to remove as many impurities as possible and then (iv) the 
analytes of interest are eluted and collected for analysis. 
It is an increasingly useful sample preparation technique. Many of the problems associated 
with liquid /liquid extraction (LLE), such as incomplete phase separations, can be avoided 
using SPE. Other disadvantages of using LLE include incomplete recoveries, use of 
expensive and specialised glassware, and disposal of large quantities of organic solvents. 
SPE is more efficient than liquid / liquid extraction and yields quantitative extractions that 
are easy to perform. It is rapid and can be automated so solvent use and lab times are 
reduced. SPE is used most often to prepare liquid samples and extract semivolatile or 
nonvolatile analytes, but it can also be used with solids that are pre-extracted into solvents. 
SPE products are excellent for sample extraction, concentration, and cleanup. They are 
available in a wide variety of chemistries, adsorbents, and size. Selecting the most suitable 
product for each application and sample is important. [273-278 
There are many types of SPE including cartridges which are more efficient, have fewer 
steps, and work with acidic and basic drugs and which are especially suitable for forensic 
laboratories. [2791 . 
The method is not ideal and an improved extraction procedure would be desirable which 
gave a single fraction containing all drugs which was clean enough to be analysed by GC- 
MS. Recent developments in SPE have included the introduction of new techniques such 
as microextraction techniques [2801 and also new types of, polymeric sorbent, including 
molecularly imprinted polymers [281,2821 
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In this study, a new sorbent, strataTM X polymeric reversed phase sorbent for polar and 
non-polar compounds was investigated as a replacement for the Certify sorbent. [2831 The 
SPE strataTM X procedure was developed for the isolation of acidic, neutral and basic drugs 
from whole blood. The sorbent in strataTM X is composed of a styrene divinylbenzene 
polymer that has hydrophilic, hydrophobic and pi-pi retention mechanisms. Full details of 
the composition of strataTM X have not been released by the manufacturer, Phenomenex, 
but it has substituents on a carbon chain as shown inFigure 5-2 (b). 
H -bonding site 
O 
N 
ý 
(a) strata TM X cartridge 
pi-pi 
interaction 
(b) Structure of strataTM X polymer 
Figure 5-2: - strataTM X 
StrataTM X (Figure5- 2a) uses a novel surface chemistry in the sorbent and offers 
significant advantages over the traditional silica-based SPE products. The selectivity of 
the strataTMX resin provides high and reproducible recoveries for a wide range of acidic, 
neutral and basic compounds, simplifying the sorbent selection process for method 
development. Not only is development simple but the unique surface properties of the resin 
remain "conditioned" even if it accidentally runs dry during the extraction, a condition that 
would significantly impair silica-based sorbents. 
StrataTM X has been used for extraction of drugs from different types of biological samples 
including tissues, plasma and urine and seemed like a good alternative to the silica-based 
sorbent Certify. [zsa-287 
This chapter describes work carried out to develop the extraction step of the proposed 
unified method and the validation of the whole method, including the extraction, 
derivatisation and GC-MS analysis steps. Three versions of a possible unified method 
were investigated based on different types of derivatising agent as described in Chapter 4. 
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These investigations were carried out using the same test standards as described in Chapter 
4. The final test of the method was to apply it to case samples. 
5.2 Method Validation - Introduction 
Method validation: this term consists of two parts. Firstly, "method": this is a 
procedure for the analysis of a specific analyte. Secondly, "validate": to support or 
corroborate on a sound or authoritative basis. E2881 Method validation is a way of testing a 
particular analytical method to see if it is acceptable for its intended purpose. [2891 
Methods which have been validated by one laboratory need to be validated before they are 
implemented in another laboratory. Commercial methods also need to be checked even if 
the manufacturer's recommended procedures are followed. Validation is also needed if 
any method is modified or used for a new application, for example, a method for the 
analysis of urine specimens should be validated if used for blood. Minor changes do not 
need re-validation, for example, changing the column in a gas chromatograph for another 
of the same type. 
The validation of a method follows a standardised set of experimental tests which produce 
data relating to accuracy, precision, linearity, limit of detection, limit of quantification and 
recovery. [2901 Guidelines have been published by several organisations. [291-2931 
Definitions of these terms are as follows. [2941 Accuracy is the ability of a method to get the 
true result. For quantitative tests the accuracy expresses the closeness of agreement 
between the true value and the value obtained by applying the test procedure a number of 
times. 
Precision is the closeness of agreement between independent test results obtained under 
specified conditions. In this study precision was measured Intra-day and Inter-day. 
Precision is usually affected by the analyte concentration and so should be measured at 
different concentrations. In this study three different concentrations were used. Precision 
is usually expressed in terms of the percentage relative standard deviation of the test 
results. 
Linearity is defined as the range of concentrations of analyte for which the procedure 
provides test results that are in direct correlation to amount of analyte in the sample. This 
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is determined from the calibration curve and values of R2 where R2 is the correlation 
coefficient between X and Y in the graph. 
LOD is defined as the lowest amount of analyte in a sample that can be detected, but not 
necessarily quantified. J2951 usually the limit of detection is evaluated as the amount of 
analyte that gives a signal-to-noise ratio of 3. Alternatively, it is equivalent to the blank 
reading plus 3 times the standard deviation of the noise or standard error of the regression 
line. The following equation was used: 
LOD = YB + 3Sy/x Equation 5-1 
where YB is the intercept on the Y-axis (equivalent to the blank reading) and Sy/x is the 
standard error of the calibration linear regression line. 
Similarly, The LOQ is the smallest amount of analyte in a sample that can be quantified 
with suitable precision and accuracy. [2951 Usually the quantitation limit is evaluated as the 
quantity of analyte that gives a signal-to-noise ratio that is equivalent to 10. Alternatively, 
it is the blank reading plus 10 times the standard deviation of the noise or standard error of 
the regression line. . 
Recovery is the percentage of the drug, metabolite, or internal standard originally 
in the specimen that reaches the end of the procedure. 
Additional parameters have tended to be added to the list of those required for full method 
validation [289] including selectivity. Selectivity was examined in this project by analysing 
negative control blood samples from real cases, to determine if interferences were present. 
In the present study, these validation parameters were measured for three possible versions 
of a unified method based on solid phase extraction with strataTM X followed by 
derivatisation with the three reagents described in Chapter 4 and GC-MS analysis. 
5.3 General Experimental Section 
5.3.1 Introduction 
Drug-free blood samples were spiked with different amounts of drug mixture including 
amphetamine, methamphetamine, morphine, benzoylecgonine, THC-OH and THC-COOH 
as model compounds. The blood was then extracted by SPE using the novel strata X 
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cartridges. Three different derivatisation methods were then applied to the extracts 
including PFPA with PFP-OH, PFPA with TMS-diazomethane and MTBSTFA. 
5.3.2 Preparation of drug mixtures 
a) All stock solutions were purchased or prepared at a concentration of approximately 
O. lmg/mL for spiking blood samples. Less concentrated solutions were prepared at 
1 µg/mL by dilution with methanol. 
A stock solution of amphetamine sulphate (salt) was prepared at 0.11mg/ml; correcting for 
amphetamine free base the concentration was 0.08mg/ml = 8Ong/µl. However a 
concentration of 1µg/ml was needed, therefore 100µl was taken from 80ng/µl stock and 
900µl of methanol was added. This gave a 8µg/ml solution which was diluted again by 
taking 500µl into a 5ml mixture flask solution and making up to volume with methanol, 
giving a final concentration of 0.8µg/ml = 0.8 ng/µl. 
A stock solution of methamphetamine hydrochloride was prepared at 0.105 mg/ml; 
correcting for methamphetamine free base the concentration was 0.08 mg/ml. The same 
dilution procedure was carried out as before, giving a final concentration 0.8 gg/ml = 0.8 
ng/. tl. 
A stock solution of benzoylecgonine was prepared at 0.105 mg/ml. 50gl of this solution 
was taken and 950µl of methanol was added to give a solution of 5.25gg/ml. 250gl of 
5.25 µg/ml solution was taken and 4.75m1 of methanol added to give a final concentration 
of 0.263µg/ml = 0.263 ng/µl. 
The concentrations of stock solutions of THC-OH and THC-COOH were 100µg/ml. 50µ1 
of I OOgg/m1 solution was added to 4.95m1 of methanol resulting in a final concentration of 
1 µg/ml =1 ng/gl. The final concentrations of working drug standards are summarized in 
Table 5-1. 
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Table 5-1: - Final concentrations of drug standards 
Drug Final concentration of drug 
standards(ng/gl) 
Amphetamine 0.8 
Methamphetamine 0.8 
Benzoylecgonine 0.261 
Morphine 0.91 
THC-OH 1 
THC-COOH 1 
b) Preparation of Internal Standard Solutions. 
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Stock internal standard solutions of amphetamine-ds, methamphetamine-d5, 
benzoylecgonine-d3, cocaine-d3, THC-OH-d3, THC-COOH-d3 and morphine-d3 were 
purchased at concentrations of 100µg/ml in methanol. Each of the stock solutions was 
diluted with l Oral methanol to give standard solutions at 1 gg/ml =1 ng/µl. 
5.3.3 Preparation of drug mixtures in blood 
Time expired transfusion blood supplied from a local hospital, which was kept in the fridge 
at 4°C, was used to prepare drug standards. A drug mixture was prepared containing 
amphetamine, methamphetamine, benzoylecgonine, cocaine, THC-OH, THC-COOH and 
morphine with a final concentration of approximately 1 µg/ml=ing//µl of each drug are 
listed in Table 5-1. 
Samples used for method validation were prepared by adding lml blood to 3.5 ml buffer 
solution and then adding standard solutions and 100µl of deuterated internal standard 
solution. The blood standard was mixed thoroughly and centrifuged for ten minutes before 
being applied to the extraction cartridge. Blank samples were prepared with and without 
internal standard. 
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5.3.4 Preparation of buffer solution 
A buffer is a solution characterized by the ability to resist changes in pH when limited 
amounts of acid or base are added to it. A buffer solution for the study was prepared by 
weighing 6.81g of potassium dihydrogen orthophosphate (KH2PO4. MW 136.09) into a 
500m1 beaker with 450m1 of distilled water. The pH was adjusted to pH 6 with 0.1 M 
potassium hydroxide solution and made up to 500m1 with distilled water in a volumetric 
flask. 
5.3.5 Extraction method: SPE on Strata TM X 
The method used followed the manufacturer's instructions and was as follows: 
A- Conditioning: prior to loading the sample, the SPE column was washed and wetted with 
1 ml methanol. 
B- Equilibration: in this study, the SPE column was equilibrated with lml distilled water. 
C- Sample loading: blood standards containing different concentrations of the test drug 
compounds were applied to the SPE columns. 
D- Washing out of impurities. 5% methanol in distilled water was prepared by mixing 
95ml of distilled water with 5m1 methanol. 1.5 ml of this solution was applied before 
drying for 30 seconds at full vacuum. 
E- Elution was carried out in one step with 1.5m1 of methanol. 
The extracts were then evaporated to dryness under a stream of nitrogen, without heating. 
5.3.6 Derivatisation 
Extracts were derivatised with each of the three reagents described in Chapter 4 before 
being analysed by GC-MS 
5.3.7 GC-MS analysis 
Derivatised extracts were analysed by GC-MS using the conditions described in Chapter 4, 
Table 4-1. Data was collected in the SIM mode using the ions listed in Tables 4-2,4-4 and 
4-5. 
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5.3.8 Validation parameters 
The parameters measured for each of the three derivatision procedures were: - Linearity, 
Intra-day Precision, Inter-day Precision, Limit of Detection, Limit of Quantification and 
Recovery. Each parameter was measured using 5 replicate standards. 
5.3.9 Application to case samples 
Each version of the poroposed unified method was applied to real case samples taken at 
autopsy and received by the Section of Forensic medicine and Science, University of 
Glasgow. Cases were selected for analyses which were known to be positive for the drug 
groups of interest which were used as test substances in this study, to serve as positive 
controls. In addition, a second group of cases was analysed which had not been found to 
contain the drugs of interest to serve as negative controls. These were kept frozen until 
analysed. 
5.4 Method Validation for Drug Derivatisation with PFPA- 
PFPOH 
5.4.1 Introduction 
These reagents produce pentafluoropropionyl (acyl) derivatives of amines and alcohols and 
simultaneously the anhydride activates carboxylic acids so that PFPOH will react with 
them to produce the pentafluoropropyl ester derivatives. The following paragraphs 
describe the validation procedures carried out. 
5.4.2 Linearity 
Five replicate analyses were carried out at each concentration and linearity was determined 
from the calibration curve and values of R2 where R2 is the correlation coefficient between 
X and Y in the graph. Calibration curves for the target analytes were linear over a 
concentration range of 16-80 ng/ml of blood for amphetamine and methamphetamine, 
4.55-22.75 ng/ml of blood for morphine, 5.25-26.25 ng/ml of blood benzoylecgonine and 
20-100 ng/ml blood for THC-OH, THC-COOH. The correlation coefficient (R) values 
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are listed in Table 5-2, and curves (averaged values of 5 replicates) are shown below in 
Figure 5-3 to Figure 5-8. 
Table 5-2: -Summary of Values of correlation coefficient (R2) for all compounds analysed as 
the PFP-PFP-OH derivatives 
Compound R2 Values 
Amphetamine 0.9966 
Methamphetamine 0.9947 
Morphine 0.9992 
Benzoylecgonine 0.9945 
THC-OH 0.9989 
THC-COOH 0.9934 
Amphetamine 
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-Linear (Arrphetarrine PFP) 
Figure 5-3: - Calibration curve for Amphetamine analysed as the PFP derivative 
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Figure 5-4: - Calibration curve for Methamphetamine analysed as the PFP derivative. 
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Figure 5-5: - Calibration curve for Morphine analysed as the bis-PFP derivative 
Chapter Five Page 97 
Benzoylecgonine 
0.2 
f Benzoylecgonine-PFP 
Linear (Benzoylecgonine- 
PFP) 
0 5 10 15 
ng/m I 
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Figure 5-6: - Calibration curve for Benzoylecgonine analysed as the PFP ester derivative 
Figure 5-7: - Calibration curve for THC-OH analysed as the PFP derivative 
THC-COOH 
f THC-COOH PFP 
-Linear (THC-00OH PFP) 
120 
ng/m l 
Figure 5-8: - Calibration curve for THC-COOH analysed as the PFP/PFP ester derivative 
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5.4.3 Intra-Day variation 
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Different concentrations for the test drugs in the range 16-80ng/ml of blood for 
amphetamine and methamphetamine, 4.55-22.75ng/ml of blood for morphine, 5.25- 
26.25ng/ml of blood benzoylecgonine and 20-100ng/ml blood for THC-OH, THC-COOH 
were extracted five times to calculate the intra-day variation of the assay. Average 
drug/internal standard ratios and relative standard deviations (%RSD) were calculated for 
each concentration as shown from Table 5-3 to Table 5-6. 
Table 5-3: - Intra-Day variation for Amphetamine and Methamphetamine analysed as the 
PFP-PFP-OH derivatives 
Added Concentration Average area Ratio (%RSD) 
(ng/ml of blood) Amp/Amp-D3 Meth/Meth-D5 
16 0.2 (22.3) 0.01 (5.8) 
48 0.9 (10.4) 0.03 (10.9) 
80 1.6 (10.3) 0.05 (6.8) 
Table 5-4: - Intra-Day variation for Morphine analysed as the bis-PFP derivative 
Added Concentration (ng/ml of blood) Average area Ratio Mor/Mor-D3 (%RSD) 
4.6 0.05 (3.0) 
13.7 0.1 (8.1) 
22.8 0.2 (13.5) 
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Table 5-5: - Intra-Day variation for Benzoylecgonine analysed as the PFP ester derivative 
Added Concentration (ng/ml of blood) Average area Ratio Bze/Bze-D3 (%RSD) 
5.3 0.07 (10.8) 
15.8 0.13 (4.8) 
26.3 0.21 (7.2) 
Table 5-6: - Intra-Day variation for THC-OH and THC-COOH analysed as the PFP/PFP ester 
derivatives 
Added Concentration Average area Ratio (%RSD) 
(ng/ml of blood) THC-OH /THC-D3 THC-COOH/THC-COOH-D3 
20 0.4 (6.5) 0.14 (15.6) 
60 0.7 (4.8) 0.61 (10.3) 
100 1.3 (6.2) 1.3 (16.5) 
5.4.4 Inter-Day variation 
A set of calibration standards in blood containing six drugs was extracted five times during 
different days with the same concentration as before (16-80ng/ml of blood for 
amphetamine and methamphetamine, 4.55-22.75ng/ml of blood for morphine, 5.25- 
26.25ng/ml of blood benzoylecgonine and 20-100ng/ml blood for THC-OH, THC-COOH). 
Calibration curves were constructed and the concentration of each standard was measured 
using the calibration curve, based on the ratio of analyte to internal standard. The inter-day 
variation for each test substance was measured and these values are displayed in Table 5-7 
to Table 5-10. 
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Table 5-7: - Inter-Day variation for Amphetamine and Methamphetamine analysed as the PFP 
derivatives 
Added Concentration 
(ng/ml of blood) 
Mean Measured Concentration (%RSD) 
Amp Meth 
16 15.9 (6.9) 16.8 (27.0) 
48 47.7 (5.4) 40.6 (12.9) 
80 80.4 (2.5) 81.0(5.1) 
Table 5-8: - Inter-Day variation for Morphine analysed as the bis-PFP derivative 
Added Concentration -Morphine 
(ng/ml of blood) 
Mean Measured Concentration (%RSD) 
4.6 4.5 (12.3) 
13.6 14.1 (10.3) 
22.7 23.0 (2.4) 
Table 5-9: - Inter-Day variation for Benzoylecgonine analysed as the PFP ester derivative 
Added Concentration -Benzoylecgonine 
(ng/ml of blood) 
Mean Measured Concentration (%RSD) 
5.3 5.5 (3.9) 
15.8 15.3 (0.8) 
26.3 26.6 (1.6) 
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Table 5-10: - Inter-Day variation for THC-OH and THC-COOH analysed as the PFP/PFP ester 
derivatives 
Added Concentration Mean Measured Concentration (%RSD) 
(ng/ml of blood) THC-OH THC-COOH 
20 21.2 (8.5) 19.8 (21.4) 
60 58.4 (7.5) 60.9 (9.0) 
100 103.5(l. 9) 98.4(3.1) 
5.4.5 Recovery 
The recovery of the method, using strata X, was calculated using spiked blood samples 
at three different concentrations. Each concentration was extracted five times without 
internal standard present. Two unextracted standards were also prepared at each 
concentration without internal standard and were kept in the fridge throughout the 
extraction. Before blowing down the samples under a stream of nitrogen, l00µl of 
internal standard was added to each vial including the unextracted standards. The recovery 
calculated was obtained from the peak area ratio of the extracted standard divided by the 
peak area ratio of the unextracted standard, multiplied by 100. Recovery for all the drugs 
is summarized in Table 5-11 and Figure5-9. 
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Table 5-11: - Recovery of six drugs analysed as PFPA-PFP-OH derivatives 
Analyte Concentration n /ml 
Recovery 
% 
16 74 
Amphetamine 48 89 
80 89 
16 23 
Methamphetamine 48 15 
80 18 
4.6 96 
Morphine 13.7 60 
22.8 71 
5.3 86 
Benzoylecgonine 15.8 91 
26.3 95 
20 62 
THC-OH 60 49 
100 44 
20 61 
THC-COOH 60 58 
100 59 
Recovery 
100 
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60 
40 x 
° 20 
0 
Amp Meth Mor Benzo THC-OH THC- 
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  Low 
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Q High 
Figure 5-9: - Recoveries of drugs from blood using StrataTmX and analysed as the PFP-PFP- 
OH derivatives 
5.4.6 Limit of Detection (LOD) 
Blood was spiked to give concentrations of 20,15,10,5,2.5,1 and 0.5 ng/ml bloods for 
amphetamine, methamphetamine, morphine, benzoylecgonine, THC-OH and THC-COOH. 
Five replicates were analysed at each concentration. The equation of the line was 
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calculated for each drug using Microsoft Excel. The regression analysis program within 
Microsoft Excel was also used to calculate Sy/x for each drug. [2951 Equation 5-2 was then 
applied to find the limit of detection based on Equation 5-1 
LOD = intercept + (3 x standard error) Equation 5-2 
Rearranging the equation of the line for x gives the following: 
Y= mx +b Equation 5-3 
Answer equation (2) applied in Equation (3) for getting limit of detection as 
x= y-b/m Equation 5-4 
5.4.7 Limit of Quantitation (LOQ) 
As presented before, Equation 5-5 was then applied to find the limit of quantitation and 
rearranging the equation of the line from x Equation 5-3 for finding limit of quantitation. 
LOQ = Ys + 10Sy/x Equation 5-5 
The limits of detection and quantitation were calculated and are shown below in Table 5- 
12. 
Table 5-12: - Limits of Detection and Limits of Quantitation of the six drugs analysed as the 
PFP-PFP-OH derivatives 
Drugs LOD (ng/ml) LOQ (ng/ml) 
Amphetamine 1.2 4.0 
Methamphetamine 0.8 2.7 
Morphine 0.8 2.6 
Benzoylecgonine 0.4 1.5 
THC-OH 1.7 5.8 
THC-COOH 3.7 12.4 
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5.4.8 Application to real case samples 
The developed method was applied to 51 cases samples of which 36 samples had 
previously been found to be positive for drugs of abuse. Case results are summarized 
below in Table 5-13 and Table 5-14. 
Table 5-13: - Results of GC/MS for drug-positive cases analysed as PFPA-PFP-OH 
derivatives 
Case No Drug Concentration (mg/L) 
Amp Meth Mor Cocaine Bze THC THC-COOH 
Blank - - - - - - - 
1 0.28 - - - - - - 
2 - - 0.5 - - - - 
3 - - 0.34 - - - - 
4 - - 1.74 - - - - 
5 - - - - 0.3 - - 
6 0.02 - - - - - - 
7 - - 0.7 - - - 
8 - - 0.01 - - - - 
9 - - 0.46 - - - - 
10 - - 0.11 - - - - 
11 - - 0.32 - - - - 
12 - - 0.15 - - - - 
13 - - - - 0.0005 - - 
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14 - - - - 0.07 - - 
15 - - - - 0.1 - - 
16 - - - - 0.03 - - 
17 - - - - - 0.09 0.23 
18 - - 0.02 - - - - 
19 0.001 - - - - - - 
20 - - 0.39 - - - - 
21 - - 0.39 - - - - 
22 - - 0.001 - - - - 
23 - - 0.31 - - - - 
24 - - 0.94 - - - - 
25 - - 0.56 - - - - 
26 - - 0.19 - - - - 
27 - - 0.22 - - - - 
28 - - 0.18 - - - - 
29 - - 0.34 - - - - 
30 - - 0.34 - - - - 
31 - - 0.423 - - - - 
32 - - - - - - 
33 - - - - - - - 
34 - - - - - - - 
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Table 5-14: - Results of GC/MS analysis of extracts containing other drugs using PFP/PFP- 
OH reagent 
Case No Drug Concentration (mg/L) 
Drugs Amitrip Metha Code Propox Dothi Indo Fluox Bupre Parcet 
Blank - - - - - - - - - 
1 1.4 - - - - - - - - 
2 - 0.84 - - - - - - - 
3 - - 0.1 - - - - - - 
4 - - 0.3 - - - - - - 
5 - - - 0.2 - - - - 
6 - - - 2.2 - - - - - 
7 - - - 0.3 - - - - - 
8 - - - 0.01 - - - - - 
9 - - - - 2.5 - - - 
10 - - 0.1 - - - - - - 
11 - - 0.02 - - - - - - 
12 - - 0.014 - - - - - - 
13 - - - - - 0.02 - - - 
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14 
15 
2.3 
2.8 
(Amitrip = Amitriptyline, Metha = Methadone, Code = Codeine, Propox = Propoxyphene, 
Doth = Dothiepin, Indo = Indomethacin, Fluox = Fluoxetine, Bupre = Buprenorphine, 
Parcet = Paracetamol) 
5.4.9 Discussion 
This version of the proposed unified method was validated using PFP-OH-PFPA as the 
derivatising agent. The validation parameters, including linearity, precision, recovery, 
limit of detection and limit of quantification were measured and are summarised in Table 
5-15 below. 
Table 5-15: - Recovery, intra and inter-day assay precision with PFPA-PFP-OH at different 
concentration 
Compound- Product Concentration 
n ml 
Recovery 
% n=5 
Intra-day 
RSD%(n=5 
Inter-day 
RSD% n=5 
16 74 22.3 6.9 
Amphetamine-PFP 48 89 10.4 5.4 
80 89 10.3 2.5 
16 23 5.8 27.0 
Methamphetamine-PFP 48 15 10.9 12.9 
80 18 6.8 5.1 
4.55 96 3.0 12.3 
Morphine-PFP 13.65 60 8.1 10.3 
22.75 71 13.5 2.4 
5.25 86 10.8 3.9 
Benzoylecgonine-PFP 
ester 
15.75 91 4.8 0.8 
26.25 95 7.2 1.6 
20 62 6.5 8.5 
THC-OH-PFP 60 49 4.82 7.5 
100 44 6.2 1.9 
20 61 15.6 21.4 
THC-COOH PFP ester 60 58 10.3 9.0 
100 59 16.5 3.1 
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The intra- and inter-day precision were evaluated at low, medium and high concentrations 
for five replicates and the % RSD was subsequently calculated. The %RSD values were 
mostly within the suggested acceptable limit of 15% (20% at the LOQ) J2891 Intra-day assay 
%RSDs ranged from 0.3 to 22.3 %. The highest intra-day %RSD was 22.3% for 
amphetamine in blood at a concentration of 16 ng /ml while the lowest %RSD was 3% for 
morphine at 4.55 ng/ml blood. The inter-day assay %RSDs ranged from 0.8 to 27 %. The 
highest inter-day %RSD was with methamphetamine while lowest %RSD was with 
Benzoylecgonine at 15.8 ng/ml blood as shown in Table 5-15. 
Calibration curves prepared with with six standards including blank experiments showed 
that the response was linear (R2 > 0.99) for all the analyzed compounds which is 
acceptable for the analysis of biological specimens. Also, although there was matrix 
interference observed using the StrataX SPE cartridge, good calibration graphs were 
obtained. 
Benzoylecgonine produced the lowest detection limit whereas THC-COOH produced a 
higher detection limit. The limits of detection and quantitation were listed in Table 5-12. 
Two conclusions can be made from these results. Firstly, the derivatisation procedure 
worked well with both amines and carboxylic acids in the same extract so it fulfils the 
requirements of a unified procedure. Secondly, the detection limits for THC-COOH and 
benzoylecgonine reflect the fragmentation patterns seen in their mass spectra. The selected 
ions for both compounds are the base peaks in their mass spectra. However, the 
percentage of the ion current carried by the base peak ion of benzoylecgonine is larger than 
that for THC-COOH, i. e. the mass spectrum of the latter shows more ions, and so the 
sensitivity is expected to be better for benzoylecgonine. The detection limits for THC-OH 
and THC-COOH would need to be improved if the method was used routinely since the 
recommended cut-off level for THC in oral fluid is 4 ng /ml. 
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The recovery ranged between 15-96 %. The lowest recovery was with methamphetamine 
and the highest with morphine. The reason for the poor recovery of methamphetamine is 
not clear, as more polar compounds such as amphetamine, and less polar compounds such 
as THC-OH had higher recoveries. Possible reasons may relate to failure of the chemical 
derivatisation step for the secondary amine or else loss of methamphetamine during the 
evaporation step. Comparison with the recovery of methamphetamine measured using 
other reagents, for example the PFPA-methyl ester (Figure 5-10) shows that the recovery is 
good and that the loss of methamphetamine must have occurred outside the extraction step 
itself. However, the limit of detection and limit of quantification of methamphetamine 
were acceptable. 
Comparison of recovery of Methamphetamine analysed as 
PFP and PFP/Methyl ester 
ý 
ý 
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ö 
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20 
0 
16 48 
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Figure 5-10: - Recovery of methamphetamine from blood using Strata 
TMX and analysed after 
derivatisation with PFPA-PFP-OH and PFPAIMethyl ester 
The validated method was applied to blood samples collected from Forensic Medicine and 
Science at the University of Glasgow. In general the method worked very well with 
strata"' X. However there was a great deal of interference in the GC-MS analysis that 
could potentially obscure the analyte peaks. Because of the interferences observed using 
the strata TM X SPE cartridge, washing of the SPE cartridge with more than 1.5 ml of 5% 
methanol in distilled water could perhaps resolve this problem Figure 5-11. The method 
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was found to be able to detect and quantify both basic and acidic drugs including drugs of 
abuse and prescribed drugs. 
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Figure 5-11: -TIC Chromatogram blank for Strata TM X SPE (A) with I ml methanol (B) with 1.5 
methanol 
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5.4.10 Conclusion 
This version of the method showed promise as a unified procedure for general use because 
of its ability to detect and meaure both acidic and basic drugs. StrataTM X also was able to 
extract both of these types of analyte from whole blood, although with different 
efficiencies and with co-extracted interferences, but nevertheless with acceptable limitis of 
quantification. 
5.5 Method validation for drug derivatisation with PFPA 
and TMS-diazomethane 
5.5.1 Introduction 
These derivatising agents produce pentafluoropropionyl (acyl) derivatives of alcohols and 
amines, as for the PFPA-PFPOH reagent but the pentafluoropropyl esters are replaced with 
the methyl ester function. In principle, it would not be necessary to repeat the validation 
parameters for drugs which lack a carboxylic acid group. However, the possibility arises 
that changes in the reaction conditions might affect other drugs in unexpected ways and 
changes in the products obtained might also affect both the subsequent gas 
chromatography and mass spectrometry. For this reason, the same set of drug standards 
was used to model the analytical method, allowing direct comparison with the other 
versions of the procedure. The following paragraphs describe the validation procedures 
carried out. 
5.5.2 Linearity 
Standards in blood were prepared and each concentration was extracted five times and 
calibration graphs of each compound were produced. The concentration ranges were the 
same as listed in Paragraph 5.4.2. As seen before, the calibration curves of peak area ratio 
against the concentration of the target analyte were linear and these are shown in Figure 
5-12 to Figure 5-17. The correlation coefficient (R2) values are listed in Table 5-16. 
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Table 5-16: - Correlation coefficient (R2) for calibration curves for all compounds analysed as 
the PFP/methyl ester derivatives 
Compound R- Values 
Amphetamine 0.9888 
Methamphetamine 0.9089 
Morphine 0.9995 
Benzoylecgonine 0.9862 
THC-OH 0.9966 
THC-COOH 0.9994 
Amphetamine 
I 
1.6 
1.4 
ýy=0.0124x 
+ 0.3973 
1 .21R? = 
0.9888 
0ý -- 
0 20 40 60 80 100 
1 
0.8 
Ob 
04 
f Amphetarrine PFP/TMS 
Linear (Amphetarrine 
PFP/TMS) 
ng/m I 
Figure 5-12: - Calibration curve for Amphetamine analysed as the PFP derivative 
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Figure 5-13: - Calibration curve for Methamphetamine analysed as the PFP derivative 
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Figure 5-14: - Calibration curve for Morphine analysed as the bis-PFP derivative 
Benzoylecgonine 
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Figure 5-15: - Calibration curve for Benzoylecgonine analysed as the methyl ester derivative 
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Figure 5-16: - Calibration curve for THC-OH analysed as the PFP derivative 
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Figure 5-17: - Calibration curve for THC-COOH analysed as the PFP/methyl ester derivative 
The calibration curves obtained in this validation work were similar to those obtained with 
the PFP-PFPOH reagent except for amphetamine and methamphetamine. For both of 
these, the blank showed significantly positive. The amphetamine curve was however, a 
reasonable straight line whereas for methamphetamine the blank reading reduced the 
correlation coefficient to 0.9089. Excluding the blank results in a better linear correlation 
with an R2 value of 0.9675. 
5.5.3 Intra -day variation 
Using the same procedure as for PFPA-PFP-OH derivatives, five sets of blood standards 
were extracted and analysed as PFPA-methyl derivatives. The main potential disadvantage 
of this reagent is that benzoylecgonine is converted to cocaine so information on extent of 
metabolism in casework samples would be lost. The average area ratios were calculated 
and are displayed from Table 5-17 to Table 5-20. 
Table 5-17: - Intra-day variation for Amphetamine and Methamphetamine analysed as the 
PFP derivatives 
Concentration Average area Ra tio (%RSD, n=5) 
(ng/ml of blood) Amp/Amp-d3 Meth/Meth-d5 
16 0.6(1.5) 0.3(6.0) 
48 1.0 (1.4) 0.8 (3.2) 
80 1.3 (4.4) 1.14 (1.4) 
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Table 5-18: - Intra-day variation for Morphine analysed as the PFP derivative 
Concentration 
(n ml of blood) 
Average area Ratio Mor/Mor-d3 
(%RSD, n=5 
4.6 0.03 (0.4) 
13.7 0.1 (1.1) 
22.8 0.12 (0.74) 
Table 5-19: - Intra-day variation for Benzoylecgonine analysed as its methyl ester 
Concentration 
(ng/ml of blood) 
Average area Ratio Bze/Bze-d3 
(%RSD, n=5 
5.3 2.25 (10.2) 
15.8 5.91 (10.6) 
26.8 11.7 (10.4 
Table 5-20: - Intra-day variation for THC-OH and THC-COOH analysed as their PFP/methyl 
ester derivatives 
Concentration 
(ng/ml of blood) 
Average area Ratio 
(%RSD, n=5) 
THC-OH/THC-OH-d3 THC-COOH/THC-COOH-d3 
20 0.59 5.6 0.21 8.6 
60 1.6 (5.1 0.64 3.2) 
100 2.4 (3.7 0.9(7.2) 
The within-day variations as shown by the %RSD are mostly less than 10%, with 
benzoylecgonine lying between 10 and 11 %RSD. These are all within the suggested 
limits for precision. [289] 
5.5.4 Inter - day variation 
The blood standards used to obtain the linearity curve were each extracted five times 
during one month for all the drugs and the average concentrations were calculated using 
the calibration curves and these are displayed from Table 5-21 to Table 5-24. The 
concentrations were the same as those used previously. 
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Table 5-21: -Inter-day variation for Amphetamine and Methamphetamine analysed as their 
PFP derivatives 
Concentration 
(ng/ml of blood) 
Mean Measured Concentration (%RSD, n=5) 
Amp Meth 
16 15.7 (2.4) 15.7 (4.8) 
48 48.7 (1.8) 48.4 (1.0) 
80 79.8 (1.6) 79.4 (1.6) 
Table 5-22: -Inter-day variation for Morphine analysed as the bis-PFP derivative 
Concentration -Morphine 
(ng/ml of blood) 
Mean Measured Concentration 
(%RSD, n=5) 
4.6 4.7 (2.4) 
13.7 13.6 (1.9) 
22.8 22.7 (0.6) 
Table 5-23: - Inter-day variation for Benzoylecgonine analysed as the methyl ester derivative 
Concentration -Benzoylecgonine 
(ng/ml of blood) 
Mean Measured Concentration 
(%RSD, n=5) 
5.3 5.4 (10.5) 
15.8 15.6 (2.9) 
26.26 26.43 (1.6) 
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Table 5-24: -Inter-day variation for THC-OH and THC-COOH analysed as the PFPlmethyl ester 
derivatives 
Concentration Mean Measured Concentration (%RSD, n=5) 
(ng/ml of blood) THC-OH THC-COOH 
20 19.8 (5.9) 20(5.1) 
60 60.3 (4.2) 59.4 (1.4) 
100 99.5 (0.84) 99.5 (1.3) 
5.5.5 Recovery 
Recoveries of drugs by the method were calculated using spiked blood samples with low, 
medium and high concentrations (Table 5-25, Figure 5-18). 
Table 5.25: - Recovery for six drugs analysed as the PFP/methyl ester derivatives 
Analyte Concentration n /ml 
Recovery 
% 
16 99 
Amphetamine 48 92 
80 95 
16 62 
Methamphetamine 48 86 
80 90 
4.55 88 
Morphine 13.65 91 
22.75 87 
5.25 85 
Benzoylecgonine 15.75 85 
26.25 83 
20 66 
THC-OH 60 50 
100 56 
20 56 
THC-COOH 60 60 
100 68 
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Figure 5-18: - Recoveries of drugs from blood using Strata 
TMX 
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It is noted that the recovery of methamphetamine in this set of tests was much better than 
in the previous set. 
5.5.6 Limit of Detection and Limit of Quantification 
The methods used for obtaining the LOD and LOQ were the same as mentioned in 
Sections 5.4.6 and 5.4.7 and the results are shown below in Table 5-26. 
Table 5-26: - LOD and LOQ for Test Drugs analysed as the PFP/methyl ester derivatives 
Drugs LOD (ng/ml) LOQ (ng/ml) 
Amphetamine 0.6 2.1 
Methamphetamine 0.6 2.1 
Morphine 0.3 1.1 
Benzoylecgonine 0.3 1.2 
THC-OH 1.3 4.3 
THC-0OOH 1.4 4.7 
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The LOD and LOQ values show some small improvements compared to the first set of 
tests. The LOQ of THC-COOH, however, is better when it is analysed as the PFP acyl 
/methyl ester derivative. 
5.5.7 Application to real case samples 
46 case samples were analysed with the PFPA/TMS-diazomethane reagent of which 36 
samples were previously found to be positive for some drugs of abuse (Table 5-27 and 
Table 5-28). These cases were not related to the cases mentioned in Table 5-13 and 5-14. 
Table 5-27: - Results of GC/MS for cases analysed using the PFP/TMS diazomethane reagent 
Case No Drug Concentration (mg/L) 
Amp Meth Mor CocaineBze THC THCCOOH 
Blank - - - - - - 
1 0.32 - - - - - 
2 - - 0.5 - - - 
3 - - 0.24 - - - 
4 - - 0.11 - - - 
5 - 0.54 - - - 
6 - - 0.18 - - - 
7 - 0.36 - - 
8 0.01 - - - - 
9 0.13 - - - - 
10 0.01 - - - - - 
11 0.02 - - - - - 
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12 0.014 - - - - - 
13 - - - 0.007 - - 
14 - - - 0.11 - - 
15 - - - 0.11 - - 
16 - - - 0.022 - - 
17 - - - 0.01 
18 - - 0.32 - - - 
19 - 0.26 - - - 
20 - - 0.1 - - - 
21 - - 0.5 - - - 
22 - - 0.04 - - - 
23 - - 0.1 - - - 
24 - - 0.2 - - - 
25 - - 0.1 - - - 
26 - - 0.5 - - - 
27 - - 0.41 - - - 
28 - - 0.1 - - - 
29 - - 0.2 - - - 
30 - - 0.2 - - - 
31 - - 0.4 - - - 
32 - - 0.4 - 
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33 
34 
35 
36 
0.4 
0.54 
0.2 
0.01 
Table 5-28: - Results of GCIMS analysis of extracts containing other drugs using PFP/TMS 
diazomethane reagent 
Drugs Amitrip Metha Code Propox Dothi Indo Fluox Bupre aracet 
Blank - - - - - - - - 
1 0.3 - - - - - - 
2 2.4 - - - - - - - 
3 - 0.2 - - - - - - 
4 - - 0.03 - - - - - 
5 - - 0.6 - - - - - 
6 - - - 0.8 - - - - 
7 - - - 2.5 - - - - 
8 - - - - - - - - 
9 - - - - - - - - 
10 - - - - - - - - 
(Amitrip = Amitriptyline, Metha = Methadone, Code = Codeine, Propox = Propoxyphene, 
Doth = Dothiepin, Indo = Indomethacin, Fluox = Fluoxetine, Bupre = Buprenophine, 
Parcet = Paracetamol) 
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5.5,8 Discussion 
The validation parameters including linearity, precision, recovery, limit of detection, and 
limit of quantification were evaluated as described previously and recoveries and precision 
are summarised in Table 5-29. 
The RZ values of calibration curves were >_0.99 for morphine and the cannabinoids but for 
amphetamine, methamphetamine and benzoylecogonine RZ S 0.98). The interference 
effects on amphetamine and methamphetamine appeared to come from SPE using Strata - 
TmX and from the TMS-diazomethane reagent so the intercepts for amphetamine and 
methamphetamine were high. 
The intra-day and inter-day precision were evaluated at low, medium and high 
concentrations for five replicates. Intra-day assay %RSDs ranged from 0.4 to 10.6 % 
while the inter-day assay RSDs ranged from 0.64 to 10.5 %. The highest intra-day %RSD 
was 10.8% for Benzoylecgonine at a concentration of 15.8 ng/ml blood while the lowest 
%RSD was 0.4% for morphine at a concentration of 4.6 ng/ml blood. A similar pattern 
was seen for inter-day precision:, the highest inter-day %RSD was 10.5% for 
benzoylecgonine at a concentration of 5.3 ng/ml blood while lowest %RSD was 0.64% for 
morphine at a concentration of 22.8 ng/ml as shown in Table 5-29. It is noted that some 
intra-day precisions are worse than for the corresponding inter-day values, although they 
mostly lie in the same range. These variations may represent basic problems in 
reproducibility of the SPE procedure, of the derivatisation procedure (due to impurities in 
the TMS-diazomethane reagent) or else of the GC-MS instrument. Comparing this 
derivatisation procedure with the previous one, it can be seen that there are some 
differences in precision between the methods for the test substances but neither is clearly 
better than the other one. 
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Recoveries ranged between 50 and 99%. The lowest recovery was for THC-OH and the 
highest was for amphetamine. As noted earlier, the recovery of methamphetamine was 
higher in this series of tests than in the first set. 
Morphine and benzoylecgonine produced the lowest detection limits and THC-COOH 
produced the highest detection limit. The limits of detection and quantitation are listed in 
Table 5-26. 
Table 5-29: - Accuracy, intra- and inter-day assay precision for the test substances analysed 
at different concentrations with PFPA-TMS-diazomethane derivatisation 
Compound- 
Product 
Concentration 
(ng/ml) 
Recovery % 
(n=5) 
Intra-day 
RSD% 
n=5 
Inter-day 
RSD% (n=5) 
16 99 1.5 2.4 
Amphetamine-PFP 48 92 1.4 1.8 
80 95 4.4 1.6 
16 62 6.02 4.8 
Methamphetamine- 
PFP 
48 86 3.2 1.03 
80 90 1.4 1.6 
4.6 88 0.4 2.4 
Morphine-bis-PFP 13.7 91 1.1 1.9 
22.8 87 0.74 0.6 
5.25 85 10.2 10.5 
Benzoylecgonine- 
Methyl ester 
15.8 85 10.6 2.9 
26.8 83 10.4 1.6 
20 66 5.63 5.9 
THC-OH-PFP 60 50 5.13 4.2 
100 56 3.7 0.84 
20 56 8.6 5.12 
THC-COOH 
PFP/Methyl ester 
60 60 3.2 1.41 
100 68 7.16 1.33 
The validated method was applied to blood samples collected from Forensic Medicine and 
Science at the University of Glasgow. In general the method worked well with this 
derivatising reagent. However as found in the first set of tests, there were interferences in 
the GC-MS analyses due to the StrataTM X cartridges and also due to the TMS- 
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diazomethane reagent. However, the method was found to be able to detect and quantify 
both basic and acidic drugs including drugs of abuse and prescribed drugs. 
5.5.9 Conclusion 
This version of the method also showed promise as a unified procedure for general use 
because of its ability to detect and meaure both acidic and basic drugs. This derivatisation 
procedure would be very useful if a pure form of the TMS-diazomethane solution could be 
prepared. The limits of quantification for cannabinoids would need to be improved if the 
method was to be used routinely. 
5.6 Method validation for drug derivatisation with 
MTBSTFA 
5.6.1 Introduction 
The third version of the proposed unified method was validated as before, using the same 
approach to the measurement of the validation parameters. Neither methamphetamine nor 
morphine could be detected as their TBDMS derivatives, as noted in Chapter 4. 
5.6.2 Linearity 
Using the procedure as before, each drug concentration in blood was extracted five times 
and the calibration curves for the target analytes were prepared. These were found to be 
linear. The correlation coefficient (R2) values are listed in Table 5-30, and the curves are 
shown below in Figure 5-19 to Figure 5-22. The ions for these derivatives used for GC- 
MS-SIM were at high mass values and were selective, so there was no interference in the 
GC-MS analysis. 
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Table 5-30: - Correlation coefficients (R2) for all compounds analysed as TBDMS derivatives. 
Compound R- Values 
Amphetamine 0.9995 
Benzoylecgonine 0.9971 
THC-OH 0.999 
THC-COOH 0.9976 
Amphetamine 
f Amphetanine- TBDMCS 
Linear (Amphetamne-TBDIv1CS) 
0 20 80 100 
Figure 5-19: - Calibration curve for Amphetamine-TBDMCS derivative 
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Figure 5-20: - Calibration curve for Benzoylecgonine-TBDMCS derivative 
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f THC-OH-TBDMCS 
Linear (THC-OH-TBDMCS) 
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Figure 5-21: - Calibration curve for THC-OH-TBDMCS derivative 
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Figure 5-22: - Cailbration curve for THC-COOH-TBDMCS 
5.6.3 Intra -Day Variation 
The set of calibration curve standards containing all six drugs was extracted five times 
during one day and the results of GC-MS analysis are displayed in Table 5-31 to Table 
5-33. 
I, 
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Table 5-31: - Intra-Day variation for Amphetamine analysed as the TBDMS derivative 
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Concentration (ng/ml of blood) Average Area Ratio of Amp/Amp-d5 
(%RSD, n=5) 
16 0.07 (8.9) 
48 0.5 (6.4) 
80 0.97 (10.3) 
Table 5-32: - Intra-Day variation for Benzoylecgonine analysed as the TBDMS derivative 
Concentration (ng/ml of blood) Average area Ratio Bze/Bze-d3 
(%RSD, n=5) 
5.3 0.32 (10.7) 
15.75 0.9 (6.7) 
26.25 0.42 (10.3) 
Table 5-33: - Intra-Day variation for THC-OHITHC-COOH analysed as the TBDMS derivatives 
Concentration 
(ng/ml of blood) 
Average area Ratio ( 
THC-OH 
%RSD, n=5) 
THC-COOH 
20 0.21 (5.2) 0.15 (1.0) 
60 0.7 (1.9) 0.52 (1.9) 
100 1.2 (10.3) 0.86 (10.0) 
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5.6.4 Inter-Day Variation 
The average area ratios were calculated for five sets of drug standards which were 
extracted five times over a period of 1 week and are displayed in Table 5-34 to Table 5-36. 
Table 5-34: - Inter- Day variation for Amphetamine analysed as the TBDMS derivative 
Concentration -Amp (ng/ml of blood) Mean Concentration (%RSD, n=5) 
16 16.3 (4.1) 
48 50.3 (12.6) 
80 79.9 (2.2) 
Table 5-35: - Inter- Day variation for Benzoylecgonine analysed as the TBDMS derivative 
Concentration Bze (ng/ml of blood) Mean Concentration (%RSD, n=5) 
5.3 5.5 (12.0) 
15.75 15.3 (8.4) 
26.25 25.9 (2.7) 
Table 5-36: - Inter- Day variation for THCITHC-COOH 
Concentration Mean Concentration (%RSD, n=5) 
(ng/ml of blood) THC-OH THC-COOH 
20 19.2 (9.36) 18.1 (5.3) 
60 58.4 (6.48) 57.8 (7.5) 
100 101.2 (2.45) 99.5 (3.3) 
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The recoveries of the method for drugs extracted from spiked blood samples at low, 
medium and high concentrations were measured as before. The results are shown below in 
Table 5-37 and Figure 5-23. 
Table 5-37: - Recovery for test substances analysed as MTBSTFA derivatives 
Analyte 
Concentration 
(n /ml) 
Recovery 
% 
16 90 
Amphetamine 48 85 
80 64 
5.25 85 
Benzoylecgonine 15.75 56 
26.25 80 
20 65 
THC-OH 60 56 
100 62 
20 64 
THC-COOH 60 72 
100 73 
Recovery 
Amp Benzo THC-OH THC-COOH 
ng/mI 
Figure 5-23: - Recoveries of drugs from blood using strata TM X and analysed as the TBDMS 
derivative 
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5.6.6 Limits of Detection and Quantification 
The method for obtaining the LOD and LOQ was described in Sections 5.4.5 and 5.4.6. 
The results for the test substances analysed as the TBDMS derivative are shown below in 
Table 5-38. 
Table 5-38: - Limits of detection and quantitation for TBDMS derivatives 
Drug LOD (ng/ml) LOQ (ng/ml) 
Amphetamine 3.3 10.8 
Benzoylecgonine 1.9 4.9 
THC-OH 7.3 24.4 
THC-COOH 5.9 19.8 
5.6.7 Application to real cases 
The developed method was applied to 26 case samples of which 16 cases were previously 
found to be positive for drugs of a buse. These were collected from Forensic Medicine and 
Science, University of Glasgow. They are summarised below in Table 5-39. No 
prescription drugs were detected in any of the blood samples using this derivatising reagent 
and all these cases different from other cases. 
Table 5-39: - Results of GC/MS for cases analysed with MTBSTFA derivatisation 
Case No Drug Concentration (mg/L) 
Amp Meth Mor Cocaine Bze THC THC- 
COOH 
Blank - - - - - - - 
1 0.54 - - - - - - 
2 0.43 - - - - - 
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3 0.7 - - - - - - 
4 0.9 - - - - - - 
5 - - - - - - 0.02 
6 - - - - - - 0.01 
7 - - - - - - 0.04 
8 - - - - - 0.03 
9 - - - - 0.35 - - 
10 - - - - 0.11 - - 
11 - - - - - - - 
12 - - - - - - 
13 - - - - 0.02 - - 
14 - - - - 0.023 - - 
15 - - - - 0.03 - - 
16 - - - - - - 
5.6.8 Discussion 
The validation parameters including linearity, precision, recovery, limit of detection (LOD) 
and limit of quantification (LOQ) were evaluated as for the other two derivatising reagents 
and the recoveries and precision measurements are summarised in Table 5-40. 
The MTBSTFA reagent produced R2 Z0.99 for all analytes and the GC-MS analyses were 
less affected by interferences than the previous reagent. The intra- and inter-day precisions 
were evaluated at low, medium and high concentrations for five replicates. Intra-day assay 
%RSDs ranged from 1 to 10.7%. The highest intra-day %RSD was for benzoylecgonine at 
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a concentration of 5.3 ng/ml blood while the lowest %RSD was for THC-OH at a 
concentration of 4.55 ng/ml blood. However, the inter-day assay %RSDs ranged from 
2.45 to 12.6 %. The highest inter-day %RSD was for amphetamine at a concentration of 
48 ng/ml while the lowest %RSD was for amphetamine at 80 ng/ml blood as shown in 
Table 5-40. 
The recovery ranged between, 56 and 90 %. The lowest recovery was for benzoylecgonine 
at a concentration of 15.75 ng/ml blood and the highest was for amphetamine at a 
concentration of 16 ng/ml blood. 
The limits of detection and quantitation are listed Table 5-38 which show that 
benzoylecgonine produced the lowest detection limit and THC-OH gave the highest 
detection limit. 
Table 5-40: - Accuracy, intra and inter-day assay precision with MTBSTFA at different 
concentration 
Compound- 
Product 
Concentration(ng/ml) Recovery 
%(n--5) 
Intra-day 
RSD%(n=5 
Inter-day 
RSD% n=5 
16 90 8.9 4.1 
Amphetamine- 48 
TBDMS 
85 6.4 12.6 
80 64 10.3 2.2 
5.25 85 10.7 12 
Benzoylecgonine- 15.75 
bis-TBDMS 
56 6.7 8.4 
26.25 80 10.3 2.7 
20 65 5.2 9.36 
THC-OH- TBDMS 60 56 1.9 6.5 
100 62 10.3 2.5 
20 64 1.0 5.3 
THC-COOH- 60 
TBDMS 
72 1.9 7.5 
100 73 10 3.3 
The method was applied to blood samples collected from Forensic Medicine and Science 
at the University of Glasgow. Drugs of abuse were detected but no prescription drugs were 
found in any of the samples. 
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5.6.9 Conclusion 
The TBDMS derivatives gave good linearity for the 4 test compounds. However, this 
derivative was found to be unsuitable for methamphetamine and morphine, which could 
not be detected. These compounds were used as model compounds which represented the 
behaviour of other drugs with similar functional groups and so it can be concluded that 
many other drugs and metabolites would not be detected using this reagent. Also, the 
limits of detection and quantification were too high with this reagent for the method to be 
usable in routine toxicology. 
5.7 General Discussion and Conclusions 
Analytical chemistry is a very important field particularly when applied to forensic 
toxicology in which gas chromatography-mass spectrometry, extraction and derivatisation 
techniques are used. This study looked into the effects of different chemical derivatisation 
procedures on separation and identification of illicit drugs such as amphetamine, 
methamphetamine, morphine, benzoylecgonine, THC-OH and THC-COOH. A single 
method was used for the extraction of these drugs from whole blood and three different 
methods were used for derivatisation. 
Extraction procedures are used to clean up the sample by removing interfering substances 
and concentrating the drug for injection into the GC-MS instrument. Solid phase 
extraction was used in this case. There are different types of solid phases available 
depending on what kind of drug needs to be extracted, acidic, basic or neutral. If drugs of 
different types are to be extracted simultaneously then two fractions can be eluted from the 
solid phase cartridge, one for acidic drugs and one for basic drugs. This can be time 
consuming. 
The aim of this study was to find a single extraction method for the simultaneous 
extraction of acidic and basic drugs. Solid phase extraction cartridges produced by 
Phenomenex, called StrataTmX were investigated. The disadvantage of using StrataTmX 
was that the eluate was relatively dirty so investigation into the use of more solvents in the 
washing steps to remove more impurities was carried out: the original method used 1.5 ml 
methanol but because of the problem with interferences, the volume was increased to 2 ml 
methanol. 
Using a microwave instead of a conventional heating block was used to assist 
derivatisation. It required less time to achieve complete derivatisation. Special heat 
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resistant vials and caps were required as the normal caps used melted in the microwave. 
The microwave temperature is mentioned in section 5.2.8. The temperature, power and 
time of irradiation were investigated. The time for derivatisation was varied from 1 to 5 
minutes. It was found that using 3 or 5 minutes at the high power setting affected the 
integrity of the caps and sample was lost. One and two minutes were similar but high 
temperature and to keep the elute by prevention evaporate under high temperature. The 
optimum time was found to be 1 minute at the high power setting. A disadvantage of using 
the microwave was that the distribution of power was uneven and therefore it was 
important to distribute the vials in a circle as shown in Figure 4-16. 
A validated, sensitive and specific method for the extraction and quantification of drugs 
abuse in blood is presented. For this project three different reagents were compared. 
Acylation with PFP-OH/PFPA was applied with 6 drugs which have different functional 
groups. Amphetamine had problems due to evaporation, as it is volatile, so it is 
recommended that the evaporation to dryness stage should be carried out slowly without 
heating to prevent loss of analyte. Methylation and acylation with PFPA-TMS- 
diazomethane was considered better than the acylation reaction because the reagent gave 
good reactions and improved the shape of chromatographic peaks. However the best 
sequence for addition of the reagents is first to put PFPA then TMS-diazomethane for 
safety reasons. Silylation with MTBSTFA was only successful with amphetamine, 
benzoylecgonine, THC-OH and THC-COOH but did not work with morphine and 
methamphetamine, which formed derivatives but these had poor fragmentation patterns 
and bad chromatographic peak shapes. However the sample can be injected directly to 
GC/MS without the need to use ethyl acetate like the other reagents. 
It is important to know the chemical structure and functional groups of the analyte to be 
derivatised when choosing a derivatising agent. No single reagent was optimum for every 
analyte. Amphetamine gave optimum results with PFPA/PFP-OH whereas 
methamphetamine, morphine, benzoylecgonine, THC-OH and THC-COOH gave optimum 
results with TMS-diazomethane/PFPA. However, using acylation-methylation gave the 
best sensitivity and improved chromatography. 
Finally, the derivatistion and validation of methods for different drugs containing different 
functional groups was interesting because the reactions are dependent on both function 
groups and reagents. Amphetamine, methamphetamine, benzylecgonine, THC-OH and 
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THC-COOH derivatised well and gave good validation results with PFPA-PFP-OH and 
PFPA-trimethylsilyl-diazomethane derivatisation. However, derivatisation of 
amphetamine, benzoylecgonine and THC-OH was optimum with MTBSTFA. Morphine 
and methamphetamine did not derivatise with MTBSTFA. PFPA-trimethylsilyl- 
diazomethane as the derivatising reagent was best for morphine and THC-COOH. Table 
5-41 summarises the validation parameters for each drug for each of the three 
derivatisation reagents. 
Table 5-41: Validation parameters for each drug according to the three derivatising reagents 
PFPA/PFPOH PFPA-ME TBDAZS 
Linearity R 
AMP 0.9966 0.9888 0.9995 
MA 0.9947 0.9089 
MOR 0.9992 0.9995 - 
BZE 0.9945 0.9862 0.9971 
THC 0.9989 0.9966 0.999 
THCOOH 0.9934 0.9994 0.9976 
Precision, I ntra day, %RSD* 
AMP 22.3-10.3 1.5-4.4 8.9-10.3 
MA 5.8-6.8 6.0-1.4 - 
MOR 3.0-13.5 0.4-0.74 - 
BZE 10.8-7.2 10.2-10.4 10.7-10.3 
THC 6.5-6.2 5.6-3.7 5.2-10.3 
THCOOH 15.6-16.5 8.6-7.2 1.0-10.0 
Precision, I nter day, %RSD* 
AMP 6.9-2.5 2.4-1.6 4.1-2.2 
MA 27-5.1 4.8-1.6 - 
MOR 12.3-2.4 2.4-0.64 - 
BZE 3.9-1.6 10.5-1.6 12-2.7 
THC 8.5-1.9 5.9-0.84 9.4-2.5 
THCOOH 21.4-3.1 5.1-1.3 5.3-3.3 
Recovery %* 
AMP 74-89 99-95 90-64 
MA 23-18 62-90 - 
MOR 96-71 88-87 - 
BZE 86-95 85-83 85-80 
THC 62-44 66-56 65-62 
THCOOH 61-59 56-68 64-73 
LOD n /ml 
AMP 1.2 0.6 3.3 
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MA 0.8 0.6 _ 
MOR 0.8 0.3 _ 
BZE 0.4 0.3 1.9 
THC 1.7 1.3 7.3 
THCOOH 3.7 1.4 5.9 
LO n /ml 
AMP 4 2.1 10.8 
MA 2.7 2.1 - 
MOR 2.6 1.1 - 
BZE 1.5 1.2 4.9 
THC 5.8 4.3 24.4 
THCOOH 12.4 4.7 19.8 
* Parameters measured at different concentrations are given as ranges, 
from the lowest to the highest concentration values. 
The summary table allows the effect of the derivatisation method to be compared. Each of 
the derivatising methods gave acceptable linearities, although the MTBSTFA reagent did 
not work with methamphetamine or morphine. However, for all of the other measured 
parameters, the PFPA/TMS-diazomethane combination gave generally better results for 
each of the test compounds and this combination warrants further investigation, especially 
with respect to developing an analytical grade of the TMS-diazomethane reagent. 
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6 Gamma-Hydroxybutyric Acid and Beta- 
Hydroxybutyric Acid 
6.1 Introduction 
This study concerned a specific application of derivatisation techniques to compounds of 
interest in forensic toxicology, although for different reasons, as described below. These 
had previously been measured individually but not simultaneously. 
The full chemical name of GHB is gamma-hydroxybutyrate (4-hydroxybutyrate) and for 
BHB the extended chemical name is (beta-hydroxybutyrate, 3-hydroxybutyrate). These 
isomers are normal components of mammalian metabolism; they occur naturally in every 
cell in the human body and are most properly considered nutrientsý296,297]. BHB is one of 
the ketone bodies which will affect GHB metabolism when they reach elevated 
concentrations. High concentrations could significantly inhibit the metabolism of 
GHBE2981. GHB is a metabolite of the inhibitory neurotransmitter, gamma-aminobutyric 
acid (GABA) and is an endogenous compound found in central nervous system (CNS) and 
peripheral tissues. At moderate doses, GHB induces a state of relaxation, euphoria and 
. 
[29 disinhibition similar to alcohol 83°°1 
GHB was first synthesized in 196013011 by the French researcher Dr. Henry. He was 
interested in exploring the effects of GABA on the brain, because little or no GABA 
crosses the blood-brain barrier. His laboratory synthesized GHB, which substitutes a 
hydroxyl group for an amino group. This difference allows GHB to cross the blood-brain 
barrier where some of it is metabolized into GABA. GHB was initially used as an 
anaesthetic to aid in surgery because of its ability to induce sleep and reversible coma [301, 
303]. In the late 1980's, GHB was marketed and sold in the health food industry as a growth 
hormone stimulator to help body builders promote muscle mass and maintain weight [304]. 
People take GHB because it helps to fight stress and depression, induces deep sleep, 
relieves anxiety, enhances sexual feelings and enhances athletic performance [3011. As an 
anti-depressant GHB is typically dissolved in water, so it appears as an odourless, 
colourless and nearly tasteless liquid and it is therefore easily dissolved in alcoholic 
beverages. Sometimes the substance is available as a powder, or in capsule form. GHB 
has more than 30 common street or slang names such as soap, liquid x, Gamma OH, salt 
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water, Georgia home body, Grievous bodily harm, Great Hormones at Bedtime, G-caps, 
GGHBA, Easy lay, Oxy-sleep, Natural sleep 500. In recent years, GHB has gained a 
reputation as an illicit drug and has become a popular drug of abuse E305-31 11 when used 
alone or in combination with other substances, as when mixed with alcohol and other drugs 
to increase its euphoric effects. GHB is also one of the drugs reputedly used in drug- 
facilitated assault and drug-facilitated sexual assault, more popularly referred to as "date 
rape, " [312] . 
GHB is a naturally-occurring substance that is present in small amounts in every cell in the 
body but is found in greater concentrations in kidney, heart, skeletal muscles and brown fat 
tissues. However liver, lung, blood, brain and white fat have low concentrations and it is 
an endogenous compound found in central nervous (CNS) and peripheral tissues that has 
been hypothesized to have a role as a neurotransmitter. GHB has been used as an 
anaesthetic and as a treatment for sleep disorders, alcohol withdrawal (alcoholism), and 
narcolepsy. GHB and BHB are both very important, especially BHB, which is thought to 
be responsible for many cases of sudden death, and therefore more information will be 
given below. BHB is considered to be one of the ketone bodiest3131 (Figure 6-1) which are 
normally present in urine and blood, but in very low concentrations. Ketone bodies consist 
. of the three substances acetoacetate, 
beta-hydroxybutyrate and acetone, 31a, 31sß ý297 
OH 00 
H CýCH 33 
Figure 6-1 Ketone Bodies 
The body typically uses glucose for energy and it supplies the tissues. Glucose, under the 
influence of insulin, is converted to glycogen and body fat. However, when there are 
excess ketone bodies available for energy, more than is required by the tissues, they cannot 
be converted into fat and so accumulate in the blood, and are excreted in the urine. This 
process is known as ketosis. Ketone production results from the breakdown of body fats 
Figure 6-1. When fats are absorbed through the walls of the small intestine, the glycerol is 
separated from the fatty acids, and the fatty acids are broken into pieces in the liver. The 
pieces are known as ketone bodies. The excretion of the excess ketones in the urine is 
important because the presence of large amounts of ketone bodies in the blood threatens to 
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upset the acid-alkaline balance of the blood, and thereby, the balance in the tissues [3161 - 
Actually, BHB and acetoacetate chemically are not ketones: they are considered to be 
physiologically equivalent to ketones because they are readily interconverted in the body 
Therefore acetone is a true ketone, and the more general term is "ketone bodies". Ketones 
are by-products of fatty acid metabolism which are increased in diabetes, alcoholic 
ketoacidosis and starvation13171 Metabolism occurs in the liver mitochondria. Ketone 
bodies are oxidized by most tissues except those of the liver [3181 to provide an energy 
source from stored lipids at times of low carbohydrate availability. Therefore normal 
glucose concentrations inhibit ketone body synthesis, and the ketone bodies only begin to 
be synthesized in high concentrations as serum glucose concentration falls (Figure 6-2) 
[3191 
Fatty Acid 
(extracellular) 
-Fatty Acid 
ýý (intracellular) 
I 
Synthesis I 
Mitochondria 
ý 
Energy' 
Cell 
Ketone Bodies 
(Export Energy) 
Figure 6-2: - The cells produce ketone bodies for energy. 
6.2 GHB and BHB in the body 
6.2.1 Chemistry, synthesis and pharmacokinetics of GHB 
GHB's chemical name is gamma-hydroxybutyrate (4-hydroxybutrate, the sodium salt 
being sodium oxybutyrate) Figure 6-3. It consists of four carbons and is a small polar 
molecule, soluble in water and a short chain fatty acid 13011. It is formed primarily from the 
precursor aminobutyric acid by the enzyme monoamine oxidase. 
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OH 
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GABA 
HO 
GHB 
Figure 6-3: - Chemical structures of GABA and GHB 
OH 
The properties of GHB include its having a neuromodulatory role in the brain and the 
ability to induce several pharmacological and behavioural effects. Following oral 
ingestion, GHB is rapidly absorbed from the gastrointestinal tract and transported by the 
portal circulation to the liver where most of it gets metabolized to carbon dioxide and 
water by first-pass metabolism pathways. A certain amount crosses the blood-brain 
barrier. GHB overdose has been reported to result in coma, cardiorespiratory depression, 
seizures and death13011. GHB has a half-life of 20-53 min, which appears to increase with 
higher doses. Because the drug is rapidly eliminated from the body, GHB exposure is 
difficult to document. 
The simplest way to produce GHB is by the hydrolysis of the corresponding lactone (a 
cyclic intramolecular ester) to the desired hydroxy acid. Ester hydrolysis can be done in 
two ways: an acid catalyzed reaction or a base catalyzed reaction. The base catalyzed 
reaction is preferred, because the reaction is not reversible, unlike the acid catalyzed one, 
and therefore higher yields are obtained. Alkaline hydrolysis gives the sodium salt of 
GHB. The free acid is not stable and will immediately cyclize into gamma -butyrolactone 
again. The reaction proceeds equimolarly (the number of moles of each substance that 
reacts), and there are no by products produced in this reaction, such as hydrogen gas or 
water Figure 6-4' 
00 
+ NaOH HO 
O- Na+ 
Figure 6-4: - Chemistry and Synthesis Sodium Gamma-Hydroxy Butyrate (NaGHB). 
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GHB is formed in the brain from GABA, derived in turn from succinic semialdehyde 
(SSA) via a specific succinic semialdehyde reductase (SSR, Figure 6-5). GHB can be 
reconverted back to SSA via GHB dehydrogenase, and GHB can be converted back to 
GABA. Succinic semialdehyde can also be metabolized by succinic semialdeyde 
dehydrogenase (SSADH) to succinic acid. Mutant mice in which the SSADH enzyme is 
t3o11 deleted display high levels of GHB and GABA 
OH 
H2N GABA transaminase 
0 0 
GABA 
OH 
0 
Succinic semialdehyde 
OH 
Succinic semialdehyde 
OH 
HO 
0 
GHB 
Figure 6-5: - GABA metabolism to GHB in body 
When GHB became illegal in the United States of America, drug users started looking for 
similar chemicals. Gamma-butyrolactone (GBL) and 1.4-butanediol (1,4-BD) are two 
such analogues of GHB. The body will convert them to GHB where GBL is metabolized 
to GHB via lactonase while 1.4-BD is first metabolized to gamma-hydroxybutyraldehyde 
via alcohol dehydrogenase, then to GHB via aldehyde dehydrogenase (Figure 6-6). 
SSA reductase 
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ýOH 
HO 
1,4 BD 
HO 
0 
gamma-hydroxybutyraldehyde 
HO 
0 
gamma -hydroxybutyraldehyde 
HO 
OH 
O 
GHB 
Figure 6-6: - Metabolism of 1,4 BD to GHB in the body. 
6.2.2 Chemistry and pharmacokinetics of BHB 
Beta-hydroxybutyrate and other ketone bodies are synthesized from acetyl CoA (Figure 
6-7) and this occurs in hepatic mitochondria. The thioester bond which links the acyl 
group to coenzyme A has a large negative standard free energy of hydrolysis, therefore an 
acyl group attached to COA in this manner is considered to be activated. 
glucose 
Pyruvate 
ý\ 
amino acids 
Fatty acids------- Acetyl CoA ketone bodies------ 
phospholipids 
eicosanoids 
cholesterol 
steroid hormones 
bile salts 
I 
CO2 + H2O +energy(ATP) 
Figure 6-7: - Major metabolic sources of acetyl CoA. 
NAD+. 4 NADH 
alcohol dehydrogenase 
NAD+) 
NADH 
aldehyde dehydrogenase 
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Acetoacetate is produced in a three step process. However, it can be reduced to beta- 
hydroxybutyrate, and acetone also arises in small amounts as a biologically inert side 
product. When mobilization of fatty acids from adipose tissue is high, hepatic beta- 
oxidation will occur at a high rate and so will synthesis of ketone bodies from the resulting 
acetyl CoA. The first step is the formation of acetoacetyl CoA in a reversal of the thiolase 
step of beta oxidation (Figure 6-8). 
0 
11 
CH3 -C -CoA + CH3 
0 
11 
-c - coA 
CoA 
O0 
11 11 
CH3 -C-CH2 -C-CoA 
Figure 6-8: - First step is formation of acetoacetate-CoA 
In the second step, a third molecule of acetyl CoA condenses with the acetoacetyl CoA, 
forming 3-hydroxy-3-methlglutaryl CoA (HMG CoA) in a reaction catalyzed by HMG 
CoA synthase Figure 6-9. 
O 
II 
00 
CH3-C-CoA 0 OH 0 
ýI 11 1 
II 
O-C-CH2-C- CH2- C-COA CH3 -C-CHZ-C- CoA 
H1 
CoA 
CH3 
Figure 6-9: - Second step is formation of 3-hydrox-3-methlglutaryl-CoA (HMG CoA) 
In the third step HMG CoA is cleaved to yield acetoacetate (ketone body) in a reaction 
catalyzed by HMG CoA lyase. One molecule of acetyl CoA is also produced (Figure 
6-10). Subsequently acetoacetate can be reduced to beta-hydroxybutyrate by beta- 
hydroxybutyrate dehydrogenase in a reaction requiring NADH. The extent of this reaction 
depends on the state of the NAD pool of the cell: when it is highly reduced, most or all of 
the ketones can be in the form of beta-hydroxybutyrate (Figure 6-11). Some acetoacetate 
spontaneously decarboxylates to yield acetone. The odour of acetone can be smelled on the 
[320) breath of individuals with severe ketosis (Figure 6-10 to Figure 6-12) . 
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Figure 6-10: - Third step is formation of acetoacetate and acetyl CoA 
acetoacetate 
i0 ý0 II II 
nO 
acetylCoA 
OH 
NADH+H+ II I ýC 
HO-C-CH2-C- H 
ýII 
CH3 NAD+ CH3 
Beta-hydroxybutyrate 
Figure 6-11: - Fourth step is formation of B-hydroxybutyrate 
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Figure 6-12: - Formation of acetone from acetoacetate by decarboxylation 
6.2.3 Toxicity 
Gamma-hydroxybutyric acid is readily absorbed after oral administration and rapidly 
metabolised in the liver by oxidative enzymes. Conversion to gamma-butyrolactone can 
occur and elimination is rapid, via the kidneys, with urine recovery virtually complete 
within 8 hours of administration. Only negligible amounts of the parent drug are recovered 
unchanged in urine (<5%) and after 12 hours, the drug is not detectable. Effects of GHB 
Chapter Six Page 145 
including drowsiness, euphoria, dizziness, nausea, visual disturbances and 
unconsciousness, are usually manifested by 15 minutes after administration and persist for 
about 3 hours on average. Serious adverse reactions have included hypotension, 
bradycardia, respiratory depression, seizures, coma and possibly death. In many forensic 
cases alcohol abusers were found dead and the cause of death could not be ascertained. In 
order to examine the possible role of ketoacidosis for the cause of death the concentration 
of ketone bodies (acetone, acetoacetate and D-ß-hydroxybutyrate) have to be determined in 
postmortem blood specimens [3213. However, beta-hydroxbutyrate is not detected by the 
screening test for ketones which detects only acetoacetic acid. Because beta- 
hydroxybutyrate is stable and also is usually present at concentrations higher than the other 
ketones, it provides a more sensitive test to use when monitoring the treatment of diabetic 
ketoacidosis. The mechanism of these deaths is obscure but could be related to a critical 
[322,3231 fall in blood pH to around pH 7 
6.2.4 Methods of Analysis of GHB and BHB 
There are several methods for the detection of GHB and BHB in blood samples by gas 
chromatography mass spectrometry (GC/MS)J324,3251 These have been used to investigate 
the relationship between GHB and depression of the central nervous system where effects 
were obsered similar to alcohol as well as induced relaxtion and tranquillity, libido 
enhancement and euphoria , 
[326,327] 
The blood samples were analysed by GC/MS using liquid-liquid extraction or solid phase 
extraction and disilyl-derivatisation with or without conversion to the gamma- 
butyrolactone (GBL). [324,328,329] Gamma hydroxybutyrate (GHB) is naturally present in 
both blood and urine but the role of GHB remains unclear. [330,331] Some authors extract 
GHB from urine because GHB remains in urine longer than blood. Of these papers the 
post-mortem blood GHB concentration range was 13.8-86.3 mg/l. [332-336] 
BHB has also been analysed by headspace gas chromatography following conversion to 
acetone, (337,338] One paper reports a method to analyse both of them in urine but not blood, 
using a single method, based on solvent extraction and silylation before GC-MS J3391 LC- 
MS methods have also been published for GHB either as the free acid [3401 or as its n-butyl 
ester. [341 ] 
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6.2.5 Aims 
Gamma-hydroxybutric acid is a central nervous system depressant that has been abused 
recreationally for its purported euphoric and relaxant effects and for the purposes of drug- 
facilitated sexual assault due to its sedative and amnesic affects at high doses. The 
dramatic increase in the abuse of GHB and association in criminal investigation over the 
past decade has created the need for forensic laboratories to develop analytical methods to 
detect GHB. The 4-hydroxy isomer of GHB is also of forensic interest. In some cases it 
may be difficult for the forensic pathologist to assign a cause of death for a known alcohol 
abuser who has been found dead, and alcoholic ketoacidosis has been implicated. One 
diagnostic test for ketoacidosis is to measure the concentration of beta-hydroxybutyric acid 
in blood. Therefore it is beneficial to have a GC/MS method which can be used in the 
forensic lab for the determination of physiological concentrations of beta-hydroxbutyrate 
in postmortem blood, so creating a method for measuring both GHB and BHB at the same 
time with the same instrumental conditions. The aims of this study were to evaluate the 
reagents for derivatisation, evaluate microwave assisted derivatisation and evaluate 
suitable chromatographic analytic procedures, and so to develop a method for the 
simultaneous quantification of GHB and BHB in blood. 
6.3 Experimental Section 
6.3.1 Chemicals and reagents 
N, O-Bis (trimethylsilyl) trifluoroacetamide with 1% Trimethylchlorosilane (BSTFA + 1% 
TMCS, Figure 6-13), is a silylation reagent. It has some desirable properties such as 
reacting faster and more completely than other reagents because of the presence of the 
trifluoroacetyl group; it has high volatility, as do its by-products; it results in separation of 
early eluting peaks, has excellent solubility in organic solvents and the addition of TMCS 
. catalyzes reactions of 
hindered functional groups in secondary alcohols and amines[342] 
The reagent was purchased from Fluka. Methanol was purchased from VWR International 
Ltd. Ammonia solution, NH4OH, and potassium dihydrogen orthophosphate were 
purchased from BDH Laboratory supplies. 
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Figure 6-13: - Chemical structure of BSTFA 
6.3.2 Standards 
The drug standards used were GHB, 1 mg/ml in methanol and GHB-d6, lmg/ml in 
methanol, as the internal standard for GHB and BHB. Both were produced by Cerilliant 
and supplied in the UK by LGC Promochem. Beta-hydroxybutyric acid sodium salt was 
obtained from Fluka. 
6.3.3 Preparation of standard solutions of GHB 
GHB working standard, 100µg/ml (O. lmg/ml) in methanol, was prepared from the stock 
lmg/ml solution by diluting 100µl of the stock solution with 900µl of methanol. The 
internal standard was GHB-d6,100µg/ml, prepared from the stock solution. 25µl of 
internal standard solution was added to each sample. Blood standards were prepared by 
adding different amounts of GHB and GHB-d6 to blood as indicated in Table 6-1. 
Table 6-1: - Preparation of different concentrations of GHB 
Working Standard Volume 
(µ1) 
Whole Blood Volume (µl) Concentration 
(gg/ml) 
10 200 5 
20 200 10 
40 200 20 
60 200 30 
80 200 40 
100 200 50 
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6.3.4 Preparation of standard solutions of BHB 
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1.0052g of BHB was weighed into 1L deionised water. This gave a free BHB 
concentration of 8.3mg/ml. The concentration range used for analysis was from 0-2 mg/L, 
therefore 12.05 ml of an 8.3 mg/ml solution was added to 50 ml flask and made up to 
volume with blank blood, resulting in a BHB working solution with a concentration of 
2 mg/ml Table 6-2.251l of internal standard solution was added to each sample. 
Table 6-2: - Preparation of different concentrations of BHB 
Number Standard in Blood 
(ml) 
Blank Blood 
(ml) 
Concentration 
(mg/ml) 
1 10 0 2 
2 7.5 2.5 1.5 
3 5 5 1 
4 2.5 7.5 0.5 
5 1 9 0.2 
6 0.5 9.5 0.1 
6.3.5 Extraction method based on SPE clean screen 
Solid phase extraction (SPE) was carried out using Clean Screen GHB® cartridges 
(200mg/3m1, Figure 6-14), supplied by United Chemical Technologies Inc (UCT 
CSGHB203) which contained phenyl and propylsulphonic acid substituents. The 
extraction mechanism of Clean Screen was efficient, robust and clean. When a sample is 
loaded onto the column at pH6, many functional groups present in the sample are ionized. 
This creates repulsion between the column and many sample borne interferences, thereby 
reducing the likelihood of their adsorbing onto the column. The SPE column can then be 
washed with water or weak aqueous buffers at or below pH6 without risking loss of the 
analytes. Many compounds of intermediate polarity and potential interferences will also 
remain on the column. The majority of these potential interferences can be removed by 
using a methanol wash. Anionic analytes bound to the column can be eluted after another 
drying step. The drying steps are necessary to remove water which would have prevented 
water immiscible elution solvents from optimally interacting with the analytes. To elute 
the anionic analytes, an organic solution with a high pH between 11 and 12 should be used. 
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A methylene chloride-isopropanol-ammonium hydroxide mixture will simultaneously 
disrupt these ionic interactions and successfully elute the desired compound. 
Figure 6-14: - UCT-GHB-SPE Solid Phase Extraction 
6.3.6 Instrumental method 
The GC was equipped with a fused silica capillary column (HP-5,30 in x 0.32 mm i. d., 
0.25µm film thickness) from J&W Scientific. The injection port was operated in the 
splitless mode at 280°C, with the purge being initiated at 0.5 minutes. The initial oven 
temperature was 65°C for 0.5 minute at which time a 15°C/min ramp was instituted until 
reaching a final temperature of 300°C. The mass spectrometer was operated using the 
same conditions listed in Table 4-1. 
The ions used for selected ion monitoring are given in Table 6-3. Representative SIM and 
full scan chromatograms and the mass spectrum for GHB are given in 
Figure 6-15 and Figure 6-16. The fragmentation pattern of GHB as its TMS derivative is 
explained in Figure 6-17. Corresponding diagrams for BHB are given in Figures 6-18 to 6- 
19. 
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Table 6-3: - selected Ions used for GC-MS SIM 
Target analyte Retention time Selected Ions 
(m/z) 
Internal 
standard 
Selected 
Ions(m/z) 
GHB 4.78 117,233 GHB-d6 239 
BHB 4.13 191,233 GHB-d6 239 
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Figure 6-16: - (a) Selected ion chromatograms from repetitive full scan GC-MS and (b) mass 
spectrum for GHB (M'248) - TMS derivative 
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Figure 6-18: - Full scan chromatograms and Mass spectrum for BHB-BSTFA/TMCS 
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Figure 6-19: - Ion chromatograms and mass spectra for GHB and BHB as their TMS 
derivatives from full scan GC-MS analysis. 
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6.3.7 Method validation for GHB 
6.3.7.1 Linearity 
Linearity was determined for the concentration range of 0 to 50µg/200µ1 blood. The 
calibration curve for the target analyte was linear and had a linear correlation coefficient 
(R2) equal to 0.9993 as shown in Figure 6-20 
GHB 
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0 ä 1.5 
1 
0.5 
0 
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Figure 6-20: - Calibration curve for GHB 
6.3.7.2 Recovery 
f GHB-BSTFA 
-Linear (GHB-BSTFA) 
The recovery of GHB from spiked blood samples was determined as described earlier in 
Chapter 5. Recoveries for the analyte were in the range 44-76% (Table 6-4, Figure 6-21 ). 
Table 6-4: - Recovery of GHB from blood using Clean Screen GHB cartridges 
Concentration ( ml) GHB % Recovery 
10 44 
30 49 
50 76 
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Figure 6-21: - Recovery of GHB from blood using Clean Screen GHB cartridges 
6.3.7.3 Limits of Detection and Quantitation 
The methods for determining limits of detection and quantitation of GHB from spiked 
blood samples have already been described in Chapter 5 (Paragraph 5.4.6 and 5.4.7). 
Blank blood was spiked with GHB to give concentrations of 1,2.5,5,10 and 20µg/ml. 
These were extracted as described previously. The detection limit was evaluated as the 
amount of analyte that gives a signal-to-noise ratio of 3 times the background noise. The 
limit of quantitation was evaluated as the signal-to-noise ratio that is equivalent to 10 times 
the noise (Table 6-5). 
Table 6-5: - Limit of Detection and Quantitation for GHB 
GHB (µg/ml) 
LOD 
LOQ 
6.3.7.4 Inter-Day Precision 
0.4 
1.30 
The calibration curve standards were extracted five times during different days and the 
inter-day variation at each concentration was assessed and is displayed below in Table 6-6. 
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Table 6-6: - Inter-Day precision 
Concentration GHB ( ml Mean concentration (%RSD) 
5 5.1 (10.6) 
10 10.0 (18.3) 
20 19.7 11.8 
30 30.1 2.9 
40 39.9 (0.9 
50 50.0 0.4 
6.3.7.5 Intra- Day Precision 
The average area ratios (drug/internal standard ratio) and relative standard deviations were 
calculated after the linearity curve standards were extracted five times to determine the 
intra-day variation of the assay over the calibration range and this is displayed in Table 
6-7. 
Table 6-7: - Intra-Day Precision 
Concentration in blood 
( ml 
m/z 233/239 
GHB/GHB-d6 (RSD 
5 0.8(9.7) 
10 1.3(6.3) 
20 4.7 (9.6 
30 6.3 10.5 
40 6.5 (9.8) 
50 7.6(8.8) 
6.3.8 Method validation for BHB 
6.3.8.1 Linearity 
Linearity was determined for concentration range of 0 to 2mg/ml. The calibration curve 
for the target analyte was linear and the linear correlation coefficient (R) was 0.9988 
(Figure 6-22). 
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Figure 6-22: - Calibration Curve for BHB 
6.3.8.2 Recovery 
The method for determining the recovery of the analyte from spiked blood samples has 
already been described in Chapter 5. Recoveries for the analyte were in the range 47-89% 
(Table 6-8, Figure 6-23). 
Table 6-8: - Recovery of BHB from blood samples 
Concentration (m ml) Recovery % 
0.1 47 
1 84 
2 89 
Figure 6-23: - Recovery of BHB from blood using Clean Screen GHB cartridges 
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6.3.8.3 Limits of Detection and Quantitation 
Limit of detection and quantitation of the method for spiked blood samples were measured 
as described previously in Chapter 5. Blank blood was spiked with BHB to give 
concentrations of 0.0025,0.005,0.01,0.02,0.06 mg/ml. these were extracted as described 
previously. The limit of detection was evaluated as the concentration of analyte that gave a 
signal-to-noise ratio of 3 times the noise. The limit of quantitation was evaluated as the 
concentration of analyte that gave a signal-to-noise ratio that was equivalent to 10 or else it 
is blank reading plus 10 times the standard deviation of the noise or standard error of the 
calibration curve (Table 6-9). 
Table 6-9: - Limits of Detection and Quantitation 
BHB (mg/ml) 
LOD 0.001 
LOQ 0.004 
6.3.8.4 Intra-Day precision 
The average area ratio and relative standard deviations were calculated for each 
concentration and are displayed in Table 6-10 
Table 6-10: - Intra-Day precision 
Concentration in blood (mg/ml) m/z 233/239 
BHB/GHB-d6 SD 
0.1 4.3(8.5) 
0.2 6.2 9.7) 
0.5 16.2 (7.8 
1 26.2 7.1 
1.5 27.1(0.4) 
6.3.8.5 Inter-Day Precision 
The set of standards used for the calibration curve was extracted five times during different 
days and the inter-day variation was assessed and is displayed in Table 6-11. 
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Table 6-11: - Inter-Day precision 
Concentration in blood (mg/ml) m/z 233/239 
BHB/GHB-d6 (RSD 
0.1 0.13 8.1 
0.2 0.21 10.9 
0.5 0.46 6.0) 
1 0.1 (4.0 
1.5 1.5 (0.94) 
6.4 Application to Case Samples 
The developed method was applied to 89 forensic autopsy case samples which were 
collected from Forensic Medicine and Science, University of Glasgow. The samples were 
kept frozen until analysed by GC/MS. 
These real case samples were subdivided into four groups: the first group contained cases 
which did not have a history of alcohol abuse (i. e. not known to be alcoholics) and which 
had a negative alcohol result. The second group were not known to be alcoholics but had a 
positive alcohol result. The third group had a history of alcohol abuse but had a low blood 
alcohol concentration (less than 200/100ml) at the time of death. The fourth group had a 
history of alcohol abuse and had a high blood alcohol concentration at the time of death. 
The results of the analyses of case samples are given in Table 6-12. 
Table 6-12: - Results of GC/MS analysis of cases for GHB/BHB 
Case 
Number 
BHB Concentration 
(mg/ml) 
GHB Concentration 
(mg/L) 
Group 
Blank - 
1 0.4 76 Non-alcoholic, Neg alc 
2 0.4 101 Non-alcoholic, Neg alc 
3 0.3 72 Non-alcoholic, Neg ale 
4 1.1 236 Non-alcoholic, Neg alc 
5 0.3 91 Non-alcoholic, Neg alc 
6 0.33 207 Non-alcoholic, Neg alc 
7 0.3 123 Non-alcoholic, Neg alc 
8 0.4 123 Non-alcoholic, Neg alc 
9 0.4 189 Non-alcoholic, Neg alc 
10 0.34 65 Non-alcoholic, Neg alc 
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11 0.42 211 Non-alcoholic, Neg alc 
12 0.4 312 Non-alcoholic, Neg alc 
13 0.34 89 Non-alcoholic, Neg alc 
14 0.4 150 Non-alcoholic, Neg alc 
15 0.32 81 Non-alcoholic, Neg alc 
16 0.31 237 Non-alcoholic, Neg alc 
17 0.31 88 Non-alcoholic, Neg alc 
18 0.31 56 Non-alcoholic, Neg alc 
19 0.3 102 Non-alcoholic, Neg alc 
20 0.34 112 Non-alcoholic, Neg alc 
21 0.34 24 Non-alcoholic, Neg alc 
22 0.42 100 Non-alcoholic, Neg alc 
23 0.42 185 Non-alcoholic, Neg alc 
24 0.4 143 Non-alcoholic, Neg alc 
25 0.4 88 Non-alcoholic, Neg alc 
26 0.34 9 Non-alcoholic, Neg alc 
27 0.35 103 Non-alcoholic, Neg alc 
28 0.38 93 Non-alcoholic, Neg alc 
29 0.35 285 Non-alcoholic, Neg alc 
30 0.4 72 Non-alcoholic, Neg alc 
31 0.4 236 Non-alcoholic, Neg alc 
32 0.34 84 Non-alcoholic, Neg alc 
33 0.33 126 Non-alcoholic, Neg alc 
34 0.37 187 Non-alcoholic, Neg alc 
35 0.32 24 Non-alcoholic, Neg alc 
36 0.31 186 Non-alcoholic, Neg alc 
37 1.3 251 Non-alcoholic, Pos alc 
38 1.1 256 Non-alcoholic, Pos alc 
39 0.6 138 Non-alcoholic, Pos alc 
40 0.3 242 Non-alcoholic, Pos alc 
41 0.4 509 Non-alcoholic, Pos alc 
42 1.5 123 Non-alcoholic, Pos alc 
43 0.49 509 Non-alcoholic, Pos alc 
44 0.4 177 Non-alcoholic, Pos alc 
45 0.4 310 Non-alcoholic, Pos alc 
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46 0.5 182 Non-alcoholic, Pos alc 
47 0.4 145 Non-alcoholic, Pos alc 
48 0.3 210 Non-alcoholic, Pos alc 
49 0.63 161 Non-alcoholic, Pos alc 
50 0.36 44 Non-alcoholic, Pos alc 
51 0.38 75 Non-alcoholic, Pos alc 
52 0.34 55 Non-alcoholic, Pos alc 
53 0.38 98 Non-alcoholic, Pos alc 
54 0.4 132 Non-alcoholic, Pos alc 
55 0.31 216 Non-alcoholic, Pos alc 
56 0.39 131 Non-alcoholic, Pos alc 
57 0.37 186 Non-alcoholic, Pos alc 
58 0.4 216 Non-alcoholic, Pos alc 
59 0.36 147 Non-alcoholic, Pos alc 
60 0.35 144 Non-alcoholic, Pos alc 
61 0.39 226 Non-alcoholic, Pos alc 
62 0.31 34 Non-alcoholic, Pos alc 
63 0.4 216 Non-alcoholic, Pos alc 
64 0.36 40 Non-alcoholic, Pos ale 
65 0.35 86 Non-alcoholic, Pos alc 
66 0.38 83 Non-alcoholic, Pos alc 
67 0.37 172 Alcoholic, Low alc 
68 0.37 218 Alcoholic, Low alc 
69 0.39 411 Alcoholic, Low alc 
70 0.35 53 Alcoholic, Low alc 
71 0.76 243 Alcoholic, Low alc 
72 0.4 103 Alcoholic, Low alc 
73 0.3 91 Alcoholic, Low alc 
74 0.4 54 Alcoholic, Low alc 
75 0.4 253 Alcoholic, Low alc 
76 0.38 348 Alcoholic, Low alc 
77 1.5 123 Alcoholic, Low alc 
78 0.35 123 Alcoholic, Low alc 
79 0.35 118 Alcoholic, Low alc 
80 2.2 118 Alcoholic, High alc 
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81 4.2 169 Alcoholic, High alc 
82 5.7 97 Alcoholic, High alc 
83 3.5 172 Alcoholic, High alc 
84 0.87 255 Alcoholic, High alc 
85 0.49 190 Alcoholic, High alc 
86 7.15 137 Alcoholic, High alc 
87 0.36 186 Alcoholic, High alc 
88 0.37 38.2 Alcoholic, High alc 
89 6.4 76.9 Alcoholic, High alc 
Analyses of the data for these cases was carried out by regression analysis, looking for any 
correlation between blood alcohol and either BHB or GHB or between BHB and GHB, and 
also using the Student's t-test to test for the occurrence of any significant differences 
between the four groups (two-tailed test, unequal variance). No significant correlations 
were found between alcohol concentration and either BHB or GHB concentration in blood 
or between BHB and GHB concentrations in blood (Figure 6-18, Figure 6-19). The 
significance level did not increase by selecting either alcoholics or non-alcoholics for this 
analysis. 
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Figure 6-18: - Scatter plot of blood alcohol concentration versus blood BHB concentration. 
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Figure 6-19: - Scatter plot of blood alcohol concentration versus blood GHB concentration. 
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By contrast, t-test results indicated significant differences between some of the groups 
(Table 6-13 and 6-14). At least in the cases used for this study, the alcoholics group with 
high blood alcohol concentrations has significantly higher BHB concentrations than the 
other groups. 
Table 6-13: - Statistical summary of the four groups: 
Group N BHB GHB 
Average 
(µ ml) 
Std Dev Average 
(µ ml) 
Std Dev 
1 36 0.37 0.131 130 73.6 
2 30 0.48 0.284 174 113 
3 13 0.49 0.324 178 111 
4 10 3.81 2.51 152 57 
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Table 6-14: - P-values from T-test comparison of the four groups: 
BHB 
Group 1 vs Group 2 0.060 
Group 1 vs Group 3 0.229 
Group 1 vs Group 4 0.006* 
Group 2 vs Group 3 0.912 
Group 2 vs Group 4 0.007* 
Group 3 vs Grou 4 0.007* 
GHB 
Group I vs Group 2 0.065 
Group 1 vs Group 3 0.153 
Group 1 vs Grou 4 0.363 
Group 2 vs Group 3 0.920 
Group 2 vs Grou 4 0.446 
Group 3 vs Grou 4 0.492 
* Statistically significant (p<O. 
6.5 Discussion 
GHB and BHB were derivatised by silylation using BSTFA/TMCS. In the silylation 
process a trimethylsilyl (TMS) group replaces each active hydrogen of GHB and BHB 
creating one method for determination of GHB and BHB by GC/MS in a single run[61' 
3431 
However, the same internal standard and ion at m/z 239 was used for both GHB and BHB 
which might reduce accuracy and precision for BHB and also the same ion (m/z 233) was 
used for both BHB and GHB, which creates the potential for confusion or mistaken 
identity if the retention time window is not carefully monitored. 
The fragmentation and derivatisation of GHB and BHB are very similar (Figure 6-17), 
because BHB has a similar structure to GHB. The retention times of GHB and BHB were 
4.78,4.13, respectively. The quantification ions were m/z 233 and 239 for the analytes 
GHB and BHB and Internal standard, respectively. The base peak at m/z 147 cannot be 
used because the ion appears as a fragment in the mass spectrum of both the drug and the 
internal standard. In addition, this ion is considered non-selective, because it contains only 
parts of the derivative molecule coming from the derivatising reagent. 
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It has been discussed previously (section 6.1 and 6.2) that GHB and BHB are naturally 
produced in the body in small quantities. The human body produces BHB in times of 
starvation, or if the individual is a diabetic in order to produce energy in place of glucose. 
Another theory proposes that there is a relationship between alcohol and BHB 
concentrations. Table 6-12 shows four classification groups for alcohol levels. These 
involve non-alcoholic subjects with negative and positive alcohol concentrations and 
alcoholic subjects with low or high alcohol concentrations. It was noted that when alcohol 
levels were high, the BHB levels were also high. When BHB levels are high, there is some 
indication that GHB levels are affected, in that the higher the BHB levels, the lower the 
GHB levels. However this did not reach statistical significance. [343,3441 
6.6 Conclusion 
In the method developed, SPE was used to extract both GHB and BHB from blood 
samples, followed by BSTFA /TMCS derivatisation and then 1µl in GC/MS. This method 
was effective and was found to be a simple, fast and sensitive procedure for determination 
of GHB and BHB. The silylation derivatisation method with microwave was carried out 
and improved the chromatography. There is a relationship between alcohol level and BHB 
concentration in the body. Where the alcohol level becomes high the BHB will also be 
high. In non-alcoholics with either positive or negative alcohol levels the concentration of 
BHB was less than 1. Smg/ml. However, with high alcohol levels, the BHB concentration 
was more than 0.49 mg/ml. There is some evidence for a relationship between GHB and 
BHB where each concentration affects the other, but in a normal situation the body keeps 
the balance by controlling the production mechanism. 
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7 Benzodiazepines 
7.1 Introduction 
Benzodiazepines, sometimes called "benzos", are based on the fusion of a benzene ring 
and a 7-membered diazepine ring. They are believed to act on the gamma-aminobutyric 
acid (GABA) receptor GABAA. Receptors for benzodiazepines are located throughout the 
central nervous system, including the cerebral cortex, cerebellum, hippocampus, striatum 
and spinal cord, so benzodiazepines offer a clinical therapy of primary importance in 
treating neurological disorders such as anxiety, sleep disturbance, muscle spasms and 
cp11epSi 163-165,176,177,345-3481 
(3a91 drugs. 
The benzodiazepines are a particularly large family of 
They can be taken orally or, when abused, oral formulations can be ground up for 
injection. They are used as anticonvulsants, anxiolytics, hypnotics or muscle relaxants 
with different durations of action 114S]. Since Sternbach synthesised the first benzodiazepine 
in 1955 by an unexpected ring extension of a quinazoline-3-N-oxide derivative, a number 
of structurally similar compounds have been marketed by drug companies. 
Chlordiazepoxide was the first medical benzodiazepine, introduced in 1961 and followed 
in 1963 by diazepam and in 1965 by oxazepam. More than fifty of these drugs are 
presently marketed for clinical use throughout the world. Thirty-five are subject to 
international control under the 1970 United Nations Convention on Psychotropic 
Substances. The most significant benzodiazepines in the last decade have been diazepam, 
lorazepam, alprazolam, temazepam, chlordiazepoxide and lormetazepam 
Benzodiazepines are strongly associated with opioid users and with drug-related deaths, 
and are one of the main drug classes found in poisoning-related hospital admissions. 
These drugs are frequently encountered in clinical and forensic toxicology and they have 
featured in an increasing number of misuse situations over the past years [146,1821 
Large doses are rarely fatal unless other drugs are taken concomitantly, because of their 
relative safety. Benzodiazepines and benzodiazepine-like substances such as zopiclone 
are frequently abused. Analysis of benzodiazepines, their active metabolites and 
benzodiazepine-like substances in blood samples may be indicated in many forensic cases 
such as driving under the influence of drugs, cases of date rape or violent crime and cases 
in which the cause of death is unknown. These include the 1,4-benzodiazepines such as 
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diazepam, temazepam and oxazepam and the often more potent, diazolo- and triazolo - 
groups represented by alprazolam, midazolam, triazolam. In high doses benzodiazepines 
can cause persons to exhibit classical features of central nervous system (CNS) depressant 
drugs such as nystagmus, ataxia, slurred speech and impaired divided attention skills[178, 
179,350J 
Benzodiazepine abuse is a large problem in poly drug users. They are often used to reduce 
anxiety, help sleep or counter the negative effects of other drugs. They are addictive and 
can cause significant withdrawal symptoms. Short term prescribing of benzodiazepines 
may have some benefit in supporting drug users to control their intake of other drugs when 
first coming into treatment and to stabilise their lives[161' 179] Consequently, toxicologists 
need to be able to detect these drugs in biological specimens and to understand their 
toxicology. The most commonly encountered benzodiazepines are diazepam and its three 
metabolites N-desmethyldiazepam, temazepam and oxazepam. The derivatisation 
procedure for each of these drugs with three different reagents was investigated. 
7.2 Chemistry 
Benzodiazepines (Figure 7-1) are based on the fusion of a benzene ring with the diazepine 
ring. The subsequent molecule as a benzodiazepine is characterized by two nitrogen atoms 
on the diazepine ring. These nitrogen atoms are usually in the 1 and 4 positions of the ring, 
according to the numbering convention of atoms around the molecule. Differences in the 
benzodiazepines are based on the presence of additional substituents at the 1,2,3,5 and 7 
positions of the molecule (refer to Table7-1). Variations in these substituents lead to a 
change in their pharmacological potencies and efficacies, variations in the physiochemical 
properties and of course variations in the ring. 1105J A number of modifications in the 
benzodiazepine ring structure have resulted in a number of new compounds with similar 
pharmacological activities, but differences in lipophilicity, basicity and chemical reactivity. 
These differences are also responsible for the different response of benzodiazepines to 
analytical methods (Figure 7-2)[35". 
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Figure 7-1: - General benzodiazepine structure 
Table 7-1: - Chemical structures of selected 1,4-benzodiazepines 
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Benzodiazepine Trade name R, R2 R3 R4 R5 
Diazepam Valium -CH3 -H -H -H -CI 
Nordiazepam Calmday -H -H -H -H -CI 
Temazepam Restoril, 
Levanxol 
-CH3 -H -OH -H -CI 
Oxazepam Adumbran, 
Praxiten 
-H -H -OH -H -CL 
Clonazepam Ritrovil -H -H -H -CI -NO2 
Flunitrazepam Rohypnol -CH3 -H -H -F -NO2 
Nitrazepam Mogadon -H -H -H -H -NO2 
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Figure 7-2: - Structures of some benzodiazepines 
7.3 Pharmacokinetics of benzodiazepines 
OH 
LORMETAZEPAM 
Benzodiazepines have important pharmacokinetic differences with respect to speed of 
onset and duration of action and all benzodiazepines are metabolized in the liver through 
oxidation, glucuronidation, or nitrogen reduction and are eliminated by the kidneys. The 
rate of onset of action depends on the mode of administration, the dissolution of the 
formulation, the rapidity of absorption, and the rate of entry into the brain. Diazepam is 
rapidly absorbed after oral use and enters the brain quickly thus promptly relieving anxiety. 
Given intravenously, it can rapidly stop repeated epileptic seizures. N-Desmethyldiazepam 
is absorbed more slowly than diazepam. Oxazepam is quite slowly absorbed and takes 
some time to penetrate the brain. Lorazepam is also slow to enter the brain but it can be 
used intravenously to sedate during investigative or minor surgical procedure. 
The hepatic metabolism of drugs can be phase I, mainly oxidation and de-alkylation, and 
phase H, conjugation to form glucuronides, and sulfates compounds. Benzodiazepines can 
undergo both phase I and phase II metabolism (diazepam, chordiazepoxide and 
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flurazepam) or phase II alone (lorazepam, oxazepam, and temazepam). Drugs metabolized 
via phase II processes alone are better tolerated than phase I- phase II drugs by patients 
such as alcoholics with liver impairment. In addition, phase I metabolism slows with age 
so that the elderly are more likely to suffer adverse effects when taking phase I- phase II 
drugs than phase II only drugs. The elimination half lives of benzodiazepines vary greatly, 
and usually lengthen in the aged patient for two essential reasons: firstly, the volume of 
distribution is increased and secondly, the clearance rate is decreased. N- 
desmethyldiazepam (nordiazepam) is the major active metabolite of diazepam (Figure 7-3) 
It has a prolonged half-life, over 100 hours, consequently it accumulates over the first 
month of treatment, reaching higher plasma concentrations than the parent compound, 
diazepam. N-desmethyldiazepam is also the major metabolite of clorazepate, prazepam, 
ketazolam, halazepam, medazepam and to some extent chlordiazepoxide. In contrast to 
these long-lasting drugs, lorazepam, oxazepam, temazepam and lormetazepam have half- 
lives of about 6-24 hours. As the body eliminates much of each dose between each 
administration, these compounds are suitable for acute, short-lived anxieties, fluctuating 
levels of anxiety, and for insomnia (Table 7-2) 
CH3 
3-hydroxylation 
N-deaikylation 
3-hydroxylation 
Figure 7-3: - Metabolic pathway of diazepam 
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Table 7-2: - Pharmacokinetic data of some of benzodiazepines of interest 
Benzodiazepine 
(MW) 
Half- 
life(h) 
Key active 
metabolite 
pKa Vd (LJkg) Protein 
binding 
(%) 
Diazepam (284) 20-50 Nordiazepam 3.4 0.7-2.6 98 
Nordiazepam (270) 50-99 Oxazepam 3.5,12.0 - 97 
Oxazepam (286) 4-15 None 1.7,11.6 0.7-1.6 97 
Temazepam (300) 5-15 Oxazepam 1.3 0.8-1.0 96 
7.4 Methods of analysis of benzodiazepines: previous 
work 
A large number of papers have been published on methods of analysis of benzodiazepines. 
HPLC methods and more recently LC-MS based methods have generally been preferred 
because of chromatography problems in GC based methods. Benzodiazepines have 
nevertheless been analysed by GC/MS. J236,352,3531 Several papers describe methods for 
diazepam and its metabolites. Some of these papers discuss analysis of whole blood 
samples and others the analysis of hair using liquid - liquid or solid phase extraction. 
[354] 
One paper describes derivatisation using a silylating reagent such MTBSTFA, MSTFA or 
BSTFA containing 1% TMCS. The target range concentrations were 25-6000 ng/ml of 
diazepam and oxazepam when analysed as TBDMS derivatives. [236] 
7.5 Aims 
As explained in previous chapters, chemical derivatisation is very useful for modifying 
compounds to produce a new compound which is suitable for analysis using GC/MS. 
Benzodiazepines are a very important class of drug to analyse, therefore when analysing by 
GC-MS the best derivatising reagent needs to be assessed and an evaluation made of 
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microwave assisted derivatisation. However, as mentioned above, GC-MS has not been 
successfully applied to benzodiazepine analysis because many of them are thermally 
unstable and do not chromatograph well by gas chromatographic-based techniques. For 
this reason, derivatisation procedures mentioned in Chapter 5 were applied to the most 
frequently-encountered benzodiazepines in the UK, diazepam and its three metabolites and 
this pilot study was aimed at an initial investigation of derivatisation methods which might 
extend the range of benzodiazepines which could be analysed by GC-MS. As before, these 
compounds were used as model substances as an indicator of the applicability of the 
derivatisation methods to benzodiazepine screening by GC-MS within a general STA 
procedure. Diazepam itself has no available derivatisation sites but was included to assess 
whether the derivatisation conditions would result in molecular changes to the parent 
substances. 
7.6 Derivatisation procedures 
7.6.1 Reagents 
Refer to Chapter 4 and 5 
7.6.2 Drug standards and internal standards 
The drug standards and internal standards used were diazepam, diazepam-d5, N- 
desmethyldiazepam, nordiazepam-ds, temazepam, temazepam-ds oxazepam, and 
oxazepam-d5. Stock standard solutions were obtained at a concentration of 100gg/ml in 
methanol, supplied by Cerilliant. 
7.6.3 Preparation of drug mixtures and internal standard 
solutions 
A mixed drug solution containing a concentration of 1 µg/mL of each drug was prepared 
by taking 100µl of lOOpgImL solution and making up to lOmL with methanol. The 
internal standard solution was prepared similarly using the deuterated standards. 
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7.6.4 Method and Results 
Preparation of buffers and spiked standards, and extraction, instrumentation and 
derivatisation procedures were the same as in Chapter 4 and 5. The chromatograms and 
mass spectra of the test compounds are given in Figures 7- 4 to 7-9 and the fragmentation 
reactions of some derivatives are given in Figures 7-10 to 7-14. 
ýýawoe. ý: ao n eeee r-(o, o)" ýei a-500 00 r.. 0 , 
ý. 
I 56 00-650 
öö1 ý 
, ooý 
D5? 
a3 ý 
ao _ 
)3ý 
)0= 
85= 
6 eoy 
Cs 
ý. _ )), 
15 
, oo 
I- 
ýBS t 
2711 
282 1 
]96 t 
za> > 
asSh c 
zz+a 
II 
ISl 1, ýYJ 1, 
M 
li9 
ýOS 
l 
so 200 no 
izo. ý 
LLIII a" . 
Zea z 
JOO ]50 
CI 
CH3 
-- 
N/O 
11 1r1 r 
C6H5 
41). 1 448 1 
445.1 51. 
4i eD. 1 `'ý 
ý. 
Ilif.. 
45s. 1 4T] 1 594 1 
400 410 500 
-C-C -C-F 
ii FF 
rtVz 446 
9I 565.9 
Y601.2 
550 800 
"os 
ýi 
650 
Figure 7-4: - Ion Chromatogram and Mass Spectrum for Temazepam with PFPA-PFP-OH 
Chapter Seven 
RT. 1'733-1852 SM 9G 
100- 
60- 
RT 
g +o= 
RT 17+7 
17 39 P. P. 651+ 11 56 17 67 
0 
100- 
1 Bo 
_ 
ý- 
fU= 
8= 
8 20ý_ 
"' 
RT 1]ý1 Ru 
o. 
03 
100- 
60 
"0= 
ý 20= 
ý 
11A2 
RT 1160 
MA 153628 
RT 17 82 
MV: 9757440 
RT 17 82 
A41 92C84 72 
RT 1782 
I. M 5725345 
r, 
OtE6 
MS Spp59 
5 
/ RT8. tt RT 18.36 
_ 
18.05 MSO00 1820 M<ß]ß 1842_ 1850 
,, 
ýTTTTI III, II. I1I Iý 
17.4 175 176 177 175 179 18.0 181 18.2 18.3 184 
18.5 
Time (min) 
500N1051 RT 1700 AY 1 NL 319E0 
T (0.0( "c-. 5w 00 Full mNý 50 00-050 00ý 
00 - 
95ý 
357 1 
ý CH3 
B5 ý 
BOý 
)5 ý 
/0? 
55= ä 730 
60? 
iE47 
55- 
p 
30= 
"3= 
sO= 
35= 
30= 
25ý 
20= 
t5= 
1021 178.1 
177.1 2071 
BS t 205.1 
' ,., 
i 
291 9 341 1 5=I 
... .. n... _W. . IJL... ý. ý. _A.... ni... 
d. 1... r...... 
1' 
_, _ý... _. _. ..;..;.. 
100 
359 1 
CI 
p-Si-C-CH3 
11 
CH3 CH3 
m/z 414 
3852 
3872 
391 1I 
ý` 
IIý I 401.1 4532 
185.1 
BOrýýýT29. ý S_T3.5ý71.3 B11. jý82] 2 B{. S 4 
150 200 250 300 350 400 f50 500 550 600 850 
m2 
287.1 
1 
255 1 
285 1 
2571, 
258 1 
7 
Page 176 
ý 3 t1E6 
356.5J51.5 
MS 500 
RT: 18.16 RT: 18.38 RT: 18.48 
18.01 AA 2630 1828 18.32 AA 7743 _ 
AA 9174 
2 8iE6 
z82zs-2e3 
MS 800 
0 
CH3 CH3 
Nýý iý 
Figure 7-5: - Chromatogram and Mass Spectrum for Temazepam with TBDMS 
Chapter Seven 
RT 14 18 - 15 72 SM LG 
1435 1445 
RT 15 35 RT: 15.51 RT: IS 09 
1. ý2453 
_7b, 
51 AA 3438 
q, 
oo- 
ý 
90_ 
eo- 
so- jzo 
ý 
eo_ 
eo- 
g .o 
ýzo 
1449 
RT 14 )1 
AM 381146 
\ 1f8o 
Page 177 
Yat! 
rs 
soo_o4o- 
1asua 
413"6J)3.6 
M8 
SUG_0.0)]O 
1JS33Y 
RT 15 34 
1492 1502 15.12 15.11 1523 M 1287 1f 58 
RT 1111 
w. ý0129 
14 38 1451 1158 - ý12 
14 3 144 145 146 147 
500 010)70175229M1711 RT 1111 AY I NL 250E5 
T (6. o) .c EI CM500 00 Full m" ) 56 00850 001 
100J 
691 
90j 
75 
66 
55 
Z El 
ýý3 
35 
1491 
1112 
1191 1671 
1272 
1901 
RT 15 11 
_ 
1189 11.98 15.04 517,1521 1534 
ý ýý rrlrr r-1Trrrýrr-r 
1551 15.58 15.58 
1 5.50 
RT 15 . 51 Mszn 1668 
145 119 150 151 152 15.3 154 155 15.5 157 
Tms (mm) 
232 1 268 2 
220 
,2 275.1 
i 283.2 
0FF 
IC- ý 
C-C-F 
I `F I 
.. c Fi 
il Ii ý- C-C - C-F II 
FF 
Mz 578 
3272 
410.1 
4724 
4734 
sýse s 
o. ýo 
6304 
300 350 400 450 
mh 
81 1 
532 
101 1 
Figure 7-6: - Chromatogram and Mass Spectrum for Oxazepam with PFPA- PFP-OH 
Chapter Seven Page 178 
RT ,. --I ]NS SM LG 
, ý- 
'°= 
°O- 
'o_ 
zo- zo- 
o= 
380 
RT 16 66 RT 11.23 RT 17 56 
M f206 
- 
M1663 M 501 
YYES 
=5157 
5 
100- 
ý_ ýse s. Sa a 
81- 
B0- 
2o- 
eý 
RT tý6) RT tl06 RT1667 RT 1668 RT 1)26 RTý. 17ý1 
0- 
Mý5 M385 M_4 B6 25Q -; 
z 51 
RT 1625 
10132378 
113 
it t51 
loo- 
Sa S 
F 
lo= S 
<i3 
an- 
O.. sp. m 
4 . o= 
ý 
ýo - 
o- 
118 150 152 11 1 156 158 180 
"ýý8+ H' I 516 P. V + NL 4 88E8 
' 10Oý"cEieýi. 5000CFwimýl'5800-8.50001 
2w6 r' 2as e 
2838 
32 60 
III 
327 0 
311 1 
35I. t 
3032 
31141 
U5z 
il 
3972 
ýq 25-j 
70: 
, ý- 
7123 
296 9 
]g 
ý 
2963 I 
I' 
I 
]2io 
770. o N, o 
i 
]SS t 
I 
280 300 320 340 360 
RT 16.25 
M 11212T93 
RT 16 25 
AA 11331250 
RT 1651 RT 1666 RT 1898 RT 17.25 RT. 17.61 
AA 15$ 
- 
AA -- AA. 1 05 AA 1030 
- 
Ap, 151 
162 164 186 168 170 172 174 116 11.6 
T- (min) 
4574 
4172 4293 
4594 
III-1` 
4644 
C 
IH3 
C H3 
CH3 
CH3-Si-C-CH3 
I i ru ru LI 
CI 
499.5 
4012 
1 
15 2 1,431 3 IIIIIII 
ý', ý4183ý'4, N. 3 
438. ] 
400 420 440 480 
mn 
465.5 
III 15 
448 4 479 5 
480 500 
514 6 
5158 m/z 514 
5166 
5176 
5196 
7ý '3 
-Si-C-CH 
I13 
CH3 CH3 
320 B 
5228 532 5 558.0 5U6 1811 
520 540 580 5ý80 
Figure 7-7: - Chromatogram and Mass Spectrum for Oxazepam with TBDMS (also contains 
oxazepam-d5) 
Chapter Seven 
.11.1. - 1... 1. - 
ooý 
s_ 
ý_= 
s ýo- 
. '° - , e= 
fi 
'ý - 
!ý- 
ý1 
ie_ 
ý 60 
sýf 
i 20- 
1. - iew , 6» +e. o 
DIZMMANDNORDtPM61600 RT 1643 AV I NL 026l6 
T (0 0) " c! I -600 00 -m" I 66 00260 00) 
, o03 
95 - 
60 
ea '. 
eo ': 
11 76 
ý SSý 
451 g "o1 
as 
ao 
3 
25 
20 
16 
10 
1291 
117 1 
131 1 
931 91 1 
tp0 t50 200 250 300 350 400 
I 30ý i ill+jl I1. 
ýj. . 
ýý 2272 2412 2833 ]35.7., 
-13 369- 
.. 4 
MA ý805506 
hM "03pp5 
005 
/ý 
ý5"'. ý6.50 
T me (m n) 
321 3 
]Y9 4 
329 J 
Page 179 
tB pa 
t 8.55 16 00 t p. 03 
CH3 CH3 
CH3 - Si -C-CH3 
CI 
m/z 384 
I 
/O 
CH3 
439 1 463.5 475 5 503 2 
450 500 600 650 
Figure 7-8: - Chromatogram and Mass Spectrum for Desmethyldiazepam with TBDMS 
Chapter Seven 
R' '3 .n a55 54 Ss 
100- 
SO-: - 
3= 
2= 
40- 
o= 
o- 
100- 
60 
60- 
ao- 
i0- 
o, 
133 
600 010136'35226Y1249 kF 
T ((. D) "ý raý 5.., . . f. -. ý. 
)5ý 
B't 
66 
0u 
55 
ý 
il 
"5 
40 113 1 353 221 2 303 
1II 
1252 652 
25 
ý63 ý iB31 
5ý 
O i 14 I L 
256 
2562 
Z252 1 
2O5 2 
23ý2 
2W 2ý 
253 1 
261 z 
2. <22 
2862 
.- 
Page 180 
CI 
m/z 284 
1440 
C6H5 
1459 
2@12 
3112 343.2 42]. 2 355.1 413ý 455 2 471.2 505 1 544.6 49 1 601 4 628.1 
300 350 400 450 500 550 800 650 
mh 
202 3202 $ 
rs 
600 02 0] 30 
t]6320 
M1SES 
1S5 5 f56 5 
500 
_040730 usza. 
Figure 7-9: - Chromatogram and Mass Spectrum for Diazepam with PFPA - PFP-OH (also 
contains diazepam-d5) 
Chapter Seven 
CI 
0FF 
ii II -C-C -CF II 
FF 
mlz 446 
+ 
CI 
CI 
CI 
m/z 282 
+ 
CH3 
Page 181 
Figure 7-10: -Fragmentation of Temazepam with PFPA-PFP-OH 
Chapter Seven Page 182 
CH3 CH3 
II - Si- C- CH3 
CI 
I CH3 
CI 
m/z 357 
CH3 
CH3 
II CH3 CH3 
C6H5 
m/z 414 
+ 
CH3 
I 
ý0- Si-CaHs 
I CH3 
C6H5 
+ 
CI 
CI 
L- m/z 283 
m/z 385 
+ 
Figure 7-11: -Fragmentation of Temazepam -TBDMS 
Chapter Seven 
OFF 
11 11 
C-C -C-F 
0 
r II 1i 
O- C-C -C- F 
+ 
ii FF 
CI 
m/z 472 
IF 
OýOFF 
OFF 
11 11 
C-C -C-F 
m/z 473 
rn/z 232 
IFI 
F v 
11 
- C-CF2 
+ 
Page 183 
+ 
Figure 7-12: -Fragmentation of Oxazepam with PFPA-PFP-OH 
Chapter Seven 
CI 
Page 184 
Ci3 CH 
(/ CH3 
CH, -Si--C--CH3 
ýi CH3 CH3 I I^ 
- Si- C- CH3 
II 
CH3 CH3 
d 
+ 
!. 
, /p) 
H 
CH3 
m/z 457 
CI 
W 
Cia CH3 j CH 3 
CH3-Si-C--CH3 
3 CI3 CI /-CH3 
CH, -Si-C-CH3 1 ýi 
m/z 514 
CI 
m/z 459 
+ 
m/z 383 
Figure 7-13: -Fragmentation of Oxazepam -TBDMS 
HI 
ý 
CH3 
+ 
Chapter Seven Page 185 
CH3 CH3 
iý CH3 - Si -C- CH3 
CI 
CI 
CH3 
Iý CH3 - Si 
i Ný /O 
C6H5 
m/z 327 
Figure 7.14: -Fragmentation of Nordiazepam -TBDMS 
7.6.5 Discussion 
+ 
This study was aimed at giving some information about GC-MS behaviour of diazepam 
and its metabolites with three derivatising reagents. These reactions were conducted under 
the same GC-MS conditions and derivatisation methods and extraction already mentioned 
in Chapters 4 and 5. Table 7-3 shows the retention times and ions selected to identify the 
derivatised benzodiazepines. 
The solid phase extraction (SPE) required fewer steps and worked with acidic and basic 
drugs, which are especially suitable for forensic laboratories. The SPE cartridge called 
StrataTMX employs a novel surface chemistry in the sorbent, offering significant 
advantages over the traditional silica-based SPE products. 
Generally, temazepam and oxazepam reacted with PFPA and MTBSTFA. The molecular 
ions for temazepam PFP and TBDMCS were m/z 446 and m/z 414 respectively. The ions 
and fragmentation patterns with PFP-OH and TMS-diazomethane were the same because 
the same reaction had occurred with both reagents. These ions gave fragmentation patterns 
as shown in Figure 7-10 and 
Figure 7-11. Temazepam derivatives had base peaks at m/z 271 and m/z 357 which were 
assigned to the fragments [C15H12N2C1O]' and [C20H22N2C1O2] +, using PFP and 
TBDMCS, respectively. Oxazepam has two different functional groups (-OH) and (-NH) 
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so during derivatisation the protons in these groups were replaced by (C3F50) and 
(SiC(CH3)5) respectively. The molecular ions for oxazepam PFP and TBDMCS were at 
m/z 578 and m/z 514 and the fragmentation patterns are shown in Figure 7-12 and Figure 
7-13. The base peaks at m/z 472 and m/z 457 were as signed to the fragment 
[C2oH7F7N204] + and [C25H34SiC1O2N2] +, respectively. The molecular ion for nordiazepam 
(desmethyldiazepam) with MTBSTFA was at m/z 384 and the fragmentation pattern is 
shown in (Figure 7-14). It has a base peak at m/z 327, assigned to the fragment [C16H12Si 
CLO2N2] +. The PFP and MTBSTFA (TBDMCS) derivatives of temazepam by loss of 
(C3F502) and (SiC (CH3)50) consecutively share the ion at m/z 283. 
Table 7-3: - Retention times and selected ion data for diazepam and its metabolites with 
different derivatising reagents 
Compound Active group Reagent Retention Time 
(min) 
Ions 
monitored 
Diazepam - PFPA-PFP-OH 14.13 256,283,284 
Nordiazepam -NH- PFPA-PFP-OH - 
Oxazepam -NH-, -OH- PFPA-PFP-OH 
14.71 472,473,232 
Temazepam -OH- PFPA-PFP-OH 
14.43 271,282,283 
Diazepam - PFPA-TMS 14.13 256,283,284 
Nordiazepam -NH- PFPA-TMS - - 
Oxazepam -NH-, -OH- PFPA-TMS 14.78 472,473,232 
Temazepam -OH- PFPA-TMS 14.78 271,282,283 
Diazepam - MTBSTFA 14.13 256,283,284 
Nordiazepam -NH- MTBSTFA 16.43 327,328,329 
Oxazepam -NH-, -OH- MTBSTFA 16.25 457,459,383 
Temazepam -OH- MTBSTFA 17.82 357,385,283 
-= underivatived 
As expected, diazepam did not react with any of the derivatising reagents nor was it 
affected structurally by any of them. The mass spectrum in Figure 7-9 is given as one 
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example of the reaction product, in this case, with PFP-PFP-OH reagent, which is the mass 
spectrum of unchanged diazepam. 
The acylation derivatisation reagent used for diazepam and its three metabolites is one of 
the most commonly used acylation reagents. This reagent reacts with alcohols, amines and 
phenols to produce derivatives with good chromatographic peak shapes. Nordiazepam was 
the exception and did not work as well with this reagent, most likely because of the 
secondary amine group. However, temazepam and oxazepam both gave derivatives. The 
spectrum of temazepam-PFP derivative has a base peak corresponding to loss of the 
derivatised hydroxyl group. There is no clear interpretation of the mass spectrum of 
oxazepam bis-PFP derivative and the proposed fragmentation pathway in Figure 7-12 is 
tentative. 
The methylation (esterification) reagent only reacts with carboxylic acid (-COOH) groups 
and was not expected to react with any of the benzodiazepines, which was confirmed 
experimentally. However, it was important to evaluate this reagent with these common 
benzodiazepine structures because the diazepine ring could in theory open and react with 
the derivatising agents. This mixture produced good peak shapes for all drugs except for 
oxazepam which can be explained by the presence of secondary amine groups. As 
expected, desmethyldiazepam did not react with the acylating reagent in this mixture 
either, also as a result of the secondary amine group. 
MTBSTFA reagent had enhanced reactivity as a result of its ability to silylate carboxyls, 
hydroxyls, thiols and primary and secondary amines; hence it reacted with diazepam and 
its three metabolites and improved the chromatography. The mass spectra showed the 
expected M-57 ions due to loss of the tertiary butyl group, and this reaction produced the 
base peak in the mass spectrum of desmethyldiazepam. [236] 
7.7 Conclusion 
Derivatisation procedures with three different reagents for some common benzodiazepines, 
including temazepam, oxazepam, diazepam and nordiazepam, were investigated. The 
extraction of diazepam and its three metabolites in blood is presented. These drugs have 
different functional groups such as NH and OH, so generally the best derivatisation method 
suitable for these functional groups used acylation or silylation reagents. PFPA-PFP-OH 
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and PFPA- TMS did not work with nordiazepam, but MTBSTFA did however work well 
with nordiazepam. Overall, the silylation derivatisation method gave the best sensitivity 
and most improved chromatography for all analytes. During the course of the work for this 
study, a literature publication appeared for the analysis of benzodiazepines in biological 
samples based on the methyl-tertiary-butylsilyl derivative. The results of this study were 
similar to those obtained in the present work except that different retention times were 
obtained for the derivatives. [2361 As mentioned earlier in Section 4.2.2, the authors of that 
study found the derivatives to be reliable, sensitive and reproducible for the analysis of 
benzodiazepines in biological samples. 
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8 Conclusions and Further Work 
8.1 Conclusions 
The use of blood in forensic toxicology was investigated by developing a reliable method 
of derivatisation for multiple drugs based on the model compounds amphetamine, 
methamphetamine, morphine, benzoylecgonine, THC-OH and THC-COOH, GHB, BHB, 
and some commonly-encountered benzodiazepines. 
The aim of this project was to develop a suitable analytical method for the qualitative and 
quantitative analysis of drugs in blood using derivatisation prior to gas chromatography- 
mass spectrometry. Derivatisation is very important for modifying a compound to produce 
a new substance which has different properties from the original compound and which is 
suitable for GC-MS. Different derivatisation reagents and procedures were investigated 
with the various analytes mentioned earlier. Prior to derivatisation a simple and rapid solid 
phase extraction was developed using a novel mixed-mode sorbent. This extraction 
procedure was used for both acidic and basic drugs. 
The first part of the study was the investigation of different derivatising reagents including 
PFPA plus PFP-OH, PFPA-TMS and MTBSTFA with different drugs of abuse. These 
were analysed by gas chromatography-mass spectrometry. The method gave good 
recoveries for the target drugs and the method validation parameters were acceptable. 
The second part of the study concerned a particular application of derivatisation reactions 
and was the investigation of the analysis in autopsy blood of GHB and BHB, which are 
both endogenous to the human body. A small amount of blood (0.2mL) was used with the 
solid phase extraction procedure developed earlier. The extraction was found to be simple, 
efficient, robust, clean and fast. The derivatising reagent which gave the best results was 
silylation by BSTFA with TMCS as catalyst. This reagent showed excellent solubility and 
derivatised faster and more completely than any other reagent. The SPE procedure worked 
very well with BHB, with recoveries shown in Table 6-8. The method was simple and 
efficient; recoveries were good resulting in a very sensitive procedure for qualitative and 
quantitative analysis. 
Chapter Eight Page 190 
Finally a derivatisation procedure for benzodiazepines was investigated. Benzodiazepines 
as a class encompass a wide variety of drugs and therefore it is a very important class of 
drug for analysis. Different derivatisation procedures were applied to diazepam and its 
three metabolites, nordiazepam, temazepam and oxazepam. These compounds have 
different functional groups and by using different reagents with them the best 
fragmentation patterns produced from each analyte and those which gave the most 
sensitivity were found. Some of these reagents did not work with analytes, for example, 
nordiazepam did not react with PFPA-PFP-OH or PFPA-TMS but worked well with 
MTBSTFA. Silylation with BSTFA containing TMCS gave the best sensitivity and 
chromatography. 
Generally, when more information is obtained about an unknown sample this will help to 
select the best and most suitable derivatisation reagent for the target drugs because 
different classes and function groups have different requirements. GC-MS parameters are 
very important to obtain stable, reproducible sensitivity during analyses. Selection of an 
SPE cartridge suitable for volume of samples is also important to avoid loss of any sample 
during the extraction step. 
8.2 Further work 
This study has worked well with blood analysis including many of drugs of abuse, but 
there are still many aspects of analysis of blood which have not yet been done. There are 
many drugs included in the benzodiazepine group and more investigation into the 
relationship with derivatisation reagents is still needed. Also, the derivatisation chemistry 
used is very important in obtaining clean, quantitative, reactions and the selection of 
suitable reagents for use with different types of drug needs further investigation, especially 
with respect to drugs containing a wider range of functional group types. 
The derivatisation and extraction procedures developed here could be applied to other 
sample matrices, including urine, hair or nail. The investigation into the use of alternative 
catalysts may help to analyse a wider range of drugs. 
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Appendix 1: Publication in support of this thesis 
COMPARISON OF CIIEIIIICAL DERIVATIVES FOR SYSTEMATIC 
TOXICOLOGICAL ANALYSIS OF AUTOPSY BLOOD USING GAS 
CHROMATOGRAPHY - MASS SPECTROMETRY 
Tareq AL-Ahmadi (") , R. A. Anderson 
Forensic Medicine and Science, University of Glasgow, Glasgow G12 8QQ, UK. 
Abstract 
Aims: Different derivatisation techniques have been developed for drug analysis in whole 
blood using GC-MS. The method was validated for six drugs of abuse and their 
metabolites. 
Method: A mixed standard stock solution was prepared to give a final concentration of 
I gg/ml for each analyte and this was used to spike whole blood. Solid phase extraction 
(SPE) was carried out using the polymeric phase Phenomenex Strat-X (60 mg/3ml 
cartridges containing 33µm particles). Blank blood (iml) was mixed with internal 
standard solution and different concentrations of mixed standard stock solution, and 
phosphate buffer (pH 6,3.5ml). This was centrifuged for 10 minutes and transferred to 
SPE columns. The extracts, in methanol, were evaporated to dryness and derivatised 
using three different methods: (a) acylation-esterification with PFPA/ PFP-OH (2: 1 v/v, 
150 µl); (b) acylation-methylation with PFPA/ trimethylsilyldiazomethane (TMS) (5: 1 
v/v, 120 µl); (c) silylation with MTBSTFA containing 1% TBDMSCI (30 µl). Reaction 
vials were heated with a microwave oven for one minute. After derivatisation, vials for 
methods (a) and (b) were cooled to room temperature and evaporated to dryness under a 
stream of nitrogen. The derivatised extracts were reconstituted in 50µl of ethyl acetate 
prior to analysis by GC-MS. Extracts derivatised by method (c) were analysed directly. 
A Thermo-Finnigan Trace GC-MS instrument was used in selected ion monitoring (SIM) 
mode except method (c) which used full scan mode. The GC was equipped with an HP5 
column (30m x 0.32 mm x 0.25µm) from J&W scientific and split/splitless injection port 
at 280°C. The oven temperature was at 100°C for 2 min, programmed at 12°C/min to 
300°C. Ions monitored for quantitative analysis were as follows : 
Derivative Amp MA MOR BZE THC THC-COOH 
PFPA/PFP- 
OH 118 204 414 82 417 459 
PFPA/TMS 118 204 414 82 417 489 
MTBSTFA 158 172 341 282 371 515 
The method was subsequently applied to 35 forensic autopsy case samples. 
Results: Recoveries for all drugs of interest were found to be over 70%. Limits of 
detection (LOD) were calculated as 3 times the standard error of the regression line plus 
the intercept. LOD's in blood ranged from 0.4 ng/ml to 3.7 ng/ml with PFPA/PFP-OH, 
0.3ng/ml to 1.4ng/ml with PFPA/TMS and with MTBSTFA were from 1.9 ng/ml to 
7.3 ng/ml. Limits of quantification (LOQ) were calculated as 10 times the standard error. 
They were 12.4 ng /ml with PFPA/PFP-OH, :! 4.7 ng/ml with PFPA/TMS and 19.8 
ng/ml with MTBSTFA of blood. The case samples analysed were found to contain 
various drugs of abuse and prescription drugs. The different derivatisation techniques 
gave varying results; however acylation-methylation gave the best sensitivity and 
chromatography. 
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Conclusion: A validated, sensitive and specific method for the extraction and 
quantification of drugs abuse in blood is presented. An alternative derivatisation method 
(acylation-methylation) is proposed which gives better sensitivity and improved 
chromatography for detection and quantification of drugs of abuse compared to silylation 
or acylation alone. 
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